exv4w2






EXECUTION VERSION




Exhibit 4.2




$85,000,000




SENIOR SUBORDINATED NOTE PURCHASE AGREEMENT



Dated as of September 30, 2010



among



CBAY INC., MEDQUIST INC.,



and



MEDQUIST TRANSCRIPTIONS, LTD,



AS ISSUERS,



CBAYSYSTEMS HOLDINGS LIMITED, AS HOLDINGS



and



BLACKROCK KELSO CAPITAL CORPORATION,



PENNANTPARK INVESTMENT CORPORATION



CITIBANK, N.A.



and



THL CREDIT, INC.



AS PURCHASERS



♦ ♦ ♦










 









 







This Agreement and the rights and obligations evidenced
hereby are subordinate in the manner and to
the extent set forth in that certain Subordination and Intercreditor Agreement (the “Subordination
Agreement”) among BlackRock Kelso Capital Corporation (“BKC”), Pennantpark Investment Corporation
(“Pennant”), Citibank, N.A. (“Citibank”), THE Credit, Inc. (“THL and together with BKC, Pennant and
Citibank, the “Purchasers”), CBay Inc., a Delaware corporation (CBay), MedQuist Inc., a New
Jersey corporation (“Medquist), MedQuist Transcriptions, Ltd., a New Jersey corporation (“MedQuist
Transcriptions, and together with CBay and MedQuist, the “Issuers”) and General Electric Capital
Corporation (“Agent”), to the indebtedness (including interest) owed by the Issuers pursuant to
that certain Credit Agreement dated as of October 1, 2010 among the Issuers, Agent and the lenders
from time to time party thereto, as such Credit Agreement has been and hereafter may be amended,
supplemented or otherwise modified from time to time and to indebtedness refinancing the
indebtedness under that agreement as contemplated by the Subordination Agreement; and each holder
of this instrument, by its acceptance hereof, irrevocably agrees to be bound by the provisions of
the Subordination Agreement.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







2









 








EXECUTION VERSION




TABLE OF CONTENTS




	 	 	 	 	 

	ARTICLE 1 DEFINITIONS, INTERPRETATION AND ACCOUNTING TERMS
	 	 	7	 
	 
	 	 	 	 
	Section 1.1 Defined Terms
	 	 	7	 
	Section 1.2 Ucc Terms
	 	 	36	 
	Section 1.3 Accounting Terms And Principles
	 	 	36	 
	Section 1.4 Pro Forma
	 	 	36	 
	Section 1.5 Payments
	 	 	36	 
	Section 1.6 Interpretation
	 	 	37	 
	 
	 	 	 	 
	ARTICLE 2 ISSUANCE AND SALE OF NOTES; INTEREST AND REPAYMENT
	 	 	37	 
	 
	 	 	 	 
	Section 2.1 Note Issuance
	 	 	37	 
	Section 2.2 Procedures For Issuance
	 	 	38	 
	Section 2.3 [Reserved.]
	 	 	38	 
	Section 2.4 [Reserved.]
	 	 	38	 
	Section 2.5 [Reserved.]
	 	 	38	 
	Section 2.6 Repayment And Prepayment Of Obligations
	 	 	38	 
	Section 2.7 Interest
	 	 	40	 
	Section 2.8 Ahydo Payments
	 	 	41	 
	Section 2.9 [Reserved.]
	 	 	41	 
	Section 2.10 Application Of Payments
	 	 	41	 
	Section 2.11 Payments And Computations
	 	 	42	 
	Section 2.12 Evidence Of Debt
	 	 	42	 
	Section 2.13 [Reserved.]
	 	 	43	 
	Section 2.14 [Reserved.]
	 	 	43	 
	Section 2.15 [Reserved.]
	 	 	43	 
	Section 2.16 [Reserved.]
	 	 	43	 
	Section 2.17 Taxes
	 	 	43	 
	Section 2.18 [Reserved.]
	 	 	46	 
	Section 2.19 Issuer Representative
	 	 	46	 
	 
	 	 	 	 
	ARTICLE 3 CONDITIONS TO PURCHASE OF NOTES
	 	 	47	 
	 
	 	 	 	 
	Section 3.1 Conditions Precedent To Purchase Of Notes
	 	 	47	 
	Section 3.2 Conditions To Funding
	 	 	49	 
	 
	 	 	 	 
	ARTICLE 4 REPRESENTATIONS AND WARRANTIES
	 	 	49	 
	 
	 	 	 	 
	Section 4.1 Corporate Existence; Compliance With Law
	 	 	49	 
	Section 4.2 Note Documents And Related Documents
	 	 	50	 
	Section 4.3 Ownership Of Group Members
	 	 	51	 
	Section 4.4 Financial Statements
	 	 	51	 
	Section 4.5 Material Adverse Effect
	 	 	52	 
	Section 4.6 Solvency
	 	 	52	 
	Section 4.7 Litigation
	 	 	52	 
	Section 4.8 Taxes
	 	 	52	 
	Section 4.9 Margin Regulations
	 	 	52	 
	Section 4.10 No Defaults
	 	 	52	 
	Section 4.11 Investment Company Act
	 	 	52	 
	Section 4.12 Labor Matters
	 	 	53	 
	Section 4.13 Erisa
	 	 	53	 
	Section 4.14 Environmental Matters
	 	 	53	 
	Section 4.15 Intellectual Property
	 	 	54	 
	Section 4.16 Title; Real Property
	 	 	54	 
	Section 4.17 Full Disclosure
	 	 	54	 






 









 





	 	 	 	 	 

	Section 4.18 Anti-Terrorism Laws
	 	 	55	 
	Section 4.19 Material Agreement
	 	 	55	 
	Section 4.20 Health Care Matters
	 	 	55	 
	Section 4.21 Health Care Permits
	 	 	55	 
	Section 4.22 Exclusion
	 	 	55	 
	Section 4.23 HIPAA
	 	 	56	 
	 
	 	 	 	 
	ARTICLE 5 FINANCIAL COVENANTS
	 	 	56	 
	 
	 	 	 	 
	Section 5.1 Maximum Consolidated Senior Leverage Ratio
	 	 	56	 
	Section 5.2 Maximum Consolidated Total Leverage Ratio
	 	 	57	 
	Section 5.3 [Reserved.]
	 	 	58	 
	Section 5.4 Minimum Consolidated Interest Coverage Ratio
	 	 	58	 
	 
	 	 	 	 
	ARTICLE 6 REPORTING COVENANTS
	 	 	58	 
	 
	 	 	 	 
	Section 6.1 Financial Statements
	 	 	59	 
	Section 6.2 Other Events
	 	 	60	 
	Section 6.3 Copies Of Notices And Reports
	 	 	61	 
	Section 6.4 Labor Matters
	 	 	61	 
	Section 6.5 ERISA-Related Information
	 	 	61	 
	 
	 	 	 	 
	ARTICLE 7 AFFIRMATIVE COVENANTS
	 	 	62	 
	 
	 	 	 	 
	Section 7.1 Maintenance Of Corporate
	 	 	62	 
	Section 7.2 Compliance With Laws, Etc.
	 	 	62	 
	Section 7.3 Payment Of Obligations
	 	 	62	 
	Section 7.4 Maintenance Of Property
	 	 	62	 
	Section 7.5 Maintenance Of Insurance
	 	 	63	 
	Section 7.6 Keeping Of Books
	 	 	63	 
	Section 7.7 Access To Books And Property
	 	 	63	 
	Section 7.8 Environmental
	 	 	64	 
	Section 7.9 Use Of Proceeds
	 	 	64	 
	Section 7.10 Additional Guaranties
	 	 	64	 
	Section 7.11 [Reserved.]
	 	 	64	 
	Section 7.12 Compliance Program
	 	 	64	 
	 
	 	 	 	 
	ARTICLE 8 NEGATIVE COVENANTS
	 	 	65	 
	 
	 	 	 	 
	Section 8.1 Indebtedness
	 	 	65	 
	Section 8.2 Liens
	 	 	67	 
	Section 8.3 Investments
	 	 	68	 
	Section 8.4 Asset Sales
	 	 	69	 
	Section 8.5 Restricted Payments
	 	 	71	 
	Section 8.6 Prepayment Of Indebtedness
	 	 	73	 
	Section 8.7 Fundamental Changes
	 	 	73	 
	Section 8.8 Change In Nature Of Business
	 	 	74	 
	Section 8.9 Transactions With Affiliates
	 	 	74	 
	Section 8.10 Third-Party Restrictions On Indebtedness, Liens,
Investments Or Restricted Payments
	 	 	76	 
	Section 8.11 Modification Of Certain Documents
	 	 	77	 
	Section 8.12 Fiscal Year
	 	 	77	 
	Section 8.13 Margin Regulations
	 	 	77	 
	Section 8.14 Compliance With Erisa
	 	 	77	 
	Section 8.15 Hazardous Materials
	 	 	77	 
	Section 8.16 Limitation On Layering Indebtedness
	 	 	77	 
	Section 8.17 Excess Cash Flow
	 	 	77	 
	 
	 	 	 	 
	ARTICLE 9 EVENTS OF DEFAULT
	 	 	78	 
	 
	 	 	 	 





NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





4









 








	 	 	 	 	 

	Section 9.1 Definition
	 	 	78	 
	Section 9.2 Remedies
	 	 	80	 
	 
	 	 	 	 
	ARTICLE 10 RESERVED
	 	 	80	 
	 
	 	 	 	 
	ARTICLE 11 MISCELLANEOUS
	 	 	80	 
	 
	 	 	 	 
	Section 11.1 Amendments, Waivers, Etc
	 	 	80	 
	Section 11.2 Assignments And Participations; Binding Effect
	 	 	82	 
	Section 11.3 Costs And Expenses
	 	 	83	 
	Section 11.4 Indemnities
	 	 	84	 
	Section 11.5 Survival
	 	 	85	 
	Section 11.6 Limitation Of Liability For Certain Damages
	 	 	85	 
	Section 11.7 Noteholder-Issuer Relationship
	 	 	85	 
	Section 11.8 [Reserved.]
	 	 	85	 
	Section 11.9 Sharing Of Payments, Etc
	 	 	85	 
	Section 11.10 [Reserved.]
	 	 	85	 
	Section 11.11 Addresses
	 	 	85	 
	Section 11.12 Electronic Transmissions
	 	 	86	 
	Section 11.13 Governing Law
	 	 	87	 
	Section 11.14 Jurisdiction
	 	 	87	 
	Section 11.15 Waiver Of Jury Trial
	 	 	88	 
	Section 11.16 Severability
	 	 	88	 
	Section 11.17 Execution In Counterparts
	 	 	88	 
	Section 11.18 Entire Agreement
	 	 	88	 
	Section 11.19 Use Of Name
	 	 	89	 
	Section 11.20 Non-Public Information; Confidentiality
	 	 	89	 
	Section 11.21 Patriot Act Notice
	 	 	89	 
	 
	 	 	 	 
	ARTICLE 12 CROSS-GUARANTY
	 	 	90	 
	 
	 	 	 	 
	Section 12.1 Cross-Guaranty
	 	 	90	 
	Section 12.2 Waivers By Issuers
	 	 	90	 
	Section 12.3 Benefit Of Guaranty
	 	 	90	 
	Section 12.4 Subordination Of Subrogation, Etc.
	 	 	91	 
	Section 12.5 Election Of Remedies
	 	 	91	 
	Section 12.6 Limitation
	 	 	91	 
	Section 12.7 Contribution With Respect To Guaranty Obligations
	 	 	91	 
	Section 12.8 Liability Cumulative
	 	 	92	 
	Section 12.9 Subordination
	 	 	92	 






NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







5









 








SCHEDULES




	 	 	 

	Schedule I

	 	Commitments
	Schedule II

	 	Addresses for Notices
	Schedule 4.3

	 	Capitalization
	Schedule 4.12

	 	Labor Matters
	Schedule 4.14

	 	Environmental Matters
	Schedule 4.19

	 	Material Agreements
	Schedule 4.21

	 	Health Care Permits
	Schedule 8.1

	 	Indebtedness
	Schedule 8.2

	 	Liens
	Schedule 8.3

	 	Investments
	Schedule 8.9

	 	Affiliate Transactions
	Schedule 8.10

	 	Contractual Obligations
	 
	 	 
	EXHIBITS
	 
	 	 
	Exhibit A

	 	Form of Assignment Agreement
	Exhibit B

	 	Form of Note
	Exhibit C

	 	PIK Toggle Notice
	Exhibit D

	 	Form of Compliance Certificate
	Exhibit E

	 	Subordination Agreement







NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





6











 





          THIS SENIOR SUBORDINATED NOTE PURCHASE AGREEMENT, DATED AS OF SEPTEMBER 30, 2010, IS
ENTERED INTO AMONG CBAY INC., A DELAWARE CORPORATION (“CBAY”), MEDQUIST INC., A NEW JERSEY
CORPORATION (“MEDQUIST”), MEDQUIST TRANSCRIPTIONS, LTD., A NEW JERSEY
CORPORATION (“MEDQUIST TRANSCRIPTIONS”, AND TOGETHER WITH CBAY AND
MEDQUIST, THE “ ISSUERS ”), CBAYSYSTEMS HOLDINGS LIMITED, A COMPANY INCORPORATED IN THE BRITISH
VIRGIN ISLANDS AND AS SUCH ENTITY MAY BE CONVERTED TO A DELAWARE CORPORATION PURSUANT TO SECTION
265 OF THE DELAWARE GENERAL CORPORATION LAW (“HOLDINGS”), MEDQUIST, AS
ISSUER REPRESENTATIVE, BLACKROCK KELSO CAPITAL CORPORATION (“BKC”),
PENNANTPARK INVESTMENT CORPORATION (“PENNANT”), CITIBANK, N.A.
(“CITIBANK”), AND  THL CREDIT, INC. (“ THL” AND TOGETHER WITH BKC,
PENNANT PARK, CITIBANK AND THE OTHER PURCHASERS FROM TIME TO TIME PARTIES HERETO (COLLECTIVELY, THE
“PURCHASERS”).


          WHEREAS, simultaneously with the transactions contemplated under the Senior Credit Agreement,
Issuers wish to sell to Purchasers and Purchasers wish to purchase from Issuers the 13.0% Senior
Subordinated Notes Due October 2016 (each, a “Note” and collectively,
the “Notes”), in an aggregate principal amount equal to $85,000,000, for the consideration and upon
the terms and conditions contained herein; and


          WHEREAS, Holdings and the Subsidiary Guarantors (each, a
“Guarantor” and collectively, the
“Guarantors”) will derive substantial direct and indirect benefits from
the issuance of the Notes hereunder and are willing to guaranty all of the Obligations of Issuers
to Purchasers under the Note Documents;


          NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained
herein, the parties hereto agree as follows:



ARTICLE 1

DEFINITIONS, INTERPRETATION AND ACCOUNTING TERMS




          Section 1.1 Defined Terms As used in this Agreement, the following terms have the
following meanings:



     “Acquired Business” means the assets of Spheris Inc. and its
subsidiaries acquired by the Issuers pursuant to the terms of the Acquisition Agreement.



     “Acquisition” means the acquisition by the Issuers of the
Acquired Business.



     “Acquisition Agreement” means that certain Stock and Asset Purchase Agreement, dated as
of February 2, 2010, by and among Spheris Inc. and certain of its affiliates as sellers and CBay
and MedQuist as purchasers.



     “Additional Available Cash” means, on any date, (i) aggregate
Excess Cash Flow of Holdings for periods after the Closing Date for which audited financial
statements and related Compliance Certificates have been delivered pursuant to Section
6.1(c) and (d) after the Closing Date not required to be paid to the Senior Agent pursuant to
Section 2.8(a) of the Senior Credit Agreement plus (ii) aggregate Net Cash Proceeds arising from
the issuance or Sale by any Group



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






7









 








Member of its own Stock (other than the Holdings IPO) not required to be paid to the Senior Agent
pursuant to Section 2.8(b) of the Senior Credit Agreement, plus (iii) Available Holdings IPO
Proceeds, plus (iv) Net Cash Proceeds arising from the A-Life Sale, and, minus (v) any such
amounts, previously used on or prior to such date to make Permitted Acquisitions, Investments,
Restricted Payments, in each case as expressly permitted hereunder to be made with Additional
Available Cash and, minus (vi) prepayments of the Notes pursuant to Section 2.6.




     “Affiliate” means, with respect to any Person, each other Person
that directly or indirectly controls, is controlled by, or is under common control with, such
Person; provided, however, that no Purchaser shall be an Affiliate of any Note
Party. For purpose of this definition, “control” means the possession
of either (a) the power to vote 10% or more of the Voting Stock of such Person or (b) the power to
direct or cause the direction of the management and policies of such Person, whether by contract or
otherwise.



     “Aggregate Accrual” has the meaning specified in
Section 2.8.



     “Agreement” means this Senior Subordinated Note Purchase
Agreement.



     “A-Life Sale” means the sale by MedQuist of its equity investment
in A-Life Medical, Inc. pursuant to that certain Agreement and Plan of Merger, dated as of
September 20, 2010, among Ingenix, Inc., Oasis Acquisition Holdings, Inc., A-Life Medical, Inc.,
MedQuist and the other equity holders of A-Life Medical, Inc., for approximately $19,000,000 in
cash at closing and $5,000,000 pursuant to an eighteen month escrow arrangement.



     “Assignment” means an assignment agreement entered into by a
Purchaser, as assignor, and any Person, as assignee, pursuant to the terms and provisions of
Section 11.2 accepted by the Required Purchasers, in substantially the form of Exhibit
A, or any other form approved by the Required Purchasers.



     “Available Holdings IPO Proceeds” means, on any date, (i) the Net
Cash Proceeds received by Holdings from the consummation of the Holdings IPO, minus (ii) in the
case of the initial Holdings IPO, the Designated IPO Proceeds Amount; provided, however, that in no
event shall Available Holdings IPO Proceeds be less than zero.



     “Bankruptcy Code” means Title 11 of the United States Code
entitled “Bankruptcy,” as now and hereafter in effect, or any successor statute.



     “Benefit Plan” means any employee benefit plan as defined in
Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise) to which any
Group Member incurs or otherwise has any obligation or liability, contingent or otherwise.



     “BKC” has the meaning set forth in the preamble.



     “Business Day” means any day of the year that is not a Saturday,
Sunday or a day on which banks are required or authorized to close in New York City.



     “Called Notes” means the principal amount of the Notes that is to
be prepaid at a voluntary redemption date on or prior to the second anniversary of the Funding Date
pursuant to Section 2.6(b)(iii).



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY




8









 








     “Capital Expenditures” means, for any Person for any period, the
aggregate of all expenditures, whether or not made through the incurrence of Indebtedness, by such
Person and its Subsidiaries during such period for the acquisition, leasing (pursuant to a Capital
Lease), construction, replacement, repair, substitution or improvement of fixed or capital assets
or additions to equipment, in each case required to be capitalized under GAAP on a Consolidated
balance sheet of such Person, excluding (a) interest capitalized during construction and (b) any
expenditure to the extent, for purpose of the definition of Permitted Acquisition, such expenditure
is part of the aggregate amounts payable in connection with, or other consideration for, any
Permitted Acquisition consummated during or prior to such period.



     “Capital Lease” means, with respect to any Person, any lease of,
or other arrangement conveying the right to use, any property (whether real, personal or mixed) by
such Person as lessee that has been or should be accounted for as a capital lease on a balance
sheet of such Person prepared in accordance with GAAP.



     “Capitalized Lease Obligations” means, at any time, with respect
to any Capital Lease, any lease entered into as part of any Sale and Leaseback Transaction of any
Person or any synthetic lease, the amount of all obligations of such Person that is (or that would
be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a
balance sheet of such Person prepared in accordance with GAAP.



     “Cash Equivalents” means (a) any readily-marketable securities
(i) issued by, or directly, unconditionally and fully guaranteed or insured by the United States
federal government or (ii) issued by any agency of the United States federal government the
obligations of which are fully backed by the full faith and credit of the United States federal
government, (b) any readily-marketable direct obligations issued by any other agency of the United
States federal government, any state of the United States or any political subdivision of any such
state or any public instrumentality thereof, in each case having a rating of at least “A-1”
from S&P or at least “P-1” from Moody’s, (c) any commercial paper rated at least
“A-1” by S&P or “P-1” by Moody’s and issued by any Person organized under the laws
of any state of the United States, (d) any Dollar-denominated time deposit, insured certificate of
deposit, overnight bank deposit or bankers’ acceptance issued or accepted by any commercial bank
that is (A) organized under the laws of the United States, any state thereof or the District of
Columbia, (B) adequately capitalized (as defined in the regulations of its primary federal
banking regulators) and (C) has Tier 1 capital (as defined in such regulations) in excess of
$250,000,000 and (e) shares of any United States money market fund that (i) has substantially all
of its assets invested continuously in the types of investments referred to in clause (a),
(b), (c) or (d) above with maturities as set forth in the proviso below,
(ii) has net assets in excess of $500,000,000 and (iii) has obtained from either S&P or Moody’s the
highest rating obtainable for money market funds in the United States; provided, however, that the
maturities of all obligations specified in any of clauses (a), (b), (c) and
(d) above shall not exceed 365 days.



     “Cash Rate” has the
meaning specified in Section 2.7(a).



     “CBay” has the meaning
specified in the preamble.



     “CBay Convertible Notes” means those certain 6.00% Convertible
Senior PIK Notes due 2015 which mature on August 6, 2015 issued by CBay to Koninklijke Philips
Electronics N.V.



     “CBay India” means CBay Systems (India) Pvt. Ltd., a
company incorporated in India.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





9









 








     “CBay Management Agreement” means that certain Services Agreement, dated as of
September 19, 2009, between Holdings and CBay.



     “CBay Transcription Agreements” means (i) that certain Sales & Services Agreement,
dated as of March 9, 2010, between MedQuist Transcriptions and CBay Systems and (ii) that certain
Transcription Services Subcontracting Agreement by and between MedQuist Transcriptions and CBay
Systems, dated as of March 31, 2009, each as in effect as of the date hereof.



     “CBay Systems” means CBay Systems & Services, Inc., a Delaware corporation.



     “CERCLA” means the United States Comprehensive Environmental Response, Compensation,
and Liability Act (42 U.S.C. §§ 9601 et seq.).



     “Change of Control” means the occurrence of any of the following: (a) the acquisition
of ownership, directly or indirectly, beneficially or of record, by any Person or group (within the
meaning of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange
Commission thereunder as in effect on the date hereof), other than Sponsor, of Stock representing
45% of the aggregate ordinary voting power represented by the issued and outstanding Stock of
Holdings, (b) the Sale by Sponsor of all or substantially all of the Stock of Holdings owned by
Sponsor to any Person or group (within the meaning of the Securities Exchange Act of 1934 and the
rules of the Securities and Exchange Commission thereunder as in effect on the date hereof) (but
excluding any sale by Sponsor of all of its shares of Stock of Holdings to the extent such shares
constitute no more than 5% of the shares of Stock of Holdings held by the Sponsor on the Closing
Date and are not sold in a series of related transactions that would otherwise be a Change of
Control), (c) the occupation of a majority of the seats on the board of directors of Holdings by
Persons who were not directors on the Closing Date and were neither (i) nominated by the board of
directors of Holdings nor (ii) appointed by directors so nominated, (c) Holdings ceases, directly
or indirectly, to own and control, beneficially and of record, ninety-five percent (95%) of the
issued and outstanding Voting Stock and Stock Equivalents of CBay on a fully diluted basis (as the
same may be adjusted for any combination, recapitalization or reclassification into a greater or
smaller number of shares, interests or other unit of equity security), (d) CBay ceases, directly or
indirectly, to own and control, beneficially and of record, a percentage equal to or greater than
the percentage owned and controlled as of the Closing Date of the issued and outstanding Voting
Stock and Stock Equivalents of MedQuist on a fully diluted basis (other than through the exercise
of options existing on the Closing Date) or (e) a Change of Control or any term of similar
effect, as defined in any Senior Loan Document.



     “Citibank” has the meaning set forth in the preamble.



     “Closing Date” means the September 30, 2010.



     “Code” means the U.S. Internal Revenue Code of 1986, as amended.



     “Commitment” means, with respect to any Purchaser, the aggregate amount set forth
opposite such Purchaser s name on Schedule I under the heading Commitment.



     “Compliance Certificate” means a certificate substantially in the form of Exhibit
D.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





10









 








     “Consolidated” means, with respect to any Person, the accounts of
such Person and its Subsidiaries consolidated in accordance with GAAP.



     “Consolidated Cash Interest Expense” means, with respect to any
Person for any period, the Consolidated Interest Expense of such Person for such period less the
sum of, in each case to the extent included in the definition of Consolidated Interest Expense, (a)
the amortized amount of debt discount and debt issuance costs, (b) charges relating to write-ups or
write-downs in the book or carrying value of existing Consolidated Total Debt, (c) interest payable
in evidences of Indebtedness or by addition to the principal of the related Indebtedness and (d)
other non-cash interest.



     “Consolidated Current Assets” means, with respect to any Person
at any date, the total Consolidated current assets of such Person at such date other than cash,
Cash Equivalents and any Indebtedness owing to such Person or any of its Subsidiaries by Affiliates
of such Person.



     “Consolidated Current Liabilities” means, with respect to any
Person at any date, all liabilities of such Person and its Subsidiaries at such date that should be
classified as current liabilities on a Consolidated balance sheet of such Person in accordance with
GAAP; provided, however, that “Consolidated Current
Liabilities” shall exclude the principal amount of the Notes then outstanding, the
current portion of any other long term Indebtedness and accrued interest payable.



     “Consolidated EBITDA” means, with respect to any Person
for any period:



     (a) the Consolidated Net Income of such Person for such period; plus



     (b) the sum of, in each case to the extent deducted in the calculation of such Consolidated
Net Income but without duplication:




     (i) any provision for United States federal income taxes or other taxes measured by net
income;




     (ii) Consolidated Interest Expense, amortization of debt discount and commissions and other
fees and charges associated with Indebtedness (except amortization of debt discount, expenses and
fees related to the consummation of the Related Transactions);




     (iii) any loss from extraordinary items as defined by GAAP; (iv) any depreciation, depletion
and amortization expense;




     (v) any aggregate net loss on the Sale of property (other than accounts (as defined under the
applicable UCC) and inventory) outside the Ordinary Course of Business;




     (vi) expenses and fees paid in cash associated with the Related Transactions accrued in the
Fiscal Years ending on December 31, 2010 or December 31, 2011 and amortization of debt discount, in
the aggregate not to exceed $14,000,000;



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





11









 









     (vii) for purposes of calculating Consolidated EBITDA for Holdings (and not
Consolidated EBITDA of MedQuist), fees and expenses, and any unusual or non-recurring cash charges,
related to the Exchange Offer and the Holdings IPO and the issuance of equity of Holdings in
connection therewith;




     (viii) any other non-cash expenditure, charge or loss for such period (other than any non-cash
expenditure, charge or loss relating to write-offs, write-downs or reserves with respect to
accounts and inventory), including the amount of any compensation deduction as the result of any
grant of Stock or Stock Equivalents to employees, officers, directors or consultants, or any other
long-term incentive arrangement;




     (ix) any non-recurring loss, including severance and restructuring costs related to the
Acquisition and the integration of the Acquired Business in an aggregate amount not to exceed
$5,500,000;




     (x) any unusual or non-recurring cash losses, cash charges or cash expenses, including
severance and restructuring costs, related to Permitted Acquisitions or Permitted Indebtedness or
equity issuances of Stock or Stock Equivalents permitted hereunder (excluding any equity issuances
in connection with the Exchange Offer or the Holdings IPO);




     (xi) costs of legal proceedings and settlements with respect to those matters disclosed in
Item 3 of MedQuist s Annual Report on Form 10-K as of December 31, 2009 filed on March 12, 2010, in
an amount not to exceed $5,000,000 in any trailing twelve-month period; and




     (xii) aggregate non-cash foreign exchange losses resulting from foreign currency fluctuation
or hedging activity related thereto; minus



     (c) the sum of, in each case to the extent included in the calculation of such Consolidated
Net Income and without duplication:




     (i) any credit for United States federal income taxes or other taxes measured by net
income;




     (ii) any gain from extraordinary items and any other non-recurring gain;




     (iii) any aggregate net gain from the Sale of property (other than accounts (as defined
in the applicable UCC) and inventory) out of the Ordinary Course of Business by such
Person;




     (iv) any other non-cash gain, including any reversal of a charge referred to in
clause (b)(vii) above by reason of a decrease in the value of any Stock or Stock
Equivalent;




     (v) any other cash payment in respect of expenditures, charges and losses that have
been added to Consolidated EBITDA of such Person pursuant to clause (b)(vii)
above in any prior period; and



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





12









 









     vi) aggregate non-cash foreign exchange gains resulting from foreign currency
fluctuation or hedging activity related thereto.



     Notwithstanding the above, for purposes of calculating the condition precedent set forth in
Section 3.1(e) and covenants under Article 5 and Article 8, Consolidated
EBITDA for the following Fiscal Quarters shall be deemed to be the amount set forth opposite such
Fiscal Quarter below:



	 	 	 	 	 
	Fiscal Quarter Ended	 	Consolidated EBITDA	 
	September 30, 2009
	 	$	22,316,000	 
	December 31, 2009
	 	$	23,540,000	 
	March 31, 2010
	 	$	19,385,000	 
	June 30, 2010
	 	$	21,911,000	 






     “Consolidated Interest Coverage Ratio” means, with respect to any Person for any
period, the ratio of (a) Consolidated EBITDA of such Person for such period to (b) Consolidated
Cash Interest Expense of such Person for such period.



     “Consolidated Interest Expense” means, for any Person for any period, (a)
Consolidated total interest expense of such Person and its Subsidiaries for such period and
including, in any event, (i) interest capitalized during such period and net losses under Interest
Rate Contracts for such period and (ii) all fees, charges, commissions, discounts and other similar
obligations (other than reimbursement obligations) with respect to letters of credit, bank
guarantees, banker s acceptances, surety bonds and performance bonds (whether or not matured)
payable by such Person and its Subsidiaries during such period minus (b) the sum of (i)
Consolidated net gains of such Person and its Subsidiaries under Interest Rate Contracts for such
period and (ii) Consolidated interest income of such Person and its Subsidiaries for such period.



     “Consolidated Net Income” means, with respect to any Person, for any period, the
Consolidated net income (or loss) of such Person and its Subsidiaries for such period;
provided, however, that the following shall be excluded: (a) the net income of any
other Person in which such Person or one of its Subsidiaries has a joint interest with a third
party (which interest does not cause the net income of such other Person to be Consolidated into
the net income of such Person), except to the extent of the amount of dividends or distributions
paid to such Person or Subsidiary, (b) the net income of any Subsidiary of such Person that is, on
the last day of such period, subject to any restriction or limitation on the payment of dividends
or the making of other distributions, to the extent of such restriction or limitation and (c) the
net income of any other Person arising prior to such other Person becoming a Subsidiary of such
Person or merging or consolidating into such Person or its Subsidiaries, other than any Permitted
Acquisition, in which case Consolidated Net Income shall include the net income of such Person
measured on a Pro



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





13









 








Forma Basis. For the avoidance of doubt, the net income (or loss) of A Life Medical Inc. shall
not be included in the Consolidated Net Income of Holdings or MedQuist.




     “Consolidated Senior Debt” means, as of any date, (i) the
Consolidated Total Debt of Holdings less (ii) all Indebtedness evidenced by the Notes.



     “Consolidated Senior Leverage Ratio” means, with respect to any
Person as of any date, the ratio of (a) Consolidated Senior Debt of such Person outstanding as of
such date to (b) Consolidated EBITDA for such Person for the last period of four (4) consecutive
Fiscal Quarters ending on or before such date.



     “Consolidated Total Debt” of any Person means all Indebtedness of
a type described in clause (a), (b), (c), (d), (f) or
(g) of the definition thereof and, without duplication, all Guaranty Obligations with
respect to any such Indebtedness, in each case of such Person and its Subsidiaries on a
Consolidated basis.



     “Consolidated Total Leverage Ratio” means, with respect to any
Person as of any date, the ratio of (a) Consolidated Total Debt of such Person outstanding as of
such date to (b) Consolidated EBITDA for such Person for the last period of four (4) consecutive
Fiscal Quarters ending on or before such date.



     “Constituent Documents” means, with respect to any Person,
collectively and, in each case, together with any modification of any term thereof, to the extent
not prohibited hereunder, (a) the articles of incorporation, certificate of incorporation,
constitution or certificate of formation of such Person, (b) the bylaws, operating agreement or
joint venture agreement of such Person, (c) any other constitutive, organizational or governing
document of such Person, whether or not equivalent, and (d) any other document setting forth the
manner of election or duties of the directors, officers or managing members of such Person or the
designation, amount or relative rights, limitations and preferences of any Stock of such Person.



     “Contingent Note Document Obligations” means contingent
indemnification obligations arising under the Note Documents for which no claims have been
asserted.



     “Contractual Obligation” means, with respect to any Person, any
provision of any Security issued by such Person or of any document or undertaking (other than a
Note Document) to which such Person is a party or by which it or any of its property is bound or to
which any of its property is subject.



     “Copyrights” means all rights, title and interests (and all
related IP Ancillary Rights) arising under any Requirement of Law in or relating to copyrights and
all mask work, database and design rights, whether or not registered or published, all
registrations and recordations thereof and all applications in connection therewith.



     “Corporate Chart” means a document setting forth, as of a date
set forth therein, for each Person that is a Note Party or a Subsidiary or joint venture of a Note
Party, (a) the full legal name of such Person, (b) the jurisdiction of organization and, if
organized under the laws of a state of the United States, any organizational number and tax
identification number of such Person, (c) the location of such Person’s chief executive office (or,
if applicable, sole place of business), (d) the number of shares of each class of Stock of such
Person (other than Holdings) authorized and



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





14









 








outstanding and (e) the number and percentage of such outstanding shares for each such class
owned, directly or indirectly, by each Group Member.




     “Customary Permitted Liens” means, with respect to any Person,
any of the following:



     (a) Liens (i) with respect to the payment of taxes, assessments or other governmental charges
that are not yet overdue or (ii) of suppliers, carriers, materialmen, warehousemen, workmen or
mechanics and other similar Liens that are not yet overdue for a period of more than 30 days
without the commencement of enforcement or foreclosure, in each case imposed by law or arising in
the Ordinary Course of Business, and, for each of the Liens in clauses (i) and (ii)
above for amounts that are being contested in good faith by appropriate proceedings diligently
conducted and with respect to which adequate reserves or other appropriate provisions are
maintained on the books of such Person in accordance with GAAP;



     (b) Liens of a collection bank on items in the course of collection arising under Section
4-208 of the UCC as in effect in the State of New York or any similar section under any applicable
UCC or any similar Requirement of Law of any foreign jurisdiction;



     (c) pledges or cash deposits made in the Ordinary Course of Business (i) in connection with
workers compensation, unemployment insurance or other types of social security benefits (other
than any Lien imposed by ERISA), (ii) to secure the performance of bids, tenders, leases (other
than Capital Leases) sales or other trade contracts (other than for the repayment of borrowed
money) or (iii) made in lieu of, or to secure the performance of, surety, customs, reclamation or
performance bonds (in each case not related to judgments or litigation);



     (d) judgment liens (other than for the payment of taxes, assessments or other governmental
charges) securing judgments and other proceedings not constituting an Event of Default under
Section 9.1(e) and pledges or cash deposits made in lieu of, or to secure the performance of,
judgment or appeal bonds in respect of such judgments and proceedings;



     (e) Liens (i) arising by reason of zoning restrictions, easements, licenses, reservations,
restrictions, covenants, rights-of-way, encroachments, minor defects or irregularities in title
(including leasehold title) and other similar encumbrances on the use of real property or (ii)
consisting of leases, licenses or subleases granted by a lessor, licensor or sublessor on its
property (in each case other than Capital Leases) otherwise permitted under Section 8.4
that, for each of the Liens in clauses (i) and (ii) above, do not, in the
aggregate, materially (x) impair the value or marketability of such real property or (y) interfere
with the ordinary conduct of the business conducted and proposed to be conducted at such real
property;



     (f) Liens of landlords and mortgagees of landlords (i) arising by statute or under any lease
or related Contractual Obligation entered into in the Ordinary Course of Business, (ii) on fixtures
and movable tangible property located on the real property leased or subleased from such landlord,
(iii) for amounts not overdue for a period of more than 30 days without the commencement of
enforcement or foreclosure or that are being contested in good faith by appropriate proceedings
diligently conducted and (iv) for which adequate reserves or other appropriate provisions are
maintained on the books of such Person in accordance with GAAP;



     (g) Liens arising from precautionary uniform commercial code financing statements filed under
any lease permitted by this Agreement;



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





15









 








     (h) licenses (including, without limitation, licenses granted by a Group Member with
respect to its Intellectual Property), sublicenses, leases or subleases granted to third parties in
the Ordinary Course of Business not interfering with the business of the Group Members;



     (i) Liens in favor of collecting banks arising under Section 4-210 of the UCC;



     (j) Liens (including the right of set-off) in favor of a bank or other depository institution
arising as a matter of law encumbering deposits, or Liens that are contractual rights of set-off
(i) relating to the establishment of depository relations with banks not given in connection with
the issuance of Indebtedness or (ii) relating to pooled deposit, automatic clearing house or sweep
accounts of the Group Members to permit satisfaction of overdraft or similar obligations incurred
in the Ordinary Course of Business of the Group Members;



     (k) Liens arising out of consignment or similar arrangements for the sale of goods entered
into by Group Member in the Ordinary Course of Business;



     (l) Liens in favor of customs and revenue authorities arising as a matter of law that secure
payment of customs duties in connection with the importation of goods of any Group Member in the
Ordinary Course of Business;



     (m) Liens (i) on cash earnest money deposits in favor of the seller of any Property to be
acquired in an Investment permitted pursuant to Section 8.3 to be applied against the
purchase price for such Investment and (ii) consisting of an agreement to sell, transfer, lease or
otherwise dispose of any Property in a transaction permitted under Section 8.4 and
affecting only the Property that is the subject of such agreement, in each case, solely to the
extent such Investment or sale, disposition, transfer or lease would have been permitted on the
date of the creation of such Lien;



     (n) Liens that are in the nature of (i) a common law or statutory right of set-off arising
solely by operation of applicable law, or (ii) a right of set-off, relating to purchase orders and
other agreements entered into with customers of the Group Members in the Ordinary Course of
Business (except to the extent such Lien was waived or subordinated to the Obligations pursuant to
the terms of the applicable Contractual Obligations or any amendment thereto);



     (o) Liens on an insurance policy and the proceeds thereof securing the financing of the
insurance premiums payable with respect to such policy; and



     (p) the title and interest of a lessor or sublessor in and to personal property leased or
subleased (other than through a Capital Lease), in each case extending only to such personal
property.



     “Default” means any Event of Default and any event that, with the passing of time or
the giving of notice or both, would become an Event of Default.



     “Designated IPO Proceeds Amount” means $19,500,000, which represents the Net Cash
Proceeds from the Holdings IPO available to fund the transactions permitted under Section
8.5(h) and Sections 8.9(j) and (k).



     “Designated Purchaser” means that Purchaser which, together with its Affiliates,
holds the greatest percentage of the outstanding principal amount of the Notes.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






16









 








     “Disclosure Documents” means, collectively, (a) all confidential
information memoranda and related materials prepared in connection with the syndication of the
Senior Credit Facilities and (b) all other documents filed by any Group Member with the United
States Securities and Exchange Commission.



     “Discounted Value” means, with respect to the Called Notes, the
amount obtained by discounting all Remaining Scheduled Payments with respect to such Called Notes
from their respective scheduled due dates to the redemption date with respect to such Called Notes
in accordance with accepted financial practice and at a discount factor (applied on the same
periodic basis as that on which interest on the Notes is payable) equal to the Reinvestment Yield
with respect to such Called Notes.



     “Dollars” and the sign “$” each
mean the lawful money of the United States of America.



     “Domestic Person” means any “United States
person” as defined in Section 7701(a)(30) of the Code.



     “E-Fax” means any system used to receive or transmit
faxes electronically.



     “E-Signature” means the process of attaching to or logically
associating with an Electronic Transmission an electronic symbol, encryption, digital signature or
process (including the name or an abbreviation of the name of the party transmitting the Electronic
Transmission) with the intent to sign, authenticate or accept such Electronic Transmission.



     “E-System” means any electronic system, including
Intralinks® and ClearPar® and any other Internet or extranet-based site, whether such
electronic system is owned, operated or hosted by the Senior Agent, any of its Related Persons or
any other Person, providing for access to data protected by passcodes or other security system.



     “Electronic Transmission” means each document, instruction,
authorization, file, information and any other communication transmitted, posted or otherwise made
or communicated by e-mail or E-Fax, or otherwise to or from an E-System or other equivalent
service.



     “Environmental Laws” means all Requirements of Law and Permits
imposing liability or standards of conduct for or relating to the regulation and protection of
human health and safety (to the extent related to Releases, Remedial Action or protection from or
exposure to Hazardous Material), the environment and natural resources, including CERCLA, the SWDA,
the Hazardous Materials Transportation Act (49 U.S.C. §§ 5101 et seq.), the Federal
Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. §§ 136 et seq.), the Toxic Substances
Control Act (15 U.S.C. §§ 2601 et seq.), the Clean Air Act (42 U.S.C. §§ 7401 et
seq.), the Federal Water Pollution Control Act (33 U.S.C. §§ 1251 et seq.), the
Occupational Safety and Health Act (29 U.S.C. §§ 651 et seq.), the Safe Drinking Water Act
(42 U.S.C. §§ 300(f) et seq.), all regulations promulgated under any of the foregoing, all
analogous Requirements of Law and Permits and any environmental transfer of ownership notification
or approval statutes, including the Industrial Site Recovery Act (N.J. Stat. Ann. §§ 13:1K-6 et
seq.).



     “Environmental Liabilities” means all Liabilities (including
costs of Remedial Actions, natural resource damages and costs and expenses of investigation and
feasibility studies) that may be imposed on, incurred by or asserted against any Group Member as a
result of, or related to,



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





17









 








any claim, suit, action, investigation, proceeding or demand by any Person, whether based in
contract, tort, implied or express warranty, strict liability, criminal or civil statute or common
law or otherwise, arising under any Environmental Law or in connection with any environmental,
health or safety condition or with any Release and resulting from the ownership, lease, sublease or
other operation or occupation of property by any Group Member, whether on, prior to or after the
date hereof.




     “ERISA” means the United States Employee Retirement Income
Security Act of 1974, as amended from time to time, and the regulations promulgated and rulings
issued thereunder.



     “ERISA Affiliate” means, collectively, any Group Member, and any
Person under common control, or treated as a single employer, with any Group Member, within the
meaning of Section 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA.



     “ERISA Event” means any of the following: (a) a reportable event
described in Section 4043 of ERISA (as to which the PBGC has not waived, under subsection .22, .23,
 .25, .27 or .28 of PBGC Regulation Section 4043, the requirement of Section 4043(a) of ERISA that
it be notified of such event) with respect to a Title IV Plan, (b) the withdrawal of any ERISA
Affiliate from a Title IV Plan subject to Section 4063 of ERISA during a plan year in which it was
a substantial employer, as defined in Section 4001(a)(2) of ERISA, (c) the complete or partial
withdrawal of any ERISA Affiliate from any Multiemployer Plan, (d) with respect to any
Multiemployer Plan, the filing of a notice of reorganization, insolvency or termination (or
treatment of a plan amendment as termination) under Section 4041A of ERISA, or the receipt by any
ERISA Affiliate of any notice, that any Multiemployer Plan is in endangered or critical status
under Section 305 of ERISA, (e) the filing of a notice of intent to terminate a Title IV Plan (or
treatment of a plan amendment as termination) under Section 4041 of ERISA, (f) the institution of
proceedings to terminate a Title IV Plan or a Multiemployer Plan by the PBGC, (g) the failure to
make any required contribution to any Title IV Plan or Multiemployer Plan when due, there being or
arising any “unpaid minimum required contribution” or “accumulated funding deficiency” (as defined
or otherwise set forth in Section 4971 of the Code or Part 3 of Subtitle B of Title 1 of ERISA)
with respect to a Multiemployer Plan or a Title IV Plan (whether or not waived), the filing of any
request for or receipt of a minimum funding waiver under Section 412 of the Code with respect to
any Benefit Plan, or that such filing may be reasonably be expected to be made, or a determination
that any Title IV Plan is, or is reasonably expected to be, in at-risk status under Title IV of
ERISA; (h) the imposition of a lien under Section 430 of the Code or Section 303 or 4068 of ERISA
on any property (or rights to property, whether real or personal) of any ERISA Affiliate, (i) the
failure of a Benefit Plan or any trust thereunder intended to qualify for tax exempt status under
Section 401 or 501 of the Code or other Requirements of Law to qualify thereunder; and (j) engaging
in a non-exempt prohibited transaction within the meaning of Section 4975 of the Code or Section
406 of ERISA; and (k) any other event or condition that might reasonably be expected to constitute
grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Title IV Plan or Multiemployer Plan or for the imposition of any liability upon any
ERISA Affiliate under Title IV of ERISA, other than for PBGC premiums due but not delinquent.



     “Event of Default” has the meaning specified in
Section 9.1.



     “Excess Availability” means, at any time, the remainder of (a)
the aggregate Revolving Credit Commitments of the lenders under the Senior Credit Agreement
less (b) the aggregate amount of the Revolving Senior Loans outstanding.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





18









 








     “Excess Cash Flow means”, for
any Person for any period,



     (a) Consolidated EBITDA of such Person;



     (b) minus, without duplication and only in each case to the extent included in
calculation of Consolidated EBITDA:




     (i) any cash principal payment on the Senior Loans during such period (but only,
in the case of payment in respect of revolving Senior Loans, to the extent that the
Revolving Credit Commitments are permanently reduced by the amount of such payment)
other than any mandatory prepayment made because of the existence of Excess Cash Flow
for a prior period;




     (ii) any scheduled cash principal payment made by such Person or any of its
Subsidiaries during such period on any Capitalized Lease Obligation or other
Indebtedness (but only, if such Indebtedness may be reborrowed, to the extent such
payment results in a permanent reduction in commitments thereof and excluding
principal payments on Indebtedness evidenced by the Notes);




     (iii) any Capital Expenditure made by such Person or any of its Subsidiaries
during such period to the extent permitted by this Agreement, excluding any such
Capital Expenditure to the extent financed through the incurrence of Capitalized Lease
Obligations or any other long-term Indebtedness (excluding the Obligations);




     (iv) the Consolidated Cash Interest Expense of such Person for such period;



      (v) any cash losses from extraordinary items;




     (vi) any cash payment made during such period to satisfy obligations for United
States federal income taxes or other taxes measured by net income;




     (vii) any increase in the Working Capital of such Person during such period
(measured as the excess of such Working Capital at the end of such period over such
Working Capital at the beginning of such period);




     (viii) consideration paid in cash with respect to the purchase price of any
Permitted Acquisition or Investment made pursuant to Section 8.3(o), except to
the extent such cash consideration is funded from the issuance of Indebtedness or
Stock of such Person or its Subsidiaries or reduces Additional Available Cash pursuant
to clause (v) of the definition thereof; provided, however, that to the extent the
A-Life Sale is consummated during such Fiscal Year, the cash consideration paid with
respect to any Permitted Acquisition or Investment made pursuant to Section 8.3(o)
that reduces Additional Available Cash pursuant to clause (v) of the definition
thereof shall, notwithstanding the foregoing, be deducted in calculating Excess Cash
Flow to the extent of any gain included in Consolidated EBITDA as a result of the
A-Life Sale;




     (ix) cash payments in respect of severance and restructuring costs related to the
Acquisition and the integration of the Acquired Business as set forth in reasonable
detail in any such applicable Compliance Certificate in an aggregate amount not to
exceed $5,500,000,



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY




19









 






     (x) cash payments of fees and expenses related to the Related Transactions and
paid prior to the end of the Fiscal Year ending December 31, 2011 as set forth in
reasonable detail in any such applicable Compliance Certificate in an aggregate amount not
to exceed $14,000,000;




     (xi) to the extent added back in calculating Consolidated EBITDA pursuant to clause
(b)(x) of the definition thereof, any unusual or non-recurring cash losses, cash charges or
cash expenses, including severance and restructuring costs, related to Permitted
Acquisitions or Permitted Indebtedness (regardless of when paid) or equity issuances of
Stock or Stock Equivalents permitted hereunder (excluding any equity issuances in
connection with the Exchange Offer or the Holdings IPO) as set forth in reasonable detail
in any such applicable Compliance Certificate; and




     (xii) to the extent added back in calculating Consolidated EBITDA pursuant to clause
(b)(xi) of the definition thereof, costs of legal proceedings and settlements with respect
to those matters disclosed in Item 3 of MedQuist s Annual Report on Form 10-K as of
December 31, 2009 filed on March 12, 2010 in an aggregate amount not to exceed $5,000,000;



     (c) plus, without duplication,




     (i) to the extent included in the calculation of Consolidated EBITDA pursuant to
clause (b)(i) of the definition thereof, any provision for United States federal income
taxes or other taxes measured by net income;




     (ii) to the extent the calculation of Excess Cash Flow is based on the Consolidated
EBITDA of MedQuist rather than Holdings, the total amount of cash payments made by MedQuist
or its Subsidiaries to Holdings or its Subsidiaries (other than MedQuist and its
Subsidiaries) in excess of (x) payments required to be made under the CBay Transcription
Agreements and (y) up to $2,000,000 of payments made pursuant to the CBay Management
Agreement;




     (iii) any decrease in the Working Capital of such Person during such period (measured
as the excess of such Working Capital at the beginning of such period over such Working
Capital at the end thereof).



     “Exchange Offer” means one or more transactions in which shareholders of MedQuist
other than CBay exchange their Stock of MedQuist for shares of common stock of Holdings, cash or a
combination of such shares and cash.



     “Excluded Foreign Subsidiary” means any Subsidiary that is not a Domestic Person
unless (i) such Subsidiary has granted a Lien on any of its property as collateral for, or incurred
any Guaranty Obligations with respect to, any Indebtedness of any Note Party (other than
Obligations) or (ii) more than 65% of the Voting Stock of such Subsidiary has been pledged as
collateral for any such Indebtedness.



     “Excluded Taxes” has the meaning specified in Section 2.17.



     “Existing Agent” means General Electric Capital Corporation, in its capacity as
administrative agent under the Existing Credit Agreement.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY




20









 





     “Existing Credit Agreement” means that certain Credit Agreement, dated
as of April 22, 2010, among MedQuist, MedQuist Transcriptions, the institutions party thereto as
lenders and issuers and the Existing Agent.



     “Existing Subordinated Note” means that certain Subordinated
Promissory Note, dated July 30, 2010, in the amount of $17,500,000 issued by MedQuist
Transcriptions to Black Horse Capital LP, Black Horse Capital (QP) LP, and Black Horse Capital
Master Fund Ltd.



     “Federal Flood Insurance” means Federally backed Flood Insurance
available under the National Flood Insurance Program to owners of real property improvements
located in Special Flood Hazard Areas in a community participating in the National Flood Insurance
Program.



     “FEMA” means the Federal Emergency Management Agency, a component
of the U.S. Department of Homeland Security that administers the National Flood Insurance Program.



     “Financial Statement” means each financial statement delivered
pursuant to Section 4.4 or 6.1.



     “Fiscal Quarter” means each three (3) fiscal month period ending
on March 31, June 30, September 30 or December 31.



     “Fiscal Year” means each twelve fiscal month period
ending on December 31.



     “Flood Insurance” means, for any real property located in a
Special Flood Hazard Area, Federal Flood Insurance or private insurance that meets the requirements
set forth by FEMA in its Mandatory Purchase of Flood Insurance Guidelines. Flood Insurance shall be
in an amount equal to the full, unpaid balance of the Notes and any prior liens on the real
property up to the maximum policy limits set under the National Flood Insurance Program, or as
otherwise required by the Senior Agent, with deductibles not to exceed $50,000.



     “Funding Date” means the date on which the Issuers sell and the
initial Purchasers purchase the Notes pursuant to this Agreement.



     “GAAP” means generally accepted accounting principles in the
United States of America, as in effect from time to time, set forth in the opinions and
pronouncements of the Accounting Principles Board and the American Institute of Certified Public
Accountants, in the statements and pronouncements of the Financial Accounting Standards Board and
in such other statements by such other entity as may be in general use by significant segments of
the accounting profession that are applicable to the circumstances as of the date of determination.
Subject to Section 1.3, all references to GAAP shall be to GAAP applied consistently with the
principles used in the preparation of the Financial Statements described in Section 4.4(a).



     “Governmental Authority” means any nation, sovereign or
government, any state or other political subdivision thereof, any agency, authority or
instrumentality thereof and any entity or authority exercising executive, legislative, taxing,
judicial, regulatory or administrative functions of or pertaining to government, including any
central bank, stock exchange, regulatory body, arbitrator, public sector entity, supra-national
entity (including the European Union and the European Central Bank) and any self-regulatory
organization (including the National Association of Insurance Commissioners).



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





21









 








     “Governmental Payor Programs” means all governmental third party
payor programs in which any Group Member participates, including, without limitation, Medicare,
Medicaid, TRICARE or any other federal or state health care programs.



     “Group Members” means, collectively, Holdings and its
Subsidiaries.



     “Group Members’ Accountants” means KPMG LLP or other
nationally-recognized independent registered certified public accountants reasonably acceptable to
the Required Purchasers.



     “Guarantor(s)” has the meaning specified in the recitals.



     “Guaranty Agreement” means that certain Guaranty Agreement dated
as of the date hereof, among the Purchasers, the Issuers and the Guarantors from time to time party
thereto.



     “Guaranty Obligation” means, as applied to any Person, any direct
or indirect liability, contingent or otherwise, of such Person for any Indebtedness, lease,
dividend or other obligation (the primary obligation) of another Person (the primary
obligor), if the purpose or intent of such Person in incurring such liability, or the economic
effect thereof, is to guarantee such primary obligation or provide support, assurance or comfort to
the holder of such primary obligation or to protect or indemnify such holder against loss with
respect to such primary obligation, including (a) the direct or indirect guaranty, endorsement
(other than for collection or deposit in the Ordinary Course of Business), co-making, discounting
with recourse or sale with recourse by such Person of any primary obligation, (b) the existence of
any Lien, or any right, contingent or otherwise, to receive a Lien, on the property of such Person
securing any part of any primary obligation and (c) any liability of such Person for a primary
obligation through any Contractual Obligation (contingent or otherwise) or other arrangement (i) to
purchase, repurchase or otherwise acquire such primary obligation or any security therefor or to
provide funds for the payment or discharge of such primary obligation (whether in the form of a
loan, advance, stock purchase, capital contribution or otherwise), (ii) to maintain the solvency,
working capital, equity capital or any balance sheet item, level of income or cash flow, liquidity
or financial condition of any primary obligor, (iii) to make take-or-pay or similar payments, if
required, regardless of non-performance by any other party to any Contractual Obligation, (iv) to
purchase, sell or lease (as lessor or lessee) any property, or to purchase or sell services,
primarily for the purpose of enabling the primary obligor to satisfy such primary obligation or to
protect the holder of such primary obligation against loss or (v) to supply funds to or in any
other manner invest in, such primary obligor (including to pay for property or services
irrespective of whether such property is received or such services are rendered); provided,
however, that “Guaranty Obligations” shall not include (x)
endorsements for collection or deposit in the Ordinary Course of Business and (y) product
warranties given in the Ordinary Course of Business. The outstanding amount of any Guaranty
Obligation shall equal the outstanding amount of the primary obligation so guaranteed or otherwise
supported or, if lower, the stated maximum amount for which such Person may be liable under such
Guaranty Obligation.



     “Hazardous Material” means any substance, material or waste that
is classified, regulated or otherwise characterized under any Environmental Law as hazardous,
toxic, a contaminant or a pollutant or by other words of similar meaning or regulatory effect,
including petroleum or any fraction thereof, asbestos, polychlorinated biphenyls and radioactive
substances.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






22









 








     “Health Care Laws” means, collectively, any and all federal,
state or local laws, rules, regulations, manuals, orders, ordinances, statutes, guidelines and
requirements issued with respect to regulatory matters relating to the provision, administration,
and/or payment for healthcare products or services, including, without limitation, to the extent
applicable, rules and regulations governing the operation and administration of Medicare, Medicaid
or any other Government Payor Program, HIPAA, any and all federal, state and local fraud and abuse
laws of any Governmental Authority, including, without limitation, the federal Anti-Kickback
Statute (42 U.S.C. § 1320a-7(b)), the Stark Law (42 U.S.C. § 1395nn and § 1395(q)), the civil False
Claims Act (31 U.S.C. § 3729 et seq.), and rules and regulations of the U.S. Food and Drug
Administration, as the same may be amended, modified or supplemented from time to time, and any
successor statute thereto.



     “Hedging Agreement” means any Interest Rate Contract, foreign
exchange, swap, option or forward contract, spot, cap, floor or collar transaction, any other
derivative instrument and any other similar transaction and any other similar agreement or
arrangement designed to alter the risks of any Person arising from fluctuations in any underlying
variable.



     “HIPAA” means the Health Insurance Portability and Accountability
Act of 1996, as the same may be amended, modified or supplemented from time to time, any successor
statute thereto, any and all rules or regulations promulgated from time to time thereunder, and any
comparable state laws.



     “HIPAA Compliance Plan” has the meaning specified in
Section 4.23.



     “Holding Company” means any Person that (i) is an Affiliate of a
Permitted Investor, (ii) is a direct or indirect holder of Stock of Holdings and (iii) owns no
substantial assets other than such Stock.



     “Holdings” has the meaning specified in the preamble.



     “Holdings IPO” means one or more sales by Holdings of its Stock
after the Closing Date pursuant to one or more underwritten public offerings pursuant to an
effective registration statement filed with the Securities and Exchange Commission pursuant to the
Securities Act of 1933, provided that the Net Cash Proceeds of the first such offering are at least
equal to the Designated IPO Proceeds Amount.



     “Indebtedness” of any Person means, without duplication, any of
the following, whether or not matured: (a) all indebtedness for borrowed money, (b) all obligations
evidenced by notes, bonds, debentures or similar instruments, (c) all reimbursement and other
obligations with respect to (i) letters of credit, bank guarantees or bankers acceptances or (ii)
surety, customs, reclamation or performance bonds (in each case not related to judgments or
litigation) other than those entered into in the Ordinary Course of Business, (d) all obligations
to pay the deferred purchase price of property or services, other than trade payables incurred in
the Ordinary Course of Business, (e) all obligations created or arising under any conditional sale
or other title retention agreement, regardless of whether the rights and remedies of the seller or
lender under such agreement in the event of default are limited to repossession or sale of such
property, (f) all Capitalized Lease Obligations, (g) all obligations, whether or not contingent, to
purchase, redeem, retire, defease or otherwise acquire for value any of its own Stock or Stock
Equivalents (or any Stock or Stock Equivalent of a direct or indirect parent entity thereof) prior
to the date that is 180 days after October 15, 2016, valued at, in the case of redeemable preferred
Stock, the greater of



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






23









 








the voluntary liquidation preference and the involuntary liquidation preference of such Stock
plus accrued and unpaid dividends, (h) all net payments that would be required to be made in
respect of any Hedging Agreement in the event of a termination (including an early termination) on
the date of determination and (i) all Guaranty Obligations for obligations of any other Person
constituting Indebtedness of such other Person; provided, however, that the items
in each of clauses (a) through (i) above shall constitute
“Indebtedness” of such Person solely to the extent (x) such Person is
liable for such item or (y) any such item is secured by a Lien on such Person s property.




     “Indemnified Matters” has the
meaning specified in Section 11.4.



     “Indemnitee” has the meaning
specified in Section 11.4.



     “Initial Projections” means those financial projections covering
the Fiscal Years ending in 2010 through 2015 and delivered to the Purchasers by the Issuer
Representative on August 22, 2010.



     “Intellectual Property” means all rights, title and interests in
or relating to intellectual property and industrial property arising under any Requirement of Law
and all IP Ancillary Rights relating thereto, including all Copyrights, Patents, Trademarks,
Internet Domain Names, Trade Secrets and IP Licenses.



     “Interest Payment Date” has the meaning specified in
Section 2.7(a).



     “Interest Rate Contracts” means all interest rate swap
agreements, interest rate cap agreements, interest rate collar agreements and interest rate
insurance.



     “Internet Domain Names” means all rights, title and interests
(and all related IP Ancillary Rights) arising under any Requirement of Law in or relating to
Internet domain names.



     “Investment” means, with respect to any Person, (a) to own,
purchase or otherwise acquire, in each case whether beneficially or otherwise, any investment in,
including any interest in, any Security of any other Person (other than any evidence of any
Obligation), (b) to purchase or otherwise acquire, whether in one transaction or in a series of
transactions, all or a significant part of the property of any other Person or a business conducted
by any other Person or all or substantially all of the assets constituting the business of a
division, branch, brand or other unit operation of any other Person, (c) to incur, or to remain
liable under, any Guaranty Obligation for Indebtedness of any other Person, to assume the
Indebtedness of any other Person or to make, hold, purchase or otherwise acquire any deposit, loan,
advance, commitment to lend or advance, or other extension of credit, excluding deposits with
financial institutions available for withdrawal on demand, prepaid expenses, accounts receivable
and similar items created in the Ordinary Course of Business or (d) to make any contribution to the
capital of any other Person; provided, however, that for purposes of Section
8.3(e) and 8.4(b), (i) any purchase of any property by any Person for more than fair
market value shall constitute an Investment in the seller of such property by such Person to the
extent of such excess over such fair market value and (ii) any Sale of any property by any Person
for less than fair market value shall constitute an Investment in the purchaser of such property by
such Person to the extent of such deficiency below such fair market value.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





24









 








     “IP Ancillary Rights” means, with respect to any other
Intellectual Property, as applicable, all foreign counterparts to, and all divisionals, reversions,
continuations, continuations-in-part, reissues, reexaminations, renewals and extensions of, such
Intellectual Property and all income, royalties, proceeds and Liabilities at any time due or
payable or asserted under or with respect to any of the foregoing or otherwise with respect to such
Intellectual Property, including all rights to sue or recover at law or in equity for any past,
present or future infringement, misappropriation, dilution, violation or other impairment thereof,
and, in each case, all rights to obtain any other IP Ancillary Right.



     “IP License” means all Contractual Obligations (and all related
IP Ancillary Rights), whether written or oral, granting any right title and interest in or relating
to any Intellectual Property.



     “IRS” means the Internal Revenue Service of the United
States and any successor thereto. “Issuer” has the meaning set forth in the preamble.



     “Issuer Representative” has the meaning specified in
Section 2.19.



     “Junior Subordinated Debt” means any Indebtedness that is
subordinated to the payment in full of the Obligations on terms and conditions satisfactory to the
Required Purchasers.



     “Lehman” means Lehman Brothers Commercial Corporation
Asia.



     “Letter of Credit” means any letter of credit Issued pursuant to
the Senior Credit Agreement.



     “Liabilities” means all claims, actions, suits, judgments,
damages, losses, liability, obligations, responsibilities, fines, penalties, sanctions, costs,
fees, Taxes, commissions, charges, disbursements and expenses, in each case of any kind or nature
(including interest accrued thereon or as a result thereto and fees, charges and disbursements of
financial, legal and other advisors and consultants), whether joint or several, whether or not
indirect, contingent, consequential, actual, punitive, treble or otherwise.



     “Lien” means any mortgage, deed of trust, pledge, hypothecation,
collateral assignment, charge, encumbrance, easement, lien (statutory or other), or preference,
priority or other security interest or preferential arrangement in the nature of a lien, including
any conditional sale contract or other title retention agreement, any assignment of any right to
receive income or profits, the interest of a lessor under a Capital Lease and any synthetic or
other financing lease having substantially the same economic effect as any of the foregoing (but
not the interest of a lessor under an operating lease).



     “Liquidity” means Excess Availability plus cash and Cash
Equivalents of Holdings and its Subsidiaries.



     “Make-Whole Amount” means an amount equal to the excess, if any,
of the Discounted Value of the Remaining Scheduled Payments with respect to the Called Notes over
such Called Notes; provided that the Make-Whole Amount may in no event be less than zero.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





25









 








     “Material Adverse Effect” means (a) a material adverse change in
the financial condition, business, operations or property of the Group Members, taken as a whole,
(b) material impairment of the ability of the Note Parties (taken as a whole) to perform in any
material respect their obligations under the Note Documents and (c) a material adverse effect upon
the validity or enforceability of the Agreement, Guaranty Agreement or the other Note Documents
taken as a whole or the rights and remedies of the Purchasers under the Note Documents.



     “Material Agreement” means the agreements between (i) any Group
Member and Multimodal Technologies, Inc., and (ii) MedQuist Inc. or any of its Subsidiaries and
Nuance Communications, Inc., together with any amendments, modifications and replacements of any
such Material Agreements permitted hereby; provided, however, that Material Agreements
shall not include that certain Dictaphone Corporation Maintenance Plan, dated on or about May 18,
2004, between HealthScribe, Inc. and Dictaphone Corporation.



     “Maturity Date” means October 15, 2016.



     “Maximum Accrual” has the meaning
specified in Section 2.8.



     “Maximum Lawful Rate” has the meaning
specified in Section 2.7(c).



     “Maximum Senior Principal Amount” has the meaning set forth in
the Subordination Agreement.



     “Medicaid” means, collectively, the health care assistance
program established by Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) and
any statutes succeeding thereto, and all laws, rules, regulations, manuals, orders, or requirements
pertaining to such program, including (a) all federal statutes affecting such program; (b) all
state statutes and plans for medical assistance enacted in connection with such program and federal
rules and regulations promulgated in connection with such program; and (c) all applicable
provisions of all rules, regulations, manuals, orders and administrative, reimbursement, and
requirements of all government authorities promulgated in connection with such program (whether or
not having the force of law), in each case as the same may be amended, supplemented or otherwise
modified from time to time.



     “Medicare” means, collectively, the health insurance program for
the aged and disabled established by Title XVIII of the Social Security Act (42 U.S.C. 1395 et
seq.) and any statutes succeeding thereto, and all laws, rules, regulations, manuals, or orders
pertaining to such program including (a) all federal statutes (whether set forth in Title XVIII of
the Social Security Act or elsewhere) affecting such program; and (b) all applicable provisions of
all rules, regulations, manuals, orders and administrative, reimbursement and requirements of all
governmental authorities promulgated in connection with such program (whether or not having the
force of law), in each case as the same may be amended, supplemented or otherwise modified from
time to time.



     “MedQuist” has the meaning specified in the preamble.



     “MedQuist Consolidation Date” means the earlier of (a) December
31, 2013 or (b) the date upon which Holdings owns, directly or indirectly, 100% of the Stock of
MedQuist.



     “MedQuist Transcriptions” has the meaning specified in
the preamble.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





26









 








     “Moody’s” means Moody’ s Investors Service, Inc.



     “Multiemployer Plan” means any multiemployer plan, as defined in Section 4001(a)(3)
of ERISA, to which any ERISA Affiliate incurs or otherwise has any obligation or liability,
contingent or otherwise.



     “National Flood Insurance Program” means the program created by the U.S. Congress
pursuant to the National Flood Insurance Act of 1968 and the Flood Disaster Protection Act of 1973,
as revised by the National Flood Insurance Reform Act of 1994, that mandates the purchase of flood
insurance to cover real property improvements located in Special Flood Hazard Areas in
participating communities and provides protection to property owners through a Federal insurance
program.



     “Net Cash Proceeds” means proceeds received in cash, checks or other cash equivalent
financial instruments (including Cash Equivalents) from (a) any Sale of, or Property Loss Event
with respect to, property, net of (i) the customary out-of-pocket cash costs, fees and expenses
paid or required to be paid in connection therewith, (ii) taxes paid or reasonably estimated to be
payable as a result thereof, (iii) any amount required to be paid or prepaid on Indebtedness (other
than the Obligations and Indebtedness owing to any Group Member) secured by the property subject
thereto and (iv) any applicable amounts required to be held in escrow until such time as such
amounts are released from escrow, whereupon such amounts shall be considered Net Cash Proceeds or
(b) any sale or issuance of Stock or incurrence of Indebtedness, in each case net of brokers’ ,
advisors’ and investment banking fees and other customary out-of-pocket underwriting discounts,
commissions and other customary out-of-pocket cash costs, fees and expenses (including costs and
expenses of legal counsel), in each case incurred in connection with such transaction;
provided, however, that any such proceeds received by any Group Member that is not
a Wholly Owned Subsidiary of Holdings shall constitute “Net Cash Proceeds” only to the
extent of the aggregate direct and indirect beneficial ownership interest of Holdings therein.



     “Non-Excluded Taxes” has the meaning specified in Section 2.17.



     “Non-U.S. Purchaser Party” means each Purchaser, in each case that is not a Domestic
Person.



     “Note” means a promissory note issued jointly and severally by the Issuers, in
substantially the form of Exhibit B, payable to the order of a Purchaser in a principal amount
equal to the amount of such Purchaser’ s Commitment.



     “Note Documents” means, collectively, this Agreement, any Notes when issued, the
Guaranty Agreement, the Subordination Agreement, and, when executed, each document executed by a
Note Party and delivered to the Purchasers in connection with or pursuant to any of the foregoing
or the Obligations, together with any modification of any term, or any waiver with respect to, any
of the foregoing.



     “Note Party” means each Issuer and each Guarantor.



     “Obligations” means, with respect to any Note Party, all amounts, obligations,
liabilities, covenants and duties of every type and description owing by such Note Party arising
out of, under or in connection with any Note Document, (regardless of whether acquired by
assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing
or hereafter



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





27









 








arising and however acquired, and whether or not evidenced by any instrument or for the
payment of money, including, without duplication, (a) if such Note Party is an Issuer, all Notes,
(b) all interest, whether or not accruing after the filing of any petition in bankruptcy or after
the commencement of any insolvency, reorganization or similar proceeding, and whether or not a
claim for post-filing or post-petition interest is allowed in any such proceeding, and (c) all
other fees, expenses (including fees, charges and disbursement of counsel), interest, commissions,
charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums to the
extent chargeable to such Note Party under any Note Document.




     “Ordinary Course of Business” means, in respect of any
transaction involving any Group Member, the ordinary course of such Person’s business, as
undertaken by such Person in good faith.



     “Other Taxes” has the meaning
specified in Section 2.17(c).



     “Participant Register” has the
meaning specified in Section 11.2(f).



     “Patents” means all rights, title and interests (and all related
IP Ancillary Rights) arising under any Requirement of Law in or relating to letters patent and
applications therefor.



     “Patriot Act” has the meaning specified in Section
11.21.



     “PBGC” means the United States Pension Benefit Guaranty
Corporation and any successor thereto.



     “Pennant” has the meaning set forth in the preamble.



     “Permit” means, with respect to any Person, any permit, approval,
authorization, license, registration, certificate, concession, grant, franchise, variance or
permission from, and any other Contractual Obligations with, any Governmental Authority, in each
case whether or not having the force of law and applicable to or binding upon such Person or any of
its property or to which such Person or any of its property is subject.



     “Permitted Acquisition” means any Proposed Acquisition satisfying
each of the following conditions: (a) the aggregate amounts payable in connection with, and other
consideration for (in each case, including all transaction costs and all Indebtedness, liabilities
and Guaranty Obligations incurred or assumed in connection therewith or otherwise reflected in a
Consolidated balance sheet of Holdings and the Proposed Acquisition Target), such Proposed
Acquisition and all other Permitted Acquisitions consummated on or prior to the date of the
consummation of such Proposed Acquisition shall not exceed (i) $25,000,000 in the aggregate in any
Fiscal Year or $75,000,000 in the aggregate during the term of this Agreement plus (ii) Additional
Available Cash as of the date of consummation of such Proposed Acquisition plus (iii) $50,000,000
in the aggregate during the term of this Agreement in the form of shares of common stock of
Holdings issued in connection with such Proposed Acquisition, (b) the Purchasers shall have
received reasonable advance notice of such Proposed Acquisition including a reasonably detailed
description thereof at least 15 days prior to the consummation of such Proposed Acquisition (or
such later date as may be agreed by the Required Purchasers) and on or prior to the date of such
Proposed Acquisition, the Purchasers shall have received copies of the acquisition agreement and
related Contractual Obligations and other documents (including financial information and analysis,
environmental assessments and reports, opinions, certificates and lien searches) and



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





28









 








information reasonably requested by the Required Purchasers, (c) as of the date of
consummation of such Proposed Acquisition and after giving effect to all transactions to occur on
such date as part of such Proposed Acquisition, (1) all conditions set forth in clauses (i)
and (ii) of Section 3.1(f) shall be satisfied or duly waived, (2) Holdings shall, on a Pro
Forma Basis as of the last day of the last Fiscal Quarter for which Financial Statements have been
delivered hereunder, have a Consolidated Total Leverage Ratio and Consolidated Senior Leverage
Ratio which are at least 0.25:1.00 less than the required thresholds set forth in Sections
5.1 and 5.2 as of such date, as applicable, and (3) Holdings shall have Liquidity of at
least $20,000,000 and (d) such Proposed Acquisition is consummated no earlier than December 31,
2010.




     “Permitted Indebtedness” means any Indebtedness of any Group Member that is permitted
in Section 8.1.



     “Permitted Investment” means any Investment of any Group Member that is permitted in
Section 8.3.



     “Permitted Investors” means, collectively, Sponsor, and any limited partners,
operating partners or Affiliates of any of the foregoing.



     “Permitted Lien” means any Lien on or with respect to the property of any Group
Member that is permitted in Section 8.2.



     “Permitted Refinancing” means Indebtedness constituting a refinancing or extension of
Permitted Indebtedness that (a) has an aggregate outstanding principal amount not greater than the
aggregate principal amount of such Permitted Indebtedness outstanding at the time of such
refinancing or extension, (b) has a weighted average maturity (measured as of the date of such
refinancing or extension) and maturity no shorter than that of such Permitted Indebtedness, (c) is
not entered into as part of a Sale and Leaseback transaction, (d) is not secured by any property or
any Lien other than those securing such Permitted Indebtedness and (e) is otherwise on terms (other
than market based interest rates, discounts and fees at the time of refinancing) no less favorable
to the Group Members, taken as a whole, than those of such Permitted Indebtedness;
provided, however, that, notwithstanding the foregoing, (x) the terms of such
Permitted Indebtedness may be modified as part of such Permitted Refinancing if such modification
would have been permitted pursuant to Section 8.11 and (y) no Guaranty Obligation for such
Indebtedness shall constitute part of such Permitted Refinancing unless similar Guaranty
Obligations with respect to such Permitted Indebtedness existed and constituted Permitted
Indebtedness prior to such refinancing or extension.



     “Permitted Reinvestment” means, with respect to the Net Cash Proceeds of any Sale or
Property Loss Event, to acquire (or make Capital Expenditures to finance the acquisition, repair,
improvement or construction of), to the extent otherwise permitted hereunder, property useful in
the business of the Group Members, as determined in good faith by the Issuers (including through a
Permitted Acquisition) or, if such Property Loss Event involves loss or damage to property, to
repair such loss or damage.



     “Person” means any individual, partnership, corporation (including a business trust
and a public benefit corporation), joint stock company, estate, association, firm, enterprise,
trust, limited liability company, unincorporated association, joint venture and any other entity or
Governmental Authority.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





29











 





     “PIK Interest” has the meaning specified in Section 2.7(a).



     “ PIK Rate” has the meaning specified in Section 2.7(a).



     “Pro Forma Balance Sheet” has the meaning specified in Section 4.4(d).



     “Pro Forma Basis” means, with respect to any determination for any period and any Pro Forma
Transaction, that such determination shall be made by giving pro forma effect to each such Pro
Forma Transaction, as if each such Pro Forma Transaction had been consummated on the first day of
such period, based on historical results accounted for in accordance with GAAP and, to the extent
applicable, reasonable assumptions that are specified in reasonable detail in the relevant
Compliance Certificate, Financial Statement or other document provided to the Purchasers in
connection herewith in accordance with Regulation S-X of the Securities Act of 1933; provided that
non-Regulation S-X adjustments approved by the Designated Purchaser in writing may also be made to
reflect operating expense reductions and other operating improvements or synergies or cost savings
reasonably expected to result from such Pro Forma Transaction, which adjustments are reasonably
anticipated by the Issuers to be realizable in connection with such Pro Forma Transaction and are
estimated on a good faith basis by the Issuers.



     “Pro Forma Transaction” means any transaction consummated as part of any Permitted Acquisition
or any Sale of Property permitted under Sections 8.4(k) or (l), together with each other
transaction relating thereto and consummated in connection therewith, including any incurrence or
repayment of Indebtedness.



     “Projections” means, collectively, the Initial Projections and the projections delivered
pursuant to Section 6.1(f).



     “Property” means any interest in any kind of property or asset, whether real, personal or
mixed, and whether tangible or intangible.



     “Property Loss Event” means, with respect to any property, any loss of or damage to such
property or any taking of such property or condemnation thereof.



     “ Proposed Acquisition” means (a) any proposed acquisition of all or substantially all of the
assets or Stock of any Proposed Acquisition Target by any Issuer or any Subsidiary of an Issuer
that is consensual and approved by the board of directors of such Proposed Acquisition Target or
the Person that owns such Proposed Acquisition Target, or (b) any proposed merger of any Proposed
Acquisition Target with or into any Issuer or any Subsidiary of an Issuer (and, in the case of a
merger with an Issuer or Holdings, with such Issuer or Holdings being the surviving corporation).



     “Proposed Acquisition Target” means any Person or any brand, line of business, division,
branch, operating division or other unit operation of any Person.



     “Pro Rata Outstanding”, of any Purchaser at any time, means the outstanding principal amount of
the Notes owing to such Purchaser.



     “Pro Rata Share” means, with respect to any Purchaser, the percentage obtained by dividing (a)
the outstanding principal amount of the Notes held by such Purchaser by (b) the aggregate
outstanding principal amount of the Notes held by all Purchasers.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







30









 








     “Purchase Price” has the meaning specified in Section 2.2.



     “Purchaser(s)” has the meaning set forth in the preamble.



     “RCM Sale” means a Sale of the revenue cycle management services Subsidiary which was disclosed
to the Administrative Agent on or before the Closing Date.



     “Recapitalization Dividend” means a dividend or distribution paid by MedQuist to the holders of
its outstanding shares of Stock in the aggregate amount of up to $177,000,000, allocated ratably to
such shareholders.



     “Redemption Offer” has the meaning specified in Section 2.6(c).



     “Redemption Price” has the meaning specified in Section 2.6(b).



     “Reinvestment Yield” means, with respect to the Called Notes, 0.50% over the yield to maturity
implied by (a) the yields reported, as of 10:00 A.M. (New York City time) on the second Business
Day preceding the redemption date with respect to such Called Notes, on display designated as Page
“PX1” on the Bloomberg Financial Market Service (or such other display as may replace Page PX1 on
the Bloomberg Financial Market Service) for actively traded U.S. Treasury securities having a
maturity equal to the Remaining Average Life of such Called Notes as of such redemption date, or
(b) if such yields are not reported as of such time or the yields reported as of such time are not
ascertainable (including by way of interpolation), the Treasury Constant Maturity Series Yields
reported, for the last day for which such yields have been so reported as of the second Business
Day preceding the redemption date with respect to such Called Notes, in Federal Reserve Statistical
Release H.15 (519) (or any comparable successor publication) for actively traded U.S. Treasury
securities having a constant maturity equal to the Remaining Average Life of such Called Notes as
of such redemption date. Such implied yield will be determined, if necessary, by (i) converting
U.S. Treasury bill quotations to bond-equivalent yields in accordance with accepted financial
practice and (ii) interpolating lineary between (1) the actively traded U.S. Treasury security with
the published maturity closest to and greater than the Remaining Average Life and (2) the actively
traded U.S. Treasury security with the published maturity closes to and less than the Remaining
Average Life.



     “Register” has the meaning specified in Section 2.12(b).



     “Related Documents” means, collectively, the Senior Loan Documents and each other document
executed with respect thereto or with respect to any Related Transaction.



     “Related Person” means, with respect to any Person, each Affiliate of such Person and each
director, officer, employee, agent, trustee, representative, attorney, accountant and each
insurance, environmental, legal, financial and other advisor (including those retained in
connection with the satisfaction or attempted satisfaction of any condition set forth in Article 3)
of or to such Person or any of its Affiliates.



     “Related Transactions” means, collectively, the funding of the initial Senior Loans and Letters
of Credit pursuant to the Senior Loan Documents and the application of the proceeds thereof in
accordance with Section 7.9 of the Senior Credit Agreement, the payment of the Recapitalization
Dividend, the issuance of the Notes on the Funding Date, the refinancing of the



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





31









 







Existing Credit Agreement and Existing Subordinated Note, the execution and delivery of all Related
Documents and the payment of all related fees, costs and expenses.




     “Release” means any release, threatened release, spill, emission, leaking, pumping, pouring,
emitting, emptying, escape, injection, deposit, disposal, discharge, dispersal, dumping, leaching
or migration of Hazardous Material into or through the environment.



     “Remaining Average Life” means, with respect to any Called Notes, the number of years
(calculated to the nearest one-twelfth year) obtained by dividing (a) such Called Notes into (b)
the sum of the products obtained by multiplying (i) the principal component of each Remaining
Scheduled Payment with respect to such Called Notes by (ii) the number of years (calculated to the
nearest one-twelfth year) that will elapse between the redemption date with respect to such Called
Notes and the scheduled due date of such Remaining Scheduled Payment.



     “Remaining Scheduled Payments” means, all principal payments with respect to the Called Notes
and interest thereon that would be payable in cash at the Cash Rate and due after the redemption
date with respect to such Called Notes if no redemption of such Called Notes were made prior to its
scheduled due date.



     “Remedial Action” means all actions required to (a) clean up, remove, treat or in any other way
address any Hazardous Material in the indoor or outdoor environment, (b) prevent or minimize any
Release so that a Hazardous Material does not migrate or endanger or threaten to endanger public
health or welfare or the indoor or outdoor environment or (c) perform pre-remedial studies and
investigations and post-remedial monitoring and care with respect to any Hazardous Material.



     “Required Purchasers” means, at any time, Purchasers having at such time in excess of 50% of
the sum of the aggregate principal amount of Notes then outstanding.



     “Requirements of Law” means, with respect to any Person, collectively, the laws (statutory or
common), treaties, rules and regulations, ordinances, orders, other legal requirements of any
Governmental Authority, in each case that are applicable to or binding upon such Person or any of
its property or to which such Person or any of its property is subject, including without
limitation all Healthcare Laws.



     “Responsible Officer” means, with respect to any Person, any of the president, chief executive
officer, treasurer, assistant treasurer, controller, managing member or general partner of such
Person but, in any event, with respect to financial matters, any such officer that is responsible
for preparing the Financial Statements delivered hereunder and, with respect to the Corporate Chart
and other documents delivered pursuant to Section 6.1(e), documents delivered on the Closing Date
and documents delivered pursuant to Section 7.10, the secretary or assistant secretary of such
Person or any other officer responsible for maintaining the corporate and similar records of such
Person.



     “Restricted Payment” means (a) any dividend or other distribution, whether in cash, Securities
or other property, on account of any Stock or Stock Equivalent of any Group Member, in each case
now or hereafter outstanding, and (b) any redemption, retirement, termination, defeasance,
cancellation, purchase or other acquisition for value of any Stock or Stock Equivalent of any Group
Member, now or hereafter outstanding, and any payment or other transfer setting



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






32









 







aside funds for any such redemption, retirement, termination, cancellation, purchase or other
acquisition, and whether to a sinking fund, a similar fund or otherwise.




     “Revolving Credit Commitments” means, with respect to each Senior Lender, the commitment of
such Senior Lender to make Revolving Senior Loans and acquire interests in other outstanding
revolving credit, pursuant to and in accordance with the Senior Credit Agreement.



     “Revolving Senior Loans” means revolving loans made by the Senior Lenders to the Issuers
pursuant to the Senior Credit Agreement.



     “ S&P” means Standard & Poor’s Rating Services.



     “Sale and Leaseback Transaction” means, with respect to any Person (the “obligor”), any
Contractual Obligation or other arrangement with any other Person (the “counterparty”) consisting
of a lease by such obligor of any property that, directly or indirectly, has been or is to be Sold
by the obligor to such counterparty or to any other Person to whom funds have been advanced by such
counterparty based on a Lien on, or an assignment of, such property or any obligations of such
obligor under such lease.



     “Security” means all Stock, Stock Equivalents, voting trust certificates, bonds, debentures,
instruments and other evidence of Indebtedness, whether or not secured, convertible or
subordinated, all certificates of interest, share or participations in, all certificates for the
acquisition of, and all warrants, options and other rights to acquire, any Security.



     “Sell” means, with respect to any property, to sell, convey, transfer, assign, license, lease
or otherwise dispose of, any interest therein or to permit any Person to acquire any such interest,
including, in each case, through a Sale and Leaseback Transaction or through a sale, factoring at
maturity, collection of or other disposal, with or without recourse, of any notes or accounts
receivable. Conjugated forms thereof and the noun “Sale” have correlative meanings.



     “Senior Agent” means the “Administrative Agent” as defined in the Senior Credit Agreement.



     “Senior Credit Agreement” means that certain Credit Agreement, dated as of October 1, 2010, by
and between the Note Parties, the Senior Agent and the Senior Lenders, as amended, restated,
supplemented, refinanced, replaced or otherwise modified from time to time in accordance with the
Subordination Agreement.



     “Senior Credit Facilities” means the “Facilities” as defined in the Senior Credit Agreement.



     “Senior Lenders” means the “Lenders” as defined in the Senior Credit Agreement.



     “Senior Loans” means “Loans” as defined in the Senior Credit Agreement.



     “Senior Loan Documents” means the Loan Documents as defined in the Senior Credit Agreement.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







33









 








     “Senior Loan Obligations” means the “Obligations” as defined in the Senior Credit Agreement.



     “ Solvent” means, with respect to any Person as of any date of determination, that, as of such
date, after giving effect to the rights of contribution against other Note Parties set forth in
Section 12.7 and in the Guaranty Agreement, (a) the value of the assets of such Person (both at
fair value and present fair saleable value) is greater than the total amount of liabilities
(including contingent and unliquidated liabilities) of such Person, (b) such Person is able to pay
all liabilities of such Person as such liabilities mature and (c) such Person does not have
unreasonably small capital. In computing the amount of contingent or unliquidated liabilities at
any time, such liabilities shall be computed at the amount that, in light of all the facts and
circumstances existing at such time, represents the amount that can reasonably be expected to
become an actual or matured liability.



     “Special Flood Hazard Area” means an area that FEMA’s current flood maps indicate has at least
a one percent (1%) chance of a flood equal to or exceeding the base flood elevation (a 100-year
flood) in any given year.



     “Sponsor” means S.A.C. Private Capital Group, LLC, a Delaware limited liability company.



     “Sponsor Affiliated Purchaser” means any Purchaser or Senior Lender that is either the Sponsor
or an Affiliate of the Sponsor (excluding its portfolio companies).



     “Sponsor Consulting Agreement” means that certain Agreement, dated as of August 19, 2008, by
and among Holdings, S.A.C. PEI CB Investment II, LLC and Lehman Brothers Commercial Corporation
Asia.



     “Stock” means all shares of capital stock (whether denominated as common stock or preferred
stock), equity interests, beneficial, partnership or membership interests, joint venture interests
or other ownership or profit interests in or equivalents (regardless of how designated) of or in a
Person (other than an individual), whether voting or non-voting.



     “Stock Equivalents” means all securities convertible into or exchangeable for Stock or any
other Stock Equivalent and all warrants, options or other rights to purchase, subscribe for or
otherwise acquire any Stock or any other Stock Equivalent, whether or not presently convertible,
exchangeable or exercisable.



     “Subordination Agreement” means that certain Subordination and Intercreditor Agreement, by and
among the initial Purchasers and the Senior Agent on behalf of the Senior Lenders, and acknowledged
by Holdings and the Issuers relating to the subordination of the Notes, in the form of Exhibit E,
as such agreement shall be amended, modified, amended and restated or otherwise changed from time
to time in accordance with the terms hereof and thereof.



     “Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture,
limited liability company, association or other entity, the management of which is, directly or
indirectly, controlled by, or of which an aggregate of more than 50% of the outstanding Voting
Stock is, at the time, owned or controlled directly or indirectly by, such Person or one or more
Subsidiaries of such Person. Unless the context otherwise clearly requires, references herein to a
“Subsidiary” refer to a Subsidiary of Holdings.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







34









 








     “Subsidiary Guarantor” means each Subsidiary of Holdings that enters into any Guaranty
Obligations with respect to the Obligations pursuant to the Guaranty Agreement or any other
Agreement acceptable to the Required Purchasers.



     “SWDA” means the Solid Waste Disposal Act (42 U.S.C. §§ 6901 et seq.).



     “Tax Return” has the meaning specified in Section 4.8.



     “Taxes” has the meaning specified in Section 2.17(a).



     “THL” has the meaning set forth in the preamble.



     “Title IV Plan” means a pension plan subject to Title IV of ERISA, other than a Multiemployer
Plan, to which any ERISA Affiliate incurs or otherwise has any obligation or liability, contingent
or otherwise.



     “Trademarks” means all rights, title and interests (and all related IP Ancillary Rights)
arising under any Requirement of Law in or relating to trademarks, trade names, corporate names,
company names, business names, fictitious business names, trade styles, service marks, logos and
other source or business identifiers and, in each case, all goodwill associated therewith, all
registrations and recordations thereof and all applications in connection therewith.



     “Trade Secrets” means all right, title and interest (and all related IP Ancillary Rights)
arising under any Requirement of Law in or relating to trade secrets.



     “TRICARE” means, collectively, a program of medical benefits covering former and active members
of the uniformed services and certain of their dependents, financed and administered by the United
States Departments of Defense, Health and Human Services and Transportation, and all laws
applicable to such programs.



     “UCC” means the Uniform Commercial Code of any applicable jurisdiction and, if the applicable
jurisdiction shall not have any Uniform Commercial Code, the Uniform Commercial Code as in effect
in the State of New York.



     “Unfunded Pension Liability” of any Title IV Plan shall mean the amount, if any, by which, as
of the date of the most recent financial statements reflecting such amounts, the value of the
accumulated plan benefits under the Title IV Plan (based on assumptions used for purposes of
Accounting Standards Codification No. 715: Compensation-Retirement Benefits), exceeds the fair
market value of all plan assets allocable to such liabilities (excluding any accrued but unpaid
contributions).



     “United States” means the United States of America.



     “U.S. Purchaser Party” means each Purchaser, each SPV and each participant, in each case that
is a Domestic Person.



     “Voting Stock” means Stock of any Person having ordinary power to vote in the election of
members of the board of directors, managers or equivalent governing body of such Person
(irrespective of whether, at the time, Stock of any other class or classes of such entity shall
have or might have voting power by reason of the occurrence of any contingency).



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







35









 








     “Wholly Owned Subsidiary” of any Person means any Subsidiary of such Person, all of the Stock
of which (other than nominal holdings and director s qualifying shares) is owned by such Person,
either directly or through one or more Wholly Owned Subsidiaries of such Person.



     “Withdrawal Liability” means, at any time, any liability incurred (whether or not assessed) by
any ERISA Affiliate and not yet satisfied or paid in full at such time with respect to any
Multiemployer Plan pursuant to Section 4201 of ERISA.



     “Working Capital” means, for any Person at any date, its Consolidated Current Assets at such
date minus its Consolidated Current Liabilities at such date.




          Section 1.2 UCC Terms. The following terms have the meanings given to them in the
applicable UCC: account , commodity account , commodity contract , commodity
intermediary , deposit account , entitlement holder , entitlement order , equipment ,
financial asset , general intangible , goods , instruments , inventory , securities
account , securities intermediary and security entitlement .




          Section 1.3 Accounting Terms and Principles.



          (a) GAAP. All accounting determinations required to be made pursuant hereto shall, unless
expressly otherwise provided herein, be made in accordance with GAAP. No material change in the
accounting principles used in the preparation of any Financial Statement hereafter adopted by
Holdings shall be given effect if such change would affect a calculation that measures compliance
with any provision of Article 5 or Article 8 unless the Issuers and the Designated Purchaser agree
to modify such provisions to reflect such material changes in GAAP and, unless such provisions are
modified, all Financial Statements, Compliance Certificates and similar documents provided
hereunder shall be provided together with a reconciliation between the calculations and amounts set
forth therein before and after giving effect to such material change in GAAP. Notwithstanding any
other provision contained herein, all terms of an accounting or financial nature used herein shall
be construed, and all computations of amounts and ratios referred to in Article 5 and Article 8
shall be made, without giving effect to any election under Accounting Standards Codification 825-10
(or any other Financial Accounting Standard having a similar result or effect) to value any
Indebtedness or other liabilities of any Note Party or any Subsidiary of any Note Party at “fair
value”.





          Section 1.4 Pro Forma. All components of financial calculations made to determine
compliance with Section 3.1(e), Article 5 and Article 8 shall be adjusted on a Pro Forma Basis to
include or exclude, as the case may be, without duplication, such components of such calculations
attributable to any Pro Forma Transaction consummated after the first day of the applicable period
of determination and prior to the end of such period, as determined in good faith by the Issuers
based on assumptions expressed therein and that were believed in good faith by the Issuers to be
reasonable based on the information available to the Issuers at the time of preparation of the
Compliance Certificate setting forth such calculations.




          Section 1.5 Payments. The Purchasers may set up standards and procedures to determine
or redetermine the equivalent in Dollars of any amount expressed in any currency other than
Dollars and otherwise may, but shall not be obligated to, rely on any determination made by
any Note Party. Any such



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





36









 









determination or redetermination by the Purchasers shall be conclusive and binding for all
purposes, absent manifest error. No determination or redetermination by any Note Party and
no other currency conversion shall change or release any obligation of any Note Party
(other than the Purchasers and their Related Persons) under any Note Document, each of
which agrees to pay separately for any shortfall remaining after any conversion and payment
of the amount as converted. The Purchasers may round up or down, and may set up appropriate
mechanisms to round up or down, any amount hereunder to nearest higher or lower amounts and
may determine reasonable de minimis payment thresholds.




          Section 1.6 Interpretation.



          (a) Certain Terms. Except as set forth in any Note Document, all accounting terms not
specifically defined herein shall be construed in accordance with GAAP (except for the term
“property” , which shall be interpreted as broadly as possible, including, in any case, cash,
Securities, other assets, rights under Contractual Obligations and Permits and any right or
interest in any property). The terms “herein” , “hereof” and similar terms refer to this Agreement
as a whole. In the computation of periods of time from a specified date to a later specified date
in any Note Document, the terms “from” means from and including and the words to and “until”
each mean to but excluding and the word “through” means to and including. In any other case,
the term “including” when used in any Note Document means including without limitation. The term
“documents” means all writings, however evidenced and whether in physical or electronic form,
including all documents, instruments, agreements, notices, demands, certificates, forms, financial
statements, opinions and reports.




          (b) Certain References. Unless otherwise expressly indicated, references (i) in this
Agreement to an Exhibit, Schedule, Article, Section or clause refer to the appropriate Exhibit or
Schedule to, or Article, Section or clause in, this Agreement and (ii) in any Note Document, to (A)
any agreement shall include, without limitation, all exhibits, schedules, appendixes and annexes to
such agreement and any modification to any term of such agreement but only to the extent such
modifications are not prohibited by the terms of any Note Document, (B) any statute shall be to
such statute as modified from time to time and to any successor legislation thereto, in each case
as in effect at the time any such reference is operative and (C) any time of day shall be a
reference to New York time. Titles of articles, sections, clauses, exhibits, schedules and annexes
contained in any Note Document are without substantive meaning or content of any kind whatsoever
and are not a part of the agreement between the parties hereto. Unless otherwise expressly
indicated, the meaning of any term defined (including by reference) in any Note Document shall be
equally applicable to both the singular and plural forms of such term.




ARTICLE 2

ISSUANCE AND SALE OF NOTES; INTEREST; REPAYMENT





          Section 2.1 Note Issuance.



          (a) On the Closing Date, the Issuers shall authorize the issuance, sale and delivery of the
Notes in an aggregate principal amount of $85,000,000, dated as of the Funding Date, to mature on
the Maturity Date, and issued substantially in the form of Exhibit B attached hereto.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







37









 








          (b) On the Funding Date, the Purchasers, severally, and not jointly shall purchase Notes in an
aggregate principal amounts set forth opposite such Purchaser s name on Schedule I under the
heading Commitments, dated as of the Funding Date, to mature on the Maturity Date.




          (c) The Notes issued pursuant hereto shall evidence the principal amounts of all Notes sold
hereunder (including any interest which is capitalized under Section 2.7) and the date and
principal amount of each purchase and sale of Notes to the Purchasers by the Issuers, as well as
each payment or prepayment made on account of the principal thereof, and in each case the resulting
aggregate unpaid principal balance thereof, shall be recorded by each Purchaser on its books;
provided, that failure by any Purchaser to make any such recordation shall not affect the
obligations of the Issuers hereunder or under such Note. Each such recordation by a Purchaser
shall be prima facie evidence of the existence and amounts of the obligations therein recorded for
all purposes in the absence of manifest error.




          (d) Notes issued under this agreement and subsequently pre-paid or repaid in whole or in part,
may not be reborrowed or reissued.





          Section 2.2 Procedures for Issuance.



          (a) Funding. The proceeds of the sale of the Notes (net of transaction costs) (the “Purchase
Price”) will be made available to the Issuers by each Purchaser by wire transfer of its applicable
Purchase Price to the Issuers on the Funding Date, pursuant to the wire transfer instructions
specified in a written document executed by the Issuer Representative.





          Section 2.3 [Reserved.]




          Section 2.4 [Reserved.]




          Section 2.5 [Reserved.]




          Section 2.6 Repayment and Prepayment of Obligations.



          (a) At Maturity. On the Maturity Date, the unpaid principal balance of the Notes to the extent
not sooner paid or prepaid hereunder, shall be paid in full, together with accrued interest and
fees thereon and all costs, expenses, indemnities and other Obligations then due and payable
hereunder or under any other Note Document.




          (b) Prepayments.





          (i) The Issuers may, at any time following the second anniversary of the Funding Date,
redeem the Notes in whole or in part (and if in part shall be in an aggregate amount that
is an integral multiple of $1,000,000) at the following redemption prices (expressed as a
percentage of the then outstanding principal balance of the Notes to be repaid) (the
“Redemption Price” ), plus accrued and unpaid interest (including PIK Interest) through the
date of redemption:



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY









38









 








	 	 	 	 	 
	Months after the Funding Date	 	Redemption Price
	25-36

	 	 	105.0	%
	37-48

	 	 	103.0	%
	49-60

	 	 	101.0	%
	Thereafter

	 	 	100.0	%







          (ii) If the Issuers elect to make any permitted redemption of the Notes pursuant to
this Section 2.6(b), the Issuer Representative shall give notice of such redemption to each
Purchaser not less than five (5) Business Days and not more than 60 days prior to the date
such redemption is to be made, specifying (i) the date on which such prepayment is to be
made and (ii) the amount of such prepayment. The aggregate principal amount of the Notes so
specified to be prepaid, together with accrued interest thereon (including any interest
payable in kind), shall be due and payable on the prepayment date set forth in such notice;
provided, however, that such notice may provide that such prepayment is contingent upon the
consummation of a related financing or acquisition transaction, in which case such Notes
shall not be due and payable if such transaction is not consummated.




          (iii) Prior to the second (2nd) anniversary of the Funding Date, upon notice given as
provided in Section 2.6(b)(ii), the Issuers, at their option, may prepay all or any part of
the principal amount of the Notes (and if in part shall be in an aggregate amount that is
an integral multiple of $1,000,000), together with accrued but unpaid interest on the
principal amount being prepaid to the date of such prepayment, plus the Make-Whole Amount.




          (iv) If as a result of an Event of Default or otherwise, the Notes are caused to be
repaid prior to the Maturity Date other than pursuant to Section 2.6(c), then the
Obligations shall be repaid taking into consideration the Make-Whole Amount or at the
Redemption Price application at the time of such Event of Default.



          (c) Mandatory Repayment on Change of Control. No later than 30 days nor earlier than 60 days
prior to the occurrence of a Change in Control, the Issuers shall make an offer to all Purchasers
to redeem all Notes pursuant to a Redemption Offer (as defined below) at a purchase price in cash
equal to 101% of the outstanding principal amount of the Notes plus accrued and unpaid interest
(including any PIK Interest) to the date of redemption, in accordance with the terms of this
Section 2.6(c); and





          (i) concurrently with the occurrence of a Change in Control, redeem all the
Notes of all Purchasers (excluding any Purchaser that elects not to have the Notes held by it
redeemed in full) in accordance with such Redemption Offer.




          (ii) A “Redemption Offer” shall mean a notice delivered to each Purchaser stating:



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







39









 










          (1) that a Change in Control is contemplated and all or a portion of such Purchaser’s Notes may be redeemed at a purchase price in cash equal to the applicable percentage
set forth above, plus accrued and unpaid interest (including any PIK Interest) to the date of redemption;




          (2) in reasonable detail, the circumstances and relevant facts regarding such Change in Control;




          (3) the redemption date (which shall be the effective date of the Change in Control);




          (4) that the Purchasers electing not to have any Notes redeemed pursuant to a
Redemption Offer will be required to notify the Issuer prior to the close of business on
the fifth (5th) Business Day preceding the proposed redemption date; and




          (5) that, up until the close of business on the fifth (5th) Business Day
preceding the proposed redemption date, any Purchaser will be entitled to withdraw its
election not to require the Issuer to redeem its Notes; provided, that the Issuer
receives, not later than the close of business on the fifth (5th) Business Day preceding
the proposed redemption date, a notice setting forth the name of the Purchaser, the
principal amount of Notes previously requested not to be redeemed, and a statement that
such Purchaser is withdrawing its election not to have such Notes redeemed.




          (iii) Notwithstanding the foregoing provisions of this Section 2.6(c), the Issuer
shall be deemed to have made a Redemption Offer if a third party makes the Redemption Offer
in the manner, at the times and otherwise in compliance with the requirements set forth in
this Section 2.6(c) applicable to a Redemption Offer made by the Issuer and redeems all
Notes as to which offers for redemption have been validly accepted and not withdrawn
pursuant to the terms of such Redemption Offer.




          Section 2.7 Interest.



          (a) Interest Rate. Subject to Section 2.7(b), (i) the Notes shall bear interest on the
outstanding principal amount thereof from the date when issued, payable in arrears on the first day
of each quarter (each such date, an “Interest Payment Date”), at the Issuers’ option, equal to
either: (x) 13.0% per annum payable in cash (the “Cash Rate”) or (y) 2% payable through an increase
in the outstanding principal amount of such Note (the “PIK Interest”) plus 12.0% per annum payable
in cash (the “PIK Rate”), which increase shall be evidenced by an amended and restated Note to the
extent requested by the Purchasers. The Issuer Representative shall give written notice of the
Issuers’ election to pay PIK Interest under clause (y) above to each Purchaser in the form of
Exhibit C not later than 5 Business Days prior to any Interest Payment Date; provided, that in the
absence of any such notice with respect to any Interest Payment Date, the interest due at such
Interest Payment Date shall be the Cash Rate. Interest shall also be paid on the date of any
payment or redemption of Notes in full or in part.




          (b) Default Interest. Notwithstanding the rates of interest specified in Section 2.7(a) above
or elsewhere in any Note Document, effective immediately upon the occurrence of any Event of
Default under Section 9.1(e)(ii) or (B) the delivery of a notice by the




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







40









 







Required Purchasers to the Issuer Representative during the continuance of any other Event of
Default, and, in each case, for as long as such Event of Default shall be continuing, the principal
balance of all Obligations (including any Obligation that bears interest by reference to the rate
applicable to any other Obligation) then due and payable shall bear interest at a rate per annum
equal to the then applicable interest rate plus 2.0%, which default rate shall be payable in cash
(notwithstanding any election by the Issuers’ to pay PIK Interest pursuant to Section 2.7(a)). All
such interest shall be payable on demand of any Purchaser.




          (c) Savings Clause. Anything herein to the contrary notwithstanding, the obligations of the
Issuers hereunder shall be subject to the limitation that payments of interest shall not be
required, for any period for which interest is computed hereunder, to the extent (but only to the
extent) that contracting for or receiving such payment by the respective Purchaser would be
contrary to the provisions of any law applicable to such Purchaser limiting the highest rate of
interest which may be lawfully contracted for, charged or received by such Purchaser, and in such
event Issuer shall pay such Purchaser interest at the highest rate permitted by applicable law (
“Maximum Lawful Rate”); provided, however, that if at any time thereafter the rate of interest
payable hereunder is less than the Maximum Lawful Rate, Issuer shall continue to pay interest
hereunder at the Maximum Lawful Rate until such time as the total interest received by the
Purchasers is equal to the total interest that would have been received had the interest payable
hereunder been (but for the operation of this paragraph) the interest rate payable since the
Funding Date as otherwise provided in this Agreement.





          Section 2.8 AHYDO Payments. Anything contained herein or in any of the other Note
Documents to the contrary notwithstanding, if the Notes shall remain outstanding after the
fifth (5th) anniversary of the initial issuance hereof and the aggregate amount
that would be includible in gross income of the Purchaser with respect to the Notes for
periods ending on or before any Interest Payment Date (within the meaning of Section 163(i)
of the Code) (the “Aggregate Accrual”) that occurs after that fifth (5th)
anniversary exceeds an amount equal to the sum of (i) the aggregate amount of interest to
be paid (within the meaning of Section 163(i) of the Code) under the Notes on or before
such Interest Payment Date, and (ii) the product of (A) the issue price (as determined
under Sections 1273(b) and 1274(a) of the Code) of the Notes and (B) the yield to maturity
(interpreted in accordance with Section 163(i) of the Code) of the Notes (such sum, the
“Maximum Accrual”), then the Issuers shall prepay to the Purchasers on each applicable
Interest Payment Date occurring after such fifth (5th) anniversary a portion of
the outstanding stated principal amount of the Notes equal to the excess, if any, of the
Aggregate Accrual over the Maximum Accrual, and the amount of such payment shall be treated
for U.S. federal and applicable state and local income tax purposes as an amount of
interest to be paid (within the meaning of Section 163(i)(2)(B)(i) of the Code) under the
Notes. The provision is intended to prevent the Notes from being classified as “applicable
high yield discount obligations,” as defined in Section 163(i) of the Code, and shall be
interpreted consistently therewith.




          Section 2.9 [Reserved.]




          Section 2.10 Application of Payments.



          (a) Application of Voluntary Redemption Payments. Unless otherwise provided in this Section
2.10 or elsewhere in any Note Document, all payments and any other amounts




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





41









 







received from or for the benefit of the Issuers pursuant to Section 2.6(b)(i) shall be applied to
repay the Obligations the Issuer Representative designates.




          (b) [Reserved.]




          (c) Application of Payments During an Event of Default. Holdings and each Issuer hereby
irrevocably waives, and agrees to cause each Note Party and each other Group Member to waive, the
right to direct the application (i) during the continuance of an Event of Default or (ii) upon any
payments pursuant to 2.6(a) or 2.6(b)(iv) of any and all payments in respect of any Obligation and
agrees that, notwithstanding the provisions of clause (a) above, the Purchasers may apply all
payments in respect of any Obligation (i) first, to pay Obligations in respect of any cost or
expense reimbursements, fees or indemnities then due to any Purchaser, (ii) second, to pay interest
then due and payable in respect of the Notes, (iii) third, to repay the outstanding principal
amounts of the Notes and (iv) fourth, to the ratable payment of all other Obligations, and, then,
any excess shall be paid to the Issuers or otherwise ordered by a court of competent jurisdiction.





          Section 2.11 Payments and Computations.



          (a) Procedure. The Issuers shall make each payment under any Note Document not later than
11:00 a.m. (New York time) on the day when due to each Purchaser by wire transfer or ACH transfer
to its account as set forth on Schedule II (or at such other account or by such other means to such
other address as such Purchaser shall have notified the Issuer Representative in writing within a
reasonable time prior to such payment) in immediately available Dollars and without setoff or
counterclaim. Any payment which is received by any Purchaser later than 11:00 a.m. (New York time)
shall be deemed to have been received on the immediately succeeding Business Day and any applicable
interest or fee shall continue to accrue.




          (b) [Reserved.]




          (c) Payment Dates. Whenever any payment hereunder shall be stated to be due on a day other
than a Business Day, the due date for such payment shall be extended to the next succeeding
Business Day without any increase in such payment as a result of additional interest or fees;
provided, however, that such interest and fees shall continue accruing as a result of such
extension of time.





          Section 2.12 Evidence of Debt.



          (a) Records of Purchasers. Each Purchaser shall maintain in accordance with its usual
practice accounts evidencing Indebtedness of the Issuers to such Purchase resulting from each Note
of such Purchaser from time to time, including the amounts of principal, capitalized principal and
interest payable and paid to such Purchaser from time to time under this Agreement. In addition,
each Purchaser having sold a participation in any of its Obligations as such to the Issuer
Representative shall establish and maintain at its address referred to in Section 11.11 (or at such
other address as such Purchaser shall notify the Issuer Representative) a record of ownership, in
which such Purchaser shall register by book entry (A) the name and address of each such participant
(and each change thereto, whether by assignment or otherwise) and (B) the rights, interest or
obligation of each such participant in any Obligation, in any Notes and in any right to receive any
payment hereunder.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







42









 








          (b) Records of Issuer Representative. The Issuer Representative shall establish and maintain
at its address referred to in Section 11.11 (or at such other address as the Issuer Representative
may notify the Purchasers) (A) a record of ownership (the “Register” ) in which the Issuer
Representative agrees to register by book entry the interests (including any rights to receive
payment hereunder) of each Purchaser in the Notes, each of their obligations under this Agreement
to participate in Notes, and any assignment of any such interest, obligation or right and (B)
accounts in the Register in accordance with its usual practice in which it shall record (1) the
names and addresses of the Purchasers (and each change thereto pursuant to Section 11.2
(Assignments and Participations; Binding Effect)), (2) the Notes held by each Purchaser, (3) the
amount of each funding of any participation described in clause (A) above, (4) the amount of any
principal or interest due and payable or paid, and (5) any other payment received by the Purchasers
from the Issuers and its application to the Obligations.




          (c) Registered Obligations. Notwithstanding anything to the contrary contained in this
Agreement, the Notes are registered obligations, and the right, title and interest of the
Purchasers and their assignees in and to such Notes, as the case may be, shall be transferable only
upon notation of such transfer in the Register and no assignment thereof shall be effective until
recorded therein. This Section 2.12 and Section 11.2 shall be construed so that the Notes are at
all times maintained in registered form within the meaning of Sections 163(f), 871(h)(2) and
881(c)(2) of the Code and any related regulations (and any successor provisions).




          (d) Prima Facie Evidence. The entries made in the Register and in the accounts maintained
pursuant to clause (a) above shall, to the extent permitted by applicable Requirements of Law and
absent manifest error, be prima facie evidence of the existence and amounts of the obligations
recorded therein; provided, however, that no error in such account and no failure of any Purchaser
or the Issuer Representative to maintain any such account shall affect the obligations of any Note
Party to repay the Notes in accordance with their terms. In addition, the Note Parties and the
Purchasers shall treat each Person whose name is recorded in the Register as a Purchaser, as
applicable, for all purposes of this Agreement. Information contained in the Register with respect
to any Purchaser shall be available for access by the Issuers or such Purchaser at any reasonable
time and from time to time upon reasonable prior notice. No Purchaser shall, in such capacity,
have access to or be otherwise permitted to review any information in the Register other than
information with respect to such Purchaser unless otherwise agreed by the Required Purchasers.





          Section 2.13 [Reserved.]




          Section 2.14 [Reserved.]




          Section 2.15 [Reserved.]




          Section 2.16 [Reserved.]




          Section 2.17 Taxes



          (a) Payments Free and Clear of Taxes. Except as otherwise provided in this Section 2.17,
each payment by any Note Party to any Purchaser under any Note Document shall be made free and
clear of all present or future taxes, levies, imposts, deductions, charges, stamp and other
duties or withholdings and all interest, penalties and liabilities with respect thereto (and
without deduction for any of them) (collectively, the




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





43









 







“Taxes” ) other than for (i) Taxes imposed on or measured by reference to net income and
franchise Taxes imposed in lieu of net income Taxes, in each case imposed on any Purchaser as
a result of a present or former connection between such Purchaser and the jurisdiction of the
Governmental Authority imposing such tax or any political subdivision or taxing authority
thereof or therein (other than any such connection arising solely from any Purchaser having
executed, delivered or performed its obligations or received a payment under, or enforced, any
Note Document), (ii) any branch profits Taxes imposed by the United States or any similar tax
imposed by any other jurisdiction in which any Purchaser is located or (iii) Taxes that are
directly attributable to the failure (other than as a result of a change in any Requirement of
Law) by any Purchaser to deliver the documentation required to be delivered pursuant to clause
(f) below (such Taxes excluded under (i), (ii) or (iii), the “Excluded Taxes” and such
non-excluded Taxes, the “Non-Excluded Taxes”).




          (b) Gross-Up. If any Taxes shall be required by applicable Requirements of Law to be
deducted from or in respect of any amount payable under any Note Document to any Purchaser (i)
in the case of Non-Excluded Taxes, such amount shall be increased as necessary to ensure that,
after all required deductions for Non-Excluded Taxes are made (including deductions applicable
to any increases to any amount under this Section 2.17), such Purchaser receives the amount it
would have received had no such deductions been made, (ii) the relevant Note Party shall make
such deductions, (iii) the relevant Note Party shall timely pay the full amount deducted to
the relevant taxing authority or other authority in accordance with applicable Requirements of
Law and (iv) within 30 days after such payment is made, the relevant Note Party shall deliver
to the Purchasers an original or certified copy of a receipt evidencing such payment;
provided, however, that, notwithstanding the provisions of clause (d) below, no such increase
shall be made with respect to, and no Note Party shall be required to indemnify any such
Purchaser pursuant to clause (d) below for, withholding Taxes to the extent that the
obligation to withhold amounts existed on the date that such Purchaser became a “Purchaser”
under this Agreement, except in each case to the extent such Purchaser is a direct or indirect
assignee of any other Purchaser that was entitled, at the time the assignment of such other
Purchaser became effective, to receive additional amounts under this clause (b).




          (c) Other Taxes. In addition, the Issuers agree to pay, and authorize the Purchasers to
pay in its name, any stamp, documentary, excise or property tax, charges or similar levies
imposed by any applicable Requirement of Law or Governmental Authority and all Liabilities
with respect thereto (including by reason of any delay in payment thereof), in each case
arising from the execution, delivery or registration of, or otherwise with respect to, any
Note Document or any transaction contemplated therein (collectively, “Other Taxes”). Within 30
days after the date of any payment of Other Taxes by any Note Party, the Issuers shall furnish
to each Purchaser, at its address referred to in Schedule II, the original or a certified copy
of a receipt evidencing payment thereof.




          (d) Indemnification. Without duplication of any additional amounts paid pursuant to
Section 2.17(b), the Issuers shall, on a joint and several basis, reimburse and indemnify,
within 30 days after receipt of demand therefor (with copy to each Purchaser), each Purchaser
for all Non-Excluded Taxes and Other Taxes (including any Non-Excluded Taxes and Other Taxes
imposed by any jurisdiction on amounts payable under this Section 2.17) paid by such Purchaser
and any Liabilities arising therefrom or with respect thereto, whether or not such
Non-Excluded Taxes or Other Taxes were correctly or legally




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





44









 







asserted. A certificate of such Purchaser claiming any compensation under this clause (d),
setting forth the amounts to be paid thereunder and delivered to the Issuer Representative
shall be conclusive, binding and final for all purposes, absent manifest error.




          (e) Mitigation. Any Purchaser claiming any additional amounts payable pursuant to this
Section 2.17 shall use its reasonable efforts (consistent with its internal policies and
Requirements of Law) to change the jurisdiction of its lending office if such a change would
reduce any such additional amounts (or any similar amount that may thereafter accrue) and
would not, in the sole determination of such Purchaser, be otherwise disadvantageous to such
Purchaser.




          (f) Tax Forms.





          (i) Each Non-U.S. Purchaser Party that, at any of the following times, is entitled to
an exemption from or reduction of United States withholding tax or, after a change in any
Requirement of Law, is subject to such withholding tax at a reduced rate under an
applicable tax treaty, shall, to the extent it is legally entitled to do so, (w) on or
prior to the date such Non-U.S. Purchaser Party becomes a Non-U.S. Purchaser Party
hereunder, (x) on or prior to the date on which any such form or certification expires or
becomes obsolete, (y) after the occurrence of any event requiring a change in the most
recent form or certification previously delivered by it pursuant to this clause (i) and (z)
from time to time if reasonably requested by the Issuer Representative or, in the case of a
participant or SPV, the relevant Purchaser, provide the Issuer Representative or, in the
case of a participant or SPV, the relevant Purchaser with two properly completed and duly
executed originals of each of the following, as applicable: (A) Forms W-8ECI (claiming
exemption from U.S. withholding tax because the income is effectively connected with a U.S.
trade or business), W-8BEN (claiming exemption from, or a reduction of, U.S. withholding
tax under an income tax treaty), as applicable, or any successor forms or W-8IMY (claiming
exemption through an intermediary), (B) in the case of a Non-U.S. Purchaser Party claiming
exemption under Sections 871(h) or 881(c) of the Code, Form W-8BEN (claiming exemption from
U.S. withholding tax under the portfolio interest exemption) or any successor form and a
certificate in form and substance reasonably acceptable to the Issuer Representative that
such “Non-U.S. Purchaser Party” is not (1) a “bank” within the meaning of Section
881(c)(3)(A) of the Code, (2) a “10 percent shareholder” of any Issuer within the meaning
of Section 881(c)(3)(B) of the Code or (3) a “controlled foreign corporation” described in
Section 881(c)(3)(C) of the Code or (C) any other applicable document prescribed by the IRS
certifying as to the entitlement of such Non-U.S. Purchaser Party to such exemption from
United States withholding tax or reduced rate with respect to all payments to be made to
such Non-U.S. Purchaser Party under the Note Documents. Unless the Issuer Representative
has received forms or other documents reasonably satisfactory to them indicating that
payments under any Note Document to or for a Non-U.S. Purchaser Party are not subject to
United States withholding tax or are subject to such tax at a rate reduced by an applicable
tax treaty, the Note Parties shall withhold amounts required to be withheld by applicable
Requirements of Law from such payments at the applicable statutory rate.




          (ii) Each U.S. Purchaser Party shall, to the extent it is legally entitled to do so,
(A) on or prior to the date such U.S. Purchaser Party becomes a “U.S. Purchaser Party”
hereunder, (B) on or prior to the date on which any such form or certification



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





45









 









expires or becomes obsolete, (C) after the occurrence of any event requiring a change in
the most recent form or certification previously delivered by it pursuant to this clause
(f) and (D) from time to time if reasonably requested by the Issuer Representative or, in
the case of a participant or SPV, the relevant Purchaser, provide the Issuer Representative
or, in the case of a participant or SPV, the relevant Purchaser with two properly completed
and duly executed originals of Form W-9 (certifying that such U.S. Purchaser Party is
entitled to an exemption from U.S. backup withholding tax) or any successor form.




          (iii) Each Purchaser having sold a participation in any of its Obligations or
identified an SPV as such to the Issuer Representative shall collect from such participant
or SPV the documents described in this clause (f) and provide them to the Issuer
Representative.




          (g) Refunds. If any Purchaser determines that it has received any refund of any
Non-Excluded Taxes or Other Taxes from the Governmental Authority to which such Non-Excluded
Taxes or Other Taxes were paid as to which it has been indemnified by the Issuers or with
respect to which the Issuers have paid additional amounts pursuant to this Section 2.17, it
shall pay over such refund to the Issuer Representative (but only to the extent of indemnity
payments made, or additional amounts paid, by the Issuers under this Section 2.17, with respect
to Non-Excluded Taxes or Other Taxes giving rise to such refund), net of all out-of-pocket
expenses of such Purchaser and without interest (other than any interest paid by the relevant
Governmental Authority with respect to such refund); provided, that the Issuer Representative,
upon request of such Purchaser agrees to repay the amount paid over to the Issuer
Representative (plus any penalties, interest or other charges imposed by the Governmental
Authority to the extent accrued from the date such refund is paid over to the Issuer
Representative) to such Purchaser together with any Liabilities relating to such refund, in the
event such Purchaser is required or requested to repay such refund to the Governmental
Authority. This paragraph shall not be construed to require any Purchaser to make available its
tax returns (or any other information relating to its taxes which it deems confidential) to the
Issuer Representative or any other Person.




          Section 2.18 [Reserved].




          Section 2.19 Issuer Representative. Each Note Party hereby designates and appoints
MedQuist as its representative and agent on its behalf (the “Issuer Representative”) for
the purposes of delivering certificates including Compliance Certificates, giving
instructions with respect to the disbursement of the proceeds of the Notes, selecting
interest rate options, giving and receiving all other notices and consents hereunder or
under any of the other Note Documents and taking all other actions (including in respect of
compliance with covenants) on behalf of any Note Party under the Note Documents. MedQuist
hereby accepts such appointment. Each Purchaser may regard any notice or other
communication pursuant to any Note Document from the Issuer Representative as a notice or
communication from all Issuers. Each action authorized to be taken on behalf of an Issuer
by the Issuer Representative hereunder shall be deemed for all purposes to have been taken
by such Issuer and shall be binding upon and enforceable against such Issuer to the same
extent as if the same had been taken directly by such Issuer.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY



46









 







ARTICLE 3

CONDITIONS TO PURCHASE OF NOTES





          Section 3.1 Conditions Precedent to Purchase of Notes. The obligation of each Purchaser to
purchase the Notes on the Funding Date is subject to the satisfaction or due waiver of each of the
following conditions precedent on or before the Closing Date:



          (a) Certain Documents. Each Purchaser shall have received on or prior to the Closing Date each of the following, each dated as of the
Closing Date unless otherwise agreed by the Purchasers, in form and substance satisfactory to each
Purchaser:





          (i) this Agreement duly executed by Holdings and the Issuers and, for the account of
each Purchaser having requested the same by notice to the Issuer Representative received at least
three (3) Business Days prior to the Closing Date, Notes conforming to the requirements set forth
in Section 2.1(c);




          (ii) the Guaranty Agreement, duly executed by Holdings and each of its
Subsidiaries (other than any Excluded Foreign Subsidiaries), together with copies of UCC, tax,
judgment, fixture and Intellectual Property search reports and of all effective prior filings
listed therein, in each case as may be reasonably requested by the Required Purchasers;




          (iii) [Reserved.]




          (iv) duly executed customary opinions of counsel to the Note Parties, each addressed to
the Purchasers and addressing such matters as Required Purchasers may reasonably request; provided,
however, if the forms of such opinions of counsel have been substantially agreed upon by the
Purchasers as of the Closing Date, the executed versions of such opinions of counsel may be
delivered promptly after the Closing Date, but in no event later than the Funding Date.




          (v) a copy of each Constituent Document of each Note Party that is on file with any
Governmental Authority in its jurisdiction of organization, certified as of a recent date
by such Governmental Authority, together with, if applicable, certificates attesting to the
good standing of such Note Party in (x) such jurisdiction and (y) each other jurisdiction
where such Note Party is qualified to do business as a foreign entity and where such
qualification is necessary for the conduct of such Note Party’s business (and, if
appropriate in any such jurisdiction, related tax certificates) except where the failure to
so qualify would not reasonably be expected to have a Material Adverse Effect;




          (vi) a certificate of the secretary or other officer of each Note Party in charge of maintaining
books and records of such Note Party certifying as to (A) the names and signatures of each
officer of such Note Party that is authorized to and will execute and deliver any Note
Document on the Closing Date, (B) the Constituent Documents of such Note Party attached to
such certificate are complete and correct copies of such Constituent Documents as in effect
on the date of such certification (or, for any such Constituent Document delivered pursuant
to clause (iv) above, that there have been no changes from such Constituent Document so
delivered) and (C) the resolutions of such Note Party’s board of directors or other
appropriate governing body approving



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







47









 









and authorizing the execution, delivery and performance of each Note Document to which such
Note Party is a party;




          (vii) the Senior Credit Agreement, duly executed by the initial
Senior Lenders, Holdings and the Issuers;




          (viii) a certificate of a Responsible Officer of the Issuer Representative to the effect that (A) each condition set forth in Sections
3.1(c) through (f) has been satisfied, (B) each Note Party is Solvent after giving effect
to consummation of the Related Transactions, and (C) attached thereto are complete and
correct copies of (x) the Related Documents and (y) all consents and authorizations
required pursuant to any material Contractual Obligations with any other Person and all
Permits of, notices to and filings with, any Governmental Authority, in each case, as are
necessary in connection with the consummation of transactions contemplated by the Note
Documents and the Related Transactions (after giving effect to the issuance of the Notes on
the Funding Date);




          (ix) (x) interim Consolidated unaudited monthly Financial Statements of
Holdings and its Subsidiaries for each fiscal month ended after June 30, 2010 and on or
prior to 45 days before the Closing Date, each in the form of the monthly Financial
Statements as of June 30, 2010 provided to the Required Purchasers prior to the Closing
Date, (y) a pro forma estimated Consolidated balance sheet of Holdings and its Subsidiaries
at the Closing Date after giving effect to the Related Transactions and (z) Holdings’
 business plan which shall include a financial forecast on a quarterly basis for the first
twelve months after the Closing Date and on an annual basis thereafter through 2015
prepared by Holdings’ management; and.



          (b) [Reserved.]




          (c) Related Transactions. MedQuist shall have conditioned the declaration of the
Recapitalization Dividend upon the funding of the Obligations under this Agreement and the Senior
Credit Agreement.




          (d) [Reserved.]




          (e) Minimum EBITDA; Maximum Leverage. Consolidated EBITDA of Holdings for the twelve fiscal
month period ended on July 31, 2010 shall be no less than $84,000,000. After giving effect to the
Related Transactions, the ratio of Consolidated Total Debt of Holdings as of the Closing Date to
Consolidated EBITDA of Holdings for the twelve fiscal month period ended on July 31, 2010 shall not
exceed 3.35 to 1.00, and the ratio of Consolidated Senior Debt of Holdings as of the Closing Date
to Consolidated EBITDA of Holdings for the twelve fiscal month period ended on July 31, 2010 shall
not exceed 2.35 to 1.00.




          (f) Representations and Warranties; No Defaults. To the extent applicable, after giving pro
forma effect to the Related Transactions as if they had occurred on the Closing Date, the following
statements shall be true on such date: (i) the representations and warranties set forth in any Note
Document shall be true and correct on and as of such date or, to the extent such representations
and warranties expressly relate to an earlier date, on and as of such earlier date and (ii) no
Default shall exist.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







48









 









          Section 3.2 Conditions to Funding. The obligation of each Purchaser to purchase the Notes on
the Funding Date is subject to the satisfaction or due waiver of each of the following conditions
precedent on or before the Funding Date:



          (a) Fee and Expenses. There shall have been paid to the Purchasers, all fees and all
reimbursements of costs or expenses, in each case due and payable under any Note Document on or
before the Funding Date and, in the case of the reimbursement of costs and expenses, invoiced at
least one Business Day prior to the Funding Date.




          (b) Related Transactions. (i) the Senior Credit Agreement shall have been duly executed and
funded and (ii) subject to the satisfaction of the condition in clause (i) and the issuance of the
Notes and the use of the proceeds thereof, all obligations due under the Existing Credit Agreement,
the Existing Subordinated Note and the CBay Convertible Notes will have been repaid in full and the
Existing Credit Agreement, all commitments to extend credit thereunder, the Existing Subordinated
Note and the CBay Convertible Notes shall have been terminated, as evidenced by payoff letters in
form and substance reasonably satisfactory to the Required Purchasers duly executed and delivered
by the Existing Agent and the holders of the Existing Subordinated Note and CBay Convertible Notes,
as applicable, along with evidence of terminations of prior UCC, tax, judgment, fixture and
Intellectual Property filings (other than with respect to Permitted Liens).




          (c) Subordination Agreement. The Subordination Agreement shall have been fully executed.




          (d) Outstanding Indebtedness. After giving effect to the Related Transactions, the Group
Members shall have no Indebtedness as of the Funding Date other than (i) Indebtedness incurred
under this Agreement, (ii) Indebtedness not to exceed $200,000,000 incurred pursuant the Senior
Credit Agreement and (iii) up to $11,000,000 of other Indebtedness existing prior the Funding Date
and not incurred in connection with the Related Transactions. There shall not occur as a result of,
and after giving effect to, the consummation of the Related Transactions, a default (or any event
which with the giving of notice or lapse of time or both will be a default) under any Material
Agreement of Holdings and its Subsidiaries.




          (e) Representations and Warranties; No Defaults. The following statements shall be true on
such date, both before and after the Funding Date giving effect to such Issuance: (i) the
representations and warranties set forth in any Note Document shall be true and correct on and as
of such date or, to the extent such representations and warranties expressly relate to an earlier
date, on and as of such earlier date and (ii) no Default shall exist.




          (f) Funding Date. That the Funding Date occur either on or prior to October 15, 2010.




ARTICLE 4

REPRESENTATIONS AND WARRANTIES




          To induce the Purchasers to enter into the Note Documents, Holdings and each Issuer represents
and warrants to each of them each of the following:





          Section 4.1 Corporate Existence; Compliance with Law. Each Group Member (a) is duly organized, validly existing and, if applicable, in good
standing



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





49









 









under the laws of the jurisdiction of its organization, (b) is duly qualified to do
business as a foreign entity and in good standing under the laws of each jurisdiction where
such qualification is necessary, except where the failure to be so qualified or in good
standing would not, in the aggregate, reasonably be expected to have a Material Adverse
Effect, (c) has all requisite corporate or similar power and authority to own, and operate
its property and to conduct its business as now or currently proposed to be conducted, (d)
is in compliance with all applicable Requirements of Law except where the failure to be in
compliance would not reasonably be expected to have a Material Adverse Effect and (e) has
all necessary Permits from or by, has made all necessary filings with, and has given all
necessary notices to, each Governmental Authority having jurisdiction, to the extent
required for such ownership, operation or conduct of business, except where the failure to
obtain such Permits, make such filings or give such notices would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect; provided, however, that the
representations and warranties under clause (a) and (b) above with respect to the Excluded
Foreign Subsidiaries are limited to the knowledge of the Note Parties.




          Section 4.2 Note Documents and Related Documents. (a) Power and Authority. The
execution, delivery and performance by each Note Party of the Note Documents and Related
Documents to which it is a party and the consummation of the Related Transactions and other
transactions contemplated therein (i) are within such Note Party’s corporate or similar
powers and, at the time of execution thereof, have been duly authorized by all necessary
corporate and similar action, (ii) do not (A) contravene such Note Party’s Constituent
Documents, (B) violate any applicable material Requirement of Law in any material respect,
(C) conflict with, contravene, constitute a default or breach under, or result in or permit
the termination or acceleration of, any material Contractual Obligation of any Group Member
(including other Related Documents or Note Documents) other than those that would not, in
the aggregate, have a Material Adverse Effect, (D) do not materially adversely affect any
Permit of such Note Party other than those that would not, in the aggregate, have a
Material Adverse Effect or (E) result in the imposition of any Lien (other than a Permitted
Lien) upon any property of any Group Member and (iii) do not require any Permit of, or
filing with, any Governmental Authority or any consent of, or notice to, any Person, other
than (A) with respect to the Senior Loan Documents, the filings required to perfect the
Liens created by the Senior Loan Documents, (B) those that have been, or will be prior to
the Closing Date, obtained or made, copies of which have been, or will be prior to the
Closing Date, delivered to the Purchasers, and each of which on the Closing Date will be in
full force and effect and (C) except with respect to the purchasing of the Notes and the
guarantying of the Obligations, those which, if not obtained or made, would not, in the
aggregate, reasonably be expected to have a Material Adverse Effect.



          (b) Due Execution and Delivery. Each Note Document and Related Document has been duly
executed and delivered to the other parties thereto by each Note Party party thereto, is the legal,
valid and binding obligation of such Note Party and is enforceable against such Note Party in
accordance with its terms, subject to the effect of any applicable bankruptcy, insolvency,
reorganization or moratorium or similar laws affecting the rights or remedies of creditors
generally and subject to general principles of equity (regardless of whether enforcement is sought
in a proceeding at law or in equity).




          (c) [Reserved.]





NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY



50









 








          Section 4.3 Ownership of Group Members. Set forth on Schedule 4.3 is a complete and
accurate list showing, as of the Closing Date, for each Group Member other than Holdings,
its jurisdiction of organization, the number of shares of each class of Stock outstanding
on the Closing Date and the number and percentage of the outstanding shares of each such
class owned (directly or indirectly) by any Issuer or Holdings. As of the Closing Date, all
outstanding Stock of each Group Member has been validly issued, is fully paid and
non-assessable (to the extent applicable) and, except in the case of Holdings, is owned
beneficially and of record by a Group Member free and clear of all Liens other than
Permitted Liens. As of the Closing Date, there are no Stock Equivalents with respect to the
Stock of any Group Member (other than Holdings). As of the Closing Date, there are no
Contractual Obligations or other understandings to which any Group Member is a party with
respect to (including any restriction on) the issuance, voting, Sale or pledge of any Stock
or Stock Equivalent of any Group Member.




          Section 4.4 Financial Statements. (a) Each of (i) the audited Consolidated balance
sheet of Holdings as at December 31, 2009, and the related Consolidated statements of
income, retained earnings and cash flows of Holdings for the Fiscal Year then ended,
certified by KPMG LLP, and (ii) subject to the absence of footnote disclosure and normal
year-end audit adjustments, the unaudited Consolidated balance sheets of Holdings as at
July 31, 2010 and the related Consolidated statements of income, retained earnings and cash
flows of Holdings for the seven (7) months then ended, copies of each of which have been
furnished to the Purchasers, fairly present in all material respects the Consolidated
financial position, results of operations and cash flow of the Group Members as at the
dates indicated and for the periods indicated in accordance with GAAP.



          (b) On the Closing Date or the Funding Date as applicable, (i) none of Holdings or its
Subsidiaries has any material liability or obligation (including Indebtedness, Guaranty
Obligations, contingent liabilities and liabilities for Taxes, long-term leases and unusual forward
or long-term commitments) that is not reflected in the Financial Statements referred to in clause
(a) above or in the notes thereto and which is otherwise prohibited by this Agreement and (ii)
since the date of the unaudited Financial Statements referenced in clause (a)(ii) above, there has
been no Sale of any material property of Holdings or its Subsidiaries and no acquisition of any
material property.




          (c) The Initial Projections have been prepared by Holdings in light of the past operations of
the business of Holdings and its Subsidiaries and reflect projections for the five-year period
beginning on July 1, 2010 on a quarterly basis through June 30, 2011 and on a year-by-year basis
thereafter. As of the Closing Date, the Initial Projections have been prepared in good faith based
upon assumptions believed by the preparer thereof to be reasonable, it being understood and agreed
that financial projections are not a guarantee of financial performance and actual results may
differ from financial projections and such differences may be material.




          (d) The unaudited Consolidated balance sheet of Holdings (the “Pro Forma Balance Sheet” )
delivered to the Purchasers prior to the date hereof, has been prepared as of July 31, 2010 and
reflects as of such date, on a Pro Forma Basis for the Related Transactions the Consolidated
financial condition of Holdings.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





51











 






          Section 4.5 Material Adverse Effect. Since December 31, 2009, no
Material Adverse Effect has occurred.




          Section 4.6 Solvency. As of the Closing Date and as of the Funding Date, both
before and after giving effect to the Note Issuance and the Related Transactions, each
Note Party is Solvent.




          Section 4.7 Litigation. There are no pending (or, to the knowledge of any
Group Member, threatened in writing) actions, investigations, suits, proceedings, audits
or claims affecting any Group Member with, by or before any Governmental Authority (x)
that would reasonably be expected to have a Material Adverse Effect or (y) that involve
the Note Documents, the Related Documents or the Related Transactions.




          Section 4.8 Taxes. Except as would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect, all Federal, state, local
and foreign tax returns, reports and statements (collectively, the “Tax Returns”) required
to be filed by any Group Member have been filed with the appropriate Governmental
Authorities in all jurisdictions in which such Tax Returns are required to be filed, all
such Tax Returns are true and correct, and all Taxes, charges and other impositions
reflected therein or otherwise due and payable have been paid prior to the date on which
any Liability may be added thereto for non-payment thereof, in each case except with
respect to matters contested in good faith by appropriate proceedings diligently conducted
and for which adequate reserves are maintained on the books of the appropriate Group
Member in accordance with GAAP. As of the Closing Date, no material Tax Return is under
audit or examination by any Governmental Authority and no notice of such an audit or
examination or any assertion of any material claim for Taxes has been given or made by any
Governmental Authority. As of the Closing Date, proper and accurate amounts have been
withheld by each Group Member from their respective employees for all periods in material
compliance with the tax, social security and unemployment withholding provisions of
applicable Requirements of Law and such withholdings have been timely paid to the
respective Governmental Authorities. No Group Member has participated in a “listed
transaction” within the meaning of Treasury Regulation Section 1.6011-4(b) or has been a
member of an affiliated, combined or unitary group other than the group of which a Group
Member is or was the common parent.




          Section 4.9 Margin Regulations. No Issuer is engaged in the business of
extending credit for the purpose of, and no proceeds of any Note or other extensions of
credit hereunder will be used for the purpose of, buying or carrying margin stock (within
the meaning of Regulation U of the Federal Reserve Board) or extending credit to others
for the purpose of purchasing or carrying any such margin stock, in each case in
contravention of Regulation T, U or X of the Federal Reserve Board.




          Section 4.10 No Defaults. No Group Member is in default under or with respect
to any Contractual Obligation of any Group Member, other than those that would not, in the
aggregate, reasonably be expected to have a Material Adverse Effect.




          Section 4.11 Investment Company Act. No Group Member is an “investment
company” as defined in, or subject to regulation or restrictions under, the



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





52









 









Investment Company Act of 1940, as amended and the rules and regulations promulgated
thereunder.




          Section 4.12 Labor Matters. There are no strikes, work stoppages, slowdowns
or lockouts existing, pending (or, to the knowledge of any Group Member, threatened)
against or involving any Group Member, except, for those that would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect. Except as set forth on
Schedule 4.12, as of the Closing Date, (a) there is no collective bargaining or
similar agreement with any union, labor organization, works council or similar
representative covering any employee of any Group Member, (b) no petition for
certification or election of any such representative is existing or pending with respect
to any employee of any Group Member and (c) no such representative has sought
certification or recognition with respect to any employee of any Group Member.




          Section 4.13 ERISA. Each Benefit Plan, and each trust thereunder, intended
to qualify for tax exempt status under Section 401 or 501 of the Code (or other
Requirements of Law) has received a favorable determination letter from the IRS (or other
applicable Governmental Authority), to the effect that it meets the requirements of
Sections 401(a) and 501(a) of the Code covering all applicable tax law changes, with
respect to such qualification, and nothing has occurred since the date of such
determination that would adversely affect such determination. Except for those that would
not, in the aggregate, be reasonably expected to result in a Material Adverse Effect, (x)
each Benefit Plan is in compliance in form and operation with its terms and with
applicable provisions of ERISA, the Code and other Requirements of Law, (y) there are no
existing or pending (or to the knowledge of any Group Member, threatened) claims (other
than routine claims for benefits in the normal course), sanctions, actions, lawsuits or
other proceedings or investigation involving any Benefit Plan to which any Group Member
has incurred or otherwise has or could have an obligation or any Liability and (z) no
ERISA Event has occurred or is reasonably expected to occur. On the Closing Date, no ERISA
Event has occurred in connection with which obligations and liabilities (contingent or
otherwise) remain outstanding. No Benefit Plan and no other employee benefit plan
maintained, sponsored or contributed to by any Note Party or ERISA Affiliate is a defined
benefit pension plan or is subject to the minimum funding requirements of Section 412 of
the Code or Title IV of ERISA. No Note Party or ERISA Affiliate has any obligation to
contribute to any Multiemployer Plan, or has within any of the five calendar years
immediately preceding the date this assurance is given, made or accrued an obligation to
make contributions to any Multiemployer Plan. Each Note Party and each ERISA Affiliate
have made all material contributions to or under each Benefit Plan and Multiemployer Plan
required by law within the applicable time limits prescribed thereby, the terms of such
Benefit Plan or Multiemployer Plan, respectively, or any contract or agreement requiring
contributions to a Benefit Plan or Multiemployer Plan, except where any failure to comply,
individually or in the aggregate, would not reasonably be expected to result in a material
liability. There exists no Unfunded Pension Liability with respect to any Title IV Plan,
except as would not reasonably be expected to result in a material liability.




          Section 4.14 Environmental Matters. Except as set forth on Schedule
4.14, (a) the operations of each Group Member are and have been in compliance with all
applicable Environmental Laws, including obtaining, maintaining



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






53









 









and complying with all Permits required by any applicable Environmental Law, other
than non-compliances that, in the aggregate, would not reasonably be expected to result in
a Material Adverse Effect, (b) no Group Member is party to, and no Group Member and no
real property currently (or to the knowledge of any Group Member previously) owned,
leased, subleased, operated or otherwise occupied by or for any Group Member (but solely
to the knowledge of the Group Members with respect to any real property neither occupied
by nor owned by any Group Member) is subject to or the subject of, any Contractual
Obligation or any pending (or, to the knowledge of any Group Member, threatened) order,
action, investigation, suit, proceeding, audit, claim, demand, dispute or notice of
violation or of potential liability or similar notice, in each instance under or pursuant
to any Environmental Law, other than those that, in the aggregate, would not reasonably be
expected to result in a Material Adverse Effect, (c) no Group Member has caused or allowed
a Release of Hazardous Materials at, to or from any real property of any Group Member and
each such real property is free of contamination by any Hazardous Materials except for
such Release or contamination that would not reasonably be expected to result, in the
aggregate, in a Material Adverse Effect, (d) no Group Member has received any information
request or notice of potential responsibility under CERCLA or similar Environmental Laws,
that, in the aggregate, would be reasonably expected to have a Material Adverse Effect and
(e) each Group Member has made available to the Purchasers copies of all existing material
environmental reports, reviews and audits and all documents containing material
information pertaining to actual or potential material Environmental Liabilities, in each
case to the extent such reports, reviews, audits and documents are in their possession,
custody or control.




          Section 4.15 Intellectual Property. Each Group Member owns or licenses all
Intellectual Property that is necessary for the operations of its businesses except as, in
the aggregate, would not be reasonably expected to have a Material Adverse Effect. To the
knowledge of each Group Member, (a) the conduct and operations of the businesses of each
Group Member does not infringe, misappropriate or violate any Intellectual Property owned
by any other Person and (b) no other Person has contested any right, title or interest of
any Group Member in, or relating to, any Intellectual Property, other than, in each case,
as would not, in the aggregate, reasonably be expected to have a Material Adverse Effect.




          Section 4.16 Title; Real Property. Each Group Member has good and valid fee
simple title to all owned real property and valid leasehold interests in all leased real
property, and owns or leases all personal property necessary for the conduct of its
business except as would not reasonably be expected to have a Material Adverse Effect, and
none of such property is subject to any Lien except Permitted Liens. As of the Closing
Date, no Group Member owns any fee simple interest in any real Property.




          Section 4.17 Full Disclosure. All of the representations or warranties made
by any Note Party or any of their respective Subsidiaries in the Note Documents as of the
date such representations and warranties were made or deemed made, and all of the
information other than the Projections and general economic or specific industry
information that has been made available to the Purchasers by or on behalf of any Group
Member or any of their respective Subsidiaries (including the information contained in any
Financial Statement or Disclosure Document), when taken as a whole and after giving effect
to all supplements previously made thereto, was, when furnished, complete



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







54









 









and correct in all material respects and did not, when furnished, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make
the statements contained therein not materially misleading in light of the circumstances
under which such statements were made. All projections that are part of such information
(including those set forth in any Projections delivered subsequent to the Closing Date)
have been prepared in good faith based upon assumptions believed by the preparer thereof
to be reasonable at the time made and at the time such projections are made available (it
being understood and agreed that financial projections are not a guarantee of financial
performance and actual results may differ from financial projections and such differences
may be material).




          Section 4.18 Anti-Terrorism Laws. No Group Member and, to the knowledge of
each Group Member, no joint venture or subsidiary thereof is in violation in any material
respects of any United States Requirements of Law relating to terrorism, sanctions or
money laundering, including the United States Executive Order No. 13224 on Terrorist
Financing and the Patriot Act.




          Section 4.19 Material Agreements. Except for matters which, either
individually or in the aggregate, would not reasonably be expected to result in a Material
Adverse Effect, each Material Agreement (a) is in full force and effect, unless it has
expired at the end of its stated term or been replaced by an agreement or agreements not
materially less favorable to the Note Parties than the Material Agreement which it
replaces and (b) has not been amended or modified (other than amendments or modifications
permitted by Section 8.11(c)).




          Section 4.20 Health Care Matters. Except as would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect, each Group Member, and any
Person acting on their behalf, is in compliance in all respects with all Health Care Laws
applicable to it, its products and its properties or other assets or its business or
operation.




          Section 4.21 Health Care Permits. Except as would not, in the aggregate,
reasonably be expected to have a Material Adverse Effect, (a) each Group Member, and any
Person acting on their behalf, has in effect all material health care Permits necessary
for it to own, lease or operate its properties and other assets and to carry on its
business and operations as presently conducted, (b) all such Permits are in full force and
effect and there exists no default under, or violation of, any such Permit, (c) no
condition exists or event has occurred which, in itself or with the giving of notice or
lapse of time or both, has resulted or would result in the suspension, revocation,
impairment, forfeiture or non-renewal of any such Permit and (d) there is no material
claim that any such Permit is not in full force and effect, and no presently existing
circumstance exists or event has occurred which could reasonably be expected to result in
a material violation of the Health Care Laws. As of the Closing Date, Schedule
4.21 sets forth an accurate, complete and current list of all material health care
Permits with respect to the business of each Group Member.




          Section 4.22 Exclusion. Except as would not, in the aggregate, reasonably be
expected to have a Material Adverse Effect, none of the Group Members, nor any Person
acting on behalf of any Group Member has been, or has been threatened to be, (i) excluded
from any Governmental Payor Program pursuant to 42 U.S.C. §



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





55









 









1320a-7b and related regulations, (ii) “suspended” or “debarred” from selling products
to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation,
relating to debarment and suspension applicable to federal government agencies generally
(42 C.F.R. Subpart 9.4), or other applicable laws or regulations, (iii) debarred,
disqualified, suspended or excluded from participation in Medicare, Medicaid or any other
health care program or is listed on the General Services Administration list of excluded
parties, nor is any such debarment, disqualification, suspension or exclusion threatened or
pending, or (iv) made a party to any other action by any Governmental Authority that may
prohibit it from selling products or providing services to any governmental or other
purchaser pursuant to any federal, state or local laws or regulations.




          Section 4.23 HIPAA. Except as would not, in the aggregate, reasonably be
expected to have a Material Adverse Effect, each Group Member is in compliance with all
applicable federal, state and local laws and regulations regarding the privacy and security
of health information and electronic transactions, including HIPAA, and the provisions of
all business associate agreements (as such term is defined by HIPAA) to which it is a party
and has implemented adequate policies, procedures and training designed to assure continued
compliance and to detect non-compliance. Except as would not, in the aggregate, reasonably
be expected to have a Material Adverse Effect, to the extent applicable to any Note Party
and for so long as (1) any Note Party is a “covered entity” as defined in 45 C.F.R. §
160.103, (2) any Note Party is a “business associate” as defined in 45 C.F.R. § 160.103,
(3) any Note Party is subject to or covered by the HIPAA Administrative Requirements
codified at 45 C.F.R. Parts 160 & 162 (the “Transactions Rule”) and/or the HIPAA Security
and Privacy Requirements codified at 45 C.F.R. Parts 160 & 164 (the “Privacy and Security
Rules”), and/or (4) any Note Party sponsors any “group health plans” as defined in 45
C.F.R. § 160.103, such Note Party has: (i) completed thorough and detailed surveys, audits,
inventories, reviews, analyses and/or assessments, including risk assessments,
(collectively “Assessments”) of all material areas of its business and operations subject
to HIPAA and/or that could be materially and adversely affected by the failure of such Note
Party, or any Person acting on behalf of any Note Party, as the case may be, to the extent
these Assessments are appropriate or required for such Note Party to be in compliance with
HIPAA; (ii) developed a detailed plan and time line for becoming in compliance with HIPAA
(a “HIPAA Compliance Plan”); and (iii) implemented those provisions of its HIPAA Compliance
Plan necessary to ensure that such Note Party is in compliance with HIPAA.



ARTICLE 5 
FINANCIAL
COVENANTS



          Each of Holdings and each Issuer agrees with the Purchasers to each of the following, as long
as any Obligation (other than any Contingent Note Document Obligation) remains outstanding: Section
5.1 Maximum Consolidated Senior Leverage Ratio.





          Section 5.1 Maximum Consolidated Senior Leverage Ratio.
Holdings shall not have, on the last day of each Fiscal Quarter set forth below, a
Consolidated Senior Leverage Ratio greater than the maximum ratio set forth opposite such
Fiscal Quarter:



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






56









 








	 	 	 
	 	 	MAXIMUM CONSOLIDATED
	FISCAL QUARTER ENDING	 	SENIOR LEVERAGE RATIO
	September 30, 2010
	 	3.30:1.00
	December 31, 2010
	 	3.00:1.00
	March 31, 2011
	 	2.90:1.00
	June 30, 2011
	 	2.60:1.00
	September 30, 2011
	 	2.40:1.00
	December 31, 2011
	 	2.40:1.00
	March 31, 2012
	 	2.20:1.00
	June 30, 2012
	 	1.90:1.00
	September 30, 2012
	 	1.80:1.00
	December 31, 2012
	 	1.70:1.00
	March 31, 2013
	 	1.50:1.00
	June 30, 2013
	 	1.30:1.00
	September 30, 2013
	 	1.20:1.00
	December 31, 2013
	 	1.20:1.00
	March 31, 2014
	 	1.20:1.00
	June 30, 2014 and thereafter
	 	1.10:1.00







          Section 5.2 Maximum Consolidated Total Leverage Ratio. Holdings shall not
have, on the last day of each Fiscal Quarter set forth below, a Consolidated Total
Leverage Ratio greater than the maximum ratio set forth opposite such Fiscal Quarter:



	 	 	 
	 	 	MAXIMUM CONSOLIDATED
	FISCAL QUARTER ENDING	 	TOTAL LEVERAGE RATIO
	September 30, 2010
	 	4.40:1.00
	December 31, 2010
	 	4.40:1.00
	March 31, 2011
	 	4.10:1.00
	June 30, 2011
	 	3.90:1.00
	September 30, 2011
	 	3.60:1.00
	December 31, 2011
	 	3.30:1.00
	March 31, 2012
	 	3.30:1.00
	June 30, 2012
	 	3.00:1.00
	September 30, 2012
	 	2.90:1.00
	December 31, 2012
	 	2.80:1.00
	March 31, 2013
	 	2.60:1.00






NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







57









 








	 	 	 
	 	 	MAXIMUM CONSOLIDATED
	FISCAL QUARTER ENDING	 	TOTAL LEVERAGE RATIO
	June 30, 2013
	 	2.40:1.00
	September 30, 2013
	 	2.30:1.00
	December 31, 2013
	 	2.20:1.00
	March 31, 2014
	 	2.20:1.00
	June 30, 2014
	 	1.90:1.00
	September 30, 2014
	 	1.90:1.00
	December 31, 2014
	 	1.80:1.00
	March 31, 2015
	 	1.80:1.00
	June 30, 2015 and thereafter
	 	1.70:1.00







          Section 5.3 [Reserved.]




          Section 5.4 Minimum Consolidated Interest Coverage Ratio. Holdings shall not
have, on the last day of each Fiscal Quarter set forth below, a Consolidated Interest
Coverage Ratio for the four (4) Fiscal Quarter period ending on such day less than the
minimum ratio set forth opposite such Fiscal Quarter:



	 	 	 
	 	 	MINIMUM CONSOLIDATED
	FISCAL QUARTER ENDING	 	INTEREST COVERAGE RATIO
	September 30, 2010
	 	2.50:1.00
	December 31, 2010
	 	2.50:1.00
	March 31, 2011
	 	2.50:1.00
	June 30, 2011
	 	2.70:1.00
	September 30, 2011
	 	2.90:1.00
	December 31, 2011
	 	2.90:1.00
	March 31, 2012
	 	3.20:1.00
	June 30, 2012
	 	3.20:1.00
	September 30, 2012
	 	3.40:1.00
	December 31, 2012
	 	3.40:1.00
	March 31, 2013 and thereafter
	 	3.60:1.00






ARTICLE 6

REPORTING COVENANTS



          Each of Holdings and each Issuer agrees with the Purchasers to each of the following, as long
as any Obligation (other than any Contingent Note Document Obligation) remains outstanding:




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







58









 









          Section 6.1 Financial Statements. The Issuers shall deliver to the Purchasers
each of the following in a format reasonably satisfactory to the Required Purchasers:



          (a) Monthly Reports. Within 30 days after the end of each month, the internal Consolidated
unaudited balance sheet of each of MedQuist and CBay as of the close of such fiscal month and
related Consolidated statements of income and cash flow for such fiscal month and that portion of
the Fiscal Year ending as of the close of such fiscal month, setting forth in comparative form the
figures for the corresponding period in the prior Fiscal Year (after the first anniversary of the
Closing Date) prepared for management and consistent with past practice.




          (b) Quarterly Reports. As soon as available, and in any event within 45 days after the
end of each Fiscal Quarter of each Fiscal Year (i) ending before the MedQuist Consolidation Date,
the Consolidated unaudited balance sheet of Holdings, the Consolidated unaudited balance sheet of
MedQuist and all eliminations necessary to reconcile such balance sheets and (ii) ending on or
after the MedQuist Consolidation Date, the Consolidated unaudited balance sheet of Holdings, in
each case as of the close of such Fiscal Quarter, and including related Consolidated statements of
income and cash flow for such Fiscal Quarter and that portion of the Fiscal Year ending as of the
close of such Fiscal Quarter, setting forth in comparative form (x) the figures for the
corresponding period in the prior Fiscal Year (after the first anniversary of the Closing Date) and
(y) the figures for the corresponding period set forth in the most recent corresponding Projections
received by the Purchasers pursuant to Section 6.1(f), in each case certified by a
Responsible Officer of the Issuer Representative as fairly presenting in all material respects the
Consolidated financial position, results of operations and cash flow of Holdings and/or MedQuist,
as applicable, as at the dates indicated and for the periods indicated in accordance with GAAP
(subject to the absence of footnote disclosure and normal year-end audit adjustments).




          (c) Annual Reports. As soon as available, and in any event within 90 days after the
end of each Fiscal Year (i) ending before the MedQuist Consolidation Date, the Consolidated balance
sheet of Holdings and the Consolidated balance sheet of MedQuist and (ii) ending on or after the
MedQuist Consolidation Date, the Consolidated balance sheet of Holdings, in each case as of the end
of such year and including related Consolidated statements of income, stockholders’ equity and cash
flow for such Fiscal Year, each prepared in accordance with GAAP, together with an opinion of the
Group Members’ Accountants that such Consolidated Financial Statements fairly present in all
material respects the Consolidated financial position, results of operations and cash flow of
Holdings and/or MedQuist, as applicable, as at the dates indicated and for the periods indicated
therein in accordance with GAAP without qualification as to the scope of the audit or as to going
concern or other similar qualification, it being understood that the Issuers may satisfy the
requirements of this clause (c) by delivery, in the manner provided in Section
11.11(a), of their annual reports on Form 10-K (or any successor form), as filed with the
Securities and Exchange Commission.




          (d) Compliance Certificate. Together with each delivery of any Financial Statement
pursuant to clause (b) or (c) above, a Compliance Certificate duly executed by a
Responsible Officer of the Issuer Representative that, among other things, (i) if delivered
together with any Financial Statement pursuant to clause (c) above, includes the calculations used
in determining Excess Cash Flow, (ii) if delivered together with any Financial Statements pursuant
to clauses (b) or (c) above, (A) demonstrates compliance with each financial
covenant contained in Article 5 and (B) contains a detailed calculation of Additional Available
Cash as of the date of




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





59









 







such Financial Statements including any reduction thereof described in clauses (v) and (vi) of
the definition thereof, and (iii) states that no Default is continuing as of the date of delivery
of such Compliance Certificate or, if a Default is continuing, states the nature thereof and the
action that the Issuers propose to take with respect thereto.




          (e) Corporate Chart and Other Collateral Updates. Together with each delivery of any
Financial Statement pursuant to clause (c) above, a certificate by a Responsible Officer of
the Issuer Representative that (i) the Corporate Chart attached thereto (or the last Corporate
Chart delivered pursuant to this clause (e)) is correct and complete as of the date of such
Compliance Certificate, (ii) there has been no material change in the information provided in the
last Compliance Certificate delivered pursuant to this clause (e), as applicable, or, if
there has been a material change in such information, complete and correct supplements to such
Schedules have been delivered to the Purchasers or are attached to such certificate, and (iii) if
any term of any Constituent Document of any Group Member has been modified on or prior to the date
of delivery of such Compliance Certificate in accordance with Section 8.11, complete and
correct copies of all documents evidencing such modification have been delivered to the Purchasers
or are attached to such certificate.




          (f) Additional Projections. As soon as available and in any event not later than 30
days after the beginning of each Fiscal Year, (i) forecasts prepared by management of the Issuers
including in such forecasts (A) a projected Consolidated balance sheet, income statement and
statement of cash flows and (B) a statement of all of the material assumptions on which such
forecasts are based for each Fiscal Quarter in such Fiscal Year containing substantially the same
type of financial information as that contained in the Initial Projections.




          (g) Audit Reports, Management Letters, Etc. Together with each delivery of any
Financial Statement for any Fiscal Year pursuant to clause (c) above, copies of each
management letter, audit report or similar letter or report received by any Group Member from any
independent registered certified public accountant (including the Group Members’ Accountants) in
connection with such Financial Statements or any audit thereof, each certified to be complete and
correct copies by a Responsible Officer of the Issuer Representative as part of the Compliance
Certificate delivered in connection with such Financial Statements.




          (h) Other. Reasonably promptly after request, such documents and information with respect to
the business, property, condition (financial or otherwise), legal, financial or corporate or
similar affairs or operations of any Note Party (and during the continuance of a Default, any Group
Member) as the Required Purchasers may from time to time reasonably request.





          Section 6.2 Other Events. The Issuer Representative shall give the Purchasers notice of each
of the following (which may be made by telephone if promptly confirmed in writing) promptly after
any Responsible Officer of any Note Party knows:



          (a) (i) the occurrence or existence of any Default or Event of Default and (ii) any event
that such Responsible Officer believes would reasonably be expected to have a Material Adverse
Effect, specifying, in each case, the nature and anticipated effect thereof and any action proposed
to be taken in connection therewith;




          (b) [Reserved.];




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






60









 








          (c) the commencement of any action, investigation, suit or proceeding by or before any
Governmental Authority brought against any Group Member that would reasonably be expected to have a
Material Adverse Effect;




          (d) notice of any material civil or criminal investigation or the commencement of proceedings
before any Governmental Authority alleging a material violation of any Health Care Laws;




          (e) [Reserved.];




          (f) any default under (after the expiration of any cure period with respect to such default
and after giving effect to any written waiver of such default) any Senior Loan Document; and




          (g) any material default under any Material Agreement (after the
expiration of any cure period with respect to such default and after giving
effect to any written waiver of such default) or any termination of any
Material Agreement, other than a termination in connection with the
replacement thereof with an agreement or agreements not materially less
favorable to the Note Parties.



Each notice pursuant to this Section shall be in electronic form accompanied by a statement by a
Responsible Officer on behalf of the Issuer Representative setting forth details of the occurrence
referred to therein, and stating what action the Issuers or other Person proposes to take with
respect thereto and at what time.





          Section 6.3 Copies of Notices and Reports. The Issuer Representative shall
promptly deliver to the Purchasers copies of each of the following: (a) all reports that
Holdings transmits to its security holders generally, (b) all periodic reports and reports
on Form 8-K that any Group Member files with the Securities and Exchange Commission and (c)
all material documents transmitted or received pursuant to, or in connection with, any
Related Document.




          Section 6.4 Labor Matters. The Issuer Representative shall give the Purchasers
notice of each of the following (which may be made by telephone if promptly confirmed in
writing), promptly after, and in any event within 30 days after any Responsible Officer of
any Note Party knows: (a) the commencement of any material labor dispute to which any Group
Member is a party, including any strikes, lockouts or other disputes relating to any of
such Person’s plants and other facilities and (b) the incurrence by any Group Member of any
Worker Adjustment and Retraining Notification Act or related or similar liability incurred
with respect to the closing of any plant or other facility of any such Person (other than,
in the case of this clause (b), those that would not, in the aggregate, be
reasonably expected to have a Material Adverse Effect).




          Section 6.5 ERISA-Related Information. The Issuer Representative shall supply to the
Purchasers:



          (a) promptly and in any event within 15 days after any ERISA Affiliate files a Schedule B (or
such other schedule as contains actuarial information) to IRS Form 5500 in




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







61









 







respect of a Title IV Plan with Unfunded Pension Liabilities, a copy of such IRS Form 5500
(including the Schedule B);




          (b) promptly and in any event within 30 days after any ERISA Affiliate knows or has reason to
know that any ERISA Event has occurred, a certificate of the chief financial officer of the ERISA
Affiliate describing such ERISA Event and the action, if any, proposed to be taken with respect to
such ERISA Event and a copy of any notice filed with the PBGC or the IRS pertaining to such ERISA
Event and any notices received by such ERISA Affiliate from the PBGC or any other governmental
agency with respect thereto; provided that, in the case of ERISA Events under paragraph (g) of the
definition thereof, the 30-day period set forth above shall be a 10-day period, and, in the case of
ERISA Events under paragraph (e) of the definition thereof, in no event shall notice be given later
than the occurrence of the ERISA Event; and




          (c) promptly and in any event within 30 days after the adoption of, or the commencement of
contributions to, any Benefit Plan subject to Section 412 of the Code or Title IV of ERISA by any
ERISA Affiliate, or the adoption of any amendment to a Benefit Plan subject to Section 412 of the
Code or Title IV of ERISA which results in a material increase in contribution obligations of any
ERISA Affiliate, a detailed written description thereof from the chief financial officer of such
ERISA Affiliate.




ARTICLE 7

AFFIRMATIVE COVENANTS



          Each of Holdings and each Issuer agrees with the Purchaers to each of the following, as long
as any Obligation (other than any Contingent Note Document Obligation) remains outstanding:





          Section 7.1 Maintenance of Corporate Existence. Each Group Member shall
preserve and maintain its legal existence, except in the consummation of transactions
expressly permitted by Sections 8.4 and 8.7.




          Section 7.2 Compliance with Laws, Etc. Each Group Member shall comply with all
applicable Requirements of Law, except for such failures to comply that would not, in the
aggregate, reasonably be expected to have a Material Adverse Effect.




          Section 7.3 Payment of Obligations. Each Group Member shall pay or discharge
before they become delinquent (a) all material claims, taxes, assessments, charges and
levies imposed by any Governmental Authority and (b) all other material lawful claims that
if unpaid would, by the operation of applicable Requirements of Law, become a Lien upon any
property of any Group Member, except, in each case, for those whose amount or validity is
being contested in good faith by proper proceedings diligently conducted and for which
adequate reserves are maintained on the books of the appropriate Group Member in accordance
with GAAP.




          Section 7.4 Maintenance of Property. Each Group Member shall maintain and
preserve (a) in good working order and condition all of its property necessary in the
conduct of its business and (b) all rights, Permits, licenses, approvals and privileges
necessary, used or useful, whether because of its ownership, lease, sublease or other
operation or occupation of property or other conduct of its business,



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







62









 









and shall make all necessary or appropriate filings with, and give all required
notices to, Government Authorities, except for such failures to maintain and preserve the
items set forth in clauses (a) and (b) above that would not, in the aggregate, reasonably
be expected to have a Material Adverse Effect.




          Section 7.5 Maintenance of Insurance. Each Group Member shall (a) maintain
or cause to be maintained in full force and effect all policies of insurance with respect
to the property and businesses of the Group Members (including policies of life, fire,
theft, product liability, public liability, Flood Insurance, property damage, other
casualty, employee fidelity, workers’ compensation, business interruption and employee
health and welfare insurance) with financially sound and reputable insurance companies or
associations (in each case that are not Affiliates of any Issuer) of a nature and
providing such coverage as is sufficient and as is customarily carried by businesses of
the size and character of the business of the Group Members. Notwithstanding the
requirement above, Federal Flood Insurance shall not be required for (x) real property not
located in a Special Flood Hazard Area, or (y) real property located in a Special Flood
Hazard Area in a community that does not participate in the National Flood Insurance
Program.




          Section 7.6 Keeping of Books. The Group Members shall keep proper
Consolidated books of record and account, in which full, true and correct entries shall be
made in accordance with GAAP and all other applicable Requirements of Law of all material
financial transactions and the assets and business of the Group Members.




          Section 7.7 Access to Books and Property. Each Note Party (and during the
continuance of a Default, each Group Member) shall permit a representative selected by the
Required Purchasers (the “Purchaser Representative”) and its Related Persons, as
often as reasonably requested, at any reasonable time during normal business hours, with
reasonable advance notice (except that, during the continuance of an Event of Default, no
such notice shall be required and each Purchaser may exercise all rights hereunder
(including the right of inspection) at any and all times during the continuance thereof)
to (a) visit and inspect the property of each Note Party (and during the continuance of a
Default, each Group Member) and examine and make copies of and abstracts from, the
corporate (and similar), financial, operating and other books and records of each Note
Party (and during the continuance of a Default, each Group Member), (b) discuss the
affairs, finances and accounts of each Note Party (and during the continuance of a
Default, each Group Member) with any officer or director of any Note Party (and during the
continuance of a Default, any Group Member) and (c) communicate directly with any
registered certified public accountants (including the Group Members’ Accountants) of any
Note Party (and during the continuance of a Default, each Group Member); provided,
the Note Parties shall not be responsible for costs and expenses other than those of the
Purchaser Representative once per year unless an Event of Default has occurred and is
continuing; provided further that any annual inspection shall be conducted on a single
date for all Purchasers each year. Each Note Party (and during the continuance of a
Default, each Group Member) shall authorize their respective registered certified public
accountants (including the Group Members’ Accountants) to communicate directly with the
Purchaser Representative and its Related Persons and to disclose to the Purchaser
Representative and its Related Persons all financial statements and other documents and
information as they might have and the



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






63









 









Purchaser Representative reasonably requests with respect to any Note Party (and
during the continuance of a Default, any Group Member).




          Section 7.8 Environmental. Each Group Member shall comply with, and maintain
its real property, whether owned, leased, subleased or otherwise operated or occupied, in
compliance with, all applicable Environmental Laws (including by implementing any Remedial
Action necessary for such Group Member to achieve such compliance or that is required by
orders and directives of any Governmental Authority) except for failures to comply or
maintain that would not, in the aggregate, reasonably be expected to have a Material
Adverse Effect.




          Section 7.9 Use of Proceeds. The proceeds of the sale of the Notes shall be
used by the Issuers (and, to the extent distributed to them by the Issuers, each other
Group Member) solely (a) to consummate the Related Transactions, the Exchange Offer and for
the payment of related transaction costs, fees and expenses and (b) for the payment of
transaction costs, fees and expenses incurred in connection with the Note Documents and the
transactions contemplated therein.




          Section 7.10 Additional Guaranties. To the extent not delivered to the Purchasers on
or before the Closing Date (including Persons that become, after the Closing Date, Domestic
Subsidiaries of any Note Party, each Group Member shall, promptly, do each of the following, unless
otherwise agreed by the Required Purchasers:



          (a) deliver to the Purchasers such modifications to the terms of the Note Documents (or such
other documents), in each case substantially in the same form as delivered to the Senior Agent
under the Senior Credit Agreement in order to ensure that each Subsidiary of any Note Party that
has entered into Guaranty Obligations with respect to the Senior Loan Obligations shall guaranty,
as primary obligor and not as surety, the payment of the Obligations of the Issuers;




          (b) [Reserved.];




          (c) [Reserved.];




          (d) take all other actions necessary or advisable to ensure the validity or continuing
validity of any guaranty for any Obligation set forth in the Note Documents executed on the Closing
Date; and




          (e) if delivered to the Senior Agent, deliver to the Purchasers legal opinions relating to the
matters described in this Section 7.10, which opinions shall be substantially in the form delivered
to the Senior Agent in connection with the comparable guaranty of the Senior Lenders.





          Section 7.11 [Reserved].




          Section 7.12 Compliance Program. The Group Members shall continue to maintain
a compliance program related to their obligations as a “business associate” of “covered
entities,” as such terms are defined by HIPAA, including employee training and policies and
procedures on the appropriate use and disclosure of protected health information. The
Group Members shall revise and update such



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY








64









 









compliance program, as appropriate, to take into account any changes in law or
regulation affecting such program in any material respect.



ARTICLE 8

NEGATIVE COVENANTS




          Each of Holdings and each Issuer agrees with the Purchasers to each of the following, as long
as any Obligation (other than any Contingent Note Document Obligation) remains outstanding:





          Section 8.1 Indebtedness. No Group Member shall incur or otherwise remain liable with
respect to, any Indebtedness except for the following:



          (a) the Obligations;




          (b) Indebtedness existing on the date hereof and set forth on Schedule 8.1, together
with any Permitted Refinancing thereof;




          (c) Indebtedness consisting of Capitalized Lease Obligations (other than with respect to a
lease entered into as part of a Sale and Leaseback Transaction) and purchase money Indebtedness to
finance the acquisition, repair, improvement or construction of fixed or capital assets of such
Group Member, in each case incurred by any Group Member (other than Holdings) together with any
Permitted Refinancing thereof; provided, however, that (i) the aggregate
outstanding principal amount of all such Indebtedness permitted under this clause (c) does
not exceed $5,750,000 (plus $1,150,000 per Fiscal Year occurring after the 2010 Fiscal Year) at any
one time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost
or fair market value (calculated at the time an acquisition, repair, improvement or construction is
made) of the property so acquired or built or of such repairs or improvements financed, whether
directly or through a Permitted Refinancing, with such Indebtedness;




          (d) Capitalized Lease Obligations incurred by any Group Member (other than Holdings) arising
under Sale and Leaseback Transactions involving the sale of assets permitted hereunder in reliance
upon Sections 8.4(d) or (e);




          (e) Indebtedness owed by one Group Member to any other Group Member to the extent that the
resulting Investment held by the payee of such Indebtedness constitutes a Permitted Investment
under Section 8.3(e);




          (f) (i) obligations under Interest Rate Contracts entered into to comply with Section 7.13 of
the Senior Credit Agreement and (ii) obligations under Hedging Agreements entered into in the
Ordinary Course of Business and not for speculation;




          (g) Guaranty Obligations of any Group Member with respect to Indebtedness of any Group Member
(except with respect to Permitted Refinancings, for which Guaranty Obligations are permitted only
to the extent set forth in the definition thereof), to the extent that such Guaranty constitutes a
Permitted Investment under Section 8.3(e);




          (h) Indebtedness of any Group Member (other than Holdings) in respect of performance bonds,
bid bonds, appeal bonds, surety bonds, performance and completion




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





65









 







guarantees and similar obligations, in each case, that are incurred in the Ordinary Course of
Business and not in connection with the borrowing of money or Hedging Agreement;




          (i) Indebtedness of any Group Member consisting of (i) obligations to pay insurance premiums,
or
(ii) take or pay obligations contained in supply agreements, in each case, with such
obligations arising in the Ordinary Course of Business and not in connection with the borrowing of
money or Hedging Agreements;




          (j) Indebtedness pursuant to the Senior Loan Documents; provided, however, that the
aggregate outstanding principal amount of all such Senior Loan Obligations (excluding Secured
Hedging Obligations and Bank Product Obligations (as defined in the Subordination Agreement)) shall
not exceed the Maximum Senior Principal Amount;




          (k) unsecured Indebtedness of any Group Member representing deferred compensation to
employees, consultants or independent contractors of a Group Member incurred in the Ordinary Course
of Business, or of a Person whose liability for such compensation has been assumed pursuant to a
Permitted Acquisition;




          (l) Indebtedness in respect of automatic clearing house arrangements, employee issued credit
or purchase cards and overdraft protections, in each case, incurred in the Ordinary Course of
Business by any Group Member, provided that (i) such Indebtedness (other than credit or
purchase cards) is extinguished within ten (10) Business Days of its incurrence and (ii) such
Indebtedness in respect of credit or purchase cards is extinguished within sixty (60) days of its
incurrence;




          (m) Indebtedness of Excluded Foreign Subsidiaries, provided that such Indebtedness is
for working capital or general corporate purposes in an aggregate principal amount not to exceed
$8,050,000 at any time outstanding;




          (n) to the extent constituting Indebtedness, any earn-out or similar obligations of any Group
Member incurred in connection with Permitted Acquisitions;




          (o) Indebtedness, and any Permitted Refinancing thereof, (i) of a Person which became a Group
Member after the Closing Date that existed at the time such Person became a Group Member, provided
that such Indebtedness was not incurred in contemplation of such Person becoming a Group Member or
(ii) otherwise incurred in connection with a Permitted Acquisition and subordinated to the
Obligations on terms and conditions reasonably acceptable to the Administrative Agent;
provided, however, that all such Indebtedness under this clause (o) shall not
exceed $5,750,000 in the aggregate at any time outstanding;




          (p) other Indebtedness of any Group Member (other than Holdings) not exceeding in the
aggregate at any time outstanding $1,725,000;




          (q) Indebtedness of Holdings or MedQuist owing to former officers, directors, consultants and
employees (or any spouses, ex-spouses or estates of any of the foregoing) of a Group Member
incurred in connection with the repurchase of Stock and Stock Equivalents of Holdings or MedQuist
that have been issued to such Persons, provided that the amount of such Indebtedness
pursuant to this clause (q) shall not exceed an aggregate outstanding principal balance of
$5,000,000 at any time, and the Indebtedness pursuant to this clause (q) shall




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







66









 







be subordinated to the Obligations on terms and conditions reasonably acceptable to the
Required Purchasers; and




          (r) all customary premiums (if any), interest (including post-petition interest), fees,
expenses, charges and additional or contingent interest on Indebtedness described in each of
Sections 8.1(a) through (q) above.





          Section 8.2 Liens. No Group Member shall incur, maintain or otherwise suffer to exist
any Lien upon or with respect to any of its property, whether now owned or hereafter acquired,
except for the following:



          (a) Liens created pursuant to any Senior Loan Document;




          (b) Customary Permitted Liens of Group Members;




          (c) Liens existing on the date hereof and set forth on Schedule 8.2;




          (d) Liens on the property of any Group Member (other than Holdings) securing Indebtedness of
such Group Member permitted hereunder in reliance upon Section 8.1(c); provided,
however, that (i) such Liens exist prior to the acquisition of, or attach substantially
simultaneously with, or within 90 days after, the acquisition, repair, improvement or construction
of, such property financed, whether directly or through a Permitted Refinancing, by such
Indebtedness and (ii) such Liens do not extend to any property of any Group Member other than the
property (and proceeds thereof) acquired or built, or the improvements or repairs, financed,
whether directly or through a Permitted Refinancing, by such Indebtedness;




          (e) Liens on the property of Group Members securing the Permitted Refinancing of any
Indebtedness secured by any Lien on such property permitted hereunder in reliance upon clause (c)
or (d) above or this clause (e) without any change in the property subject to such Liens;




          (f) Liens with respect to the Property of any Excluded Foreign Subsidiary securing
Indebtedness of such Excluded Foreign Subsidiary that is permitted under Section 8.1(m);




          (g) Liens with respect to Indebtedness permitted under Section 8.1(e) and (g),
provided that (i) any Indebtedness owing by a Note Party to a Person who is not a Note
Party shall not be secured at any time unless such Indebtedness is Junior Subordinated Debt and
(ii) any Guaranty Obligation of a Subsidiary that is not a Note Party may not be secured by
Property of any other Note Party;




          (h) Liens on Property which is the subject of a Capitalized Lease Obligation permitted by
Section 8.1(d);




          (i) Liens on Property acquired in connection with a Permitted Acquisition that was subject to
such Lien prior to such Permitted Acquisition to the extent such Lien was not made in connection
with or in contemplation of such Permitted Acquisition and which only secures Indebtedness
permitted to be assumed in connection with such Permitted Acquisition or any Permitted Refinancing
thereof; and




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY












67









 








          (j) Liens on Property of Group Members not otherwise permitted by this Section 8.2 so
long as the aggregate principal amount of Indebtedness and other obligations secured thereby does
not exceed $1,150,000 at any time.





          Section 8.3 Investments. No Group Member shall make or maintain any Investment except
for the following:



          (a) Investments existing on the date hereof and set forth on Schedule 8.3;




          (b) Investments in cash and Cash Equivalents;




          (c) (i) endorsements for collection or deposit in the Ordinary Course of Business consistent
with past practice, (ii) extensions of trade credit arising or acquired in the Ordinary Course of
Business and (iii) Investments acquired in connection with the settlement of delinquent accounts
arising in the Ordinary Course of Business, in connection with the bankruptcy or reorganization of
suppliers or customers or as security for such claims, or upon the foreclosure by a Note Party of
its Lien with respect to any secured Investment;




          (d) Investments by Note Parties made as part of a Permitted Acquisition and Investments held
by any Person acquired as part of a Permitted Acquisition (and not made in connection with or in
contemplation of such Permitted Acquisition);




          (e) Investments by (i) any Note Party in or to any other Note Party (other than Holdings,
except to the extent such Investment could be made as a Restricted Payment to Holdings), (ii) any
Note Party in or to a Group Member which is not a Note Party not to exceed, for all such
Investments, (x) $4,600,000 in the aggregate outstanding at any time when the Consolidated Total
Leverage Ratio of Holdings is equal to or greater than 1.50:1.00 and (y) $4,600,000 plus Additional
Available Cash at any time when the Consolidated Total Leverage Ratio of Holdings is less than
1.50:1.00 or (iii) a Group Member which is not a Note Party to another Group Member and (y) any
Investment constituting an extension of credit to a Note Party described in clause (i) or (iii), is
expressly subordinated to the repayment of the Obligations;




          (f) loans and advances to officers, directors, consultants and employees of a Group Member (i)
to finance the purchase of Stock and Stock Equivalents of Holdings or MedQuist, provided
that the amount of such loans and advances used to acquire such Stock and Stock Equivalents shall
not exceed an aggregate outstanding principal balance of $575,000 at any time, (ii) for reasonable
and customary business related travel expenses, entertainment expenses and moving expenses, and
similar expenses, in each case, incurred in the Ordinary Course of Business and with loans and
advances for all such expenses not to exceed $575,000 in the aggregate outstanding at any time, and
(iii) for additional purposes not contemplated by clause (i) or (ii) above,
provided that the aggregate principal amount at any time outstanding with respect to this
clause 8.3(f)(iii) shall not exceed $575,000;




          (g) Investments received as the non-cash portion of consideration received in connection with
transactions permitted pursuant to Sections 8.4(a), (d) or (e); provided that the aggregate
principal amount at any time outstanding with respect to such Investments received under
Section 8.4(a) shall not exceed $1,150,000;




          (h) Investments made to repurchase or retire Stock or Stock Equivalents of Holdings (or any
direct or indirect parent thereof) or MedQuist in accordance with Section 8.5(d);




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







68









 








          (i) Guarantees by a Group Member of leases (other than of Capital Leases) or of other
obligations that do not constitute Indebtedness, in each case, entered into in the Ordinary Course
of Business;




          (j) Guarantees permitted under Section 8.1;




          (k) advances made in connection with purchases of goods or services in the Ordinary Course of
Business;




          (l) deposits of cash made in the Ordinary Course of Business to secure performance of
operating leases;




          (m) Investments in Hedging Agreements and Interest Rate Contracts permitted under Section
8.1(f);




          (n) Investments in the common Stock of MedQuist made in connection with the Exchange Offer;
and




          (o) other Investments not exceeding (i) $2,300,000 in the aggregate since the Closing Date
plus (ii) Additional Available Cash to the extent the Consolidated Total Leverage Ratio of Holdings
both before and after giving effect to such Investment is less than 1.50:1.00.





          Section 8.4 Asset Sales. No Group Member shall Sell any of its Property (other than cash),
enter into any Sale and Leaseback Transaction or (other than with respect to Holdings) issue shares
of its own Stock, except for the following:



          (a) In each case to the extent entered into in the Ordinary Course of Business (i) obsolete,
worn-out, used or surplus Property to the extent such Property is not necessary for the operation
of the Group Members’ businesses; (ii) inventory, equipment and goods sold; and (iii) cash and Cash
Equivalents;




          (b) (i) any Sale of any property by (A) any Note Party to any other Note Party
(other than Holdings, except to the extent that such property could be distributed as a Restricted
Payment to Holdings) and (B) any Group Member that is not a Note Party to any other Group Member
that is not a Note Party, (ii) any Sale by any Note Party to a Group Member that is not a Note
Party and any Sale by a Group Member that is not a Note Party to any Note Party provided that all
such Sales do not exceed in the aggregate (x) $1,150,000 for all such sales made at any time when
the Consolidated Total Leverage Ratio of Holdings is equal to or greater than 1.5:1.0, (y)
$5,750,000 for all such sales made at any time when the Consolidated Total Leverage Ratio of
Holdings is equal to or greater than 1.0:1.0 and less than 1.5:1.0 and (z) $11,500,000 for all such
sales at any time when the Consolidated Total Leverage Ratio of Holdings is less than 1.0:1.0, and
provided further that to the extent any such Sale under this clause (ii) is not for fair
market value, the resulting Investment by such Note Party constitutes a Permitted Investment under
Sections 8.3(e) or (o), (iii) any Restricted Payment by any Group Member permitted pursuant
to Section 8.5 and (iv) any distribution by Holdings of the proceeds of Restricted Payments
from any other Group Member to the extent permitted in Section 8.5;




          (c) (i) any Sale or issuance by Holdings of its own Stock, (ii) any Sale or issuance by any
Group Member of its own Stock to any Note Party, or by any Group Member that is not a Note Party to
another Group Member that is not a Note Party to the extent that the




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







69









 







resulting Investment is a Permitted Investment under Section 8.3(e); provided,
however, that the proportion of the Stock of any Group Member (both on an outstanding and
fully-diluted basis) held by the Note Parties, taken as a whole, is not reduced as a result of such
Sale or issuance and (iii) to the extent necessary to satisfy any Requirement of Law in the
jurisdiction of incorporation of any Group Member, any Sale or issuance by such Group Member of its
own Stock constituting directors’ qualifying shares or nominal holdings;




          (d) dispositions of Property not otherwise permitted hereunder that are made for fair market
value; provided, that (i) at the time of any disposition, no Default or Event of Default
shall exist or shall result from such disposition, (ii) not less than 75% of the aggregate sales
price from such disposition shall be paid in cash or Cash Equivalents, (iii) the aggregate fair
market value of all Property so sold by the Group Members, together, shall not exceed in any Fiscal
Year the greater of (x) one percent (1%) of the total assets of the Group Members reflected on the
Financial Statements delivered to the Administrative Agent in accordance with Section 6.1
for the preceding Fiscal Year, and (y) $2,875,000 and (iv) after giving effect to such disposition,
the Note Parties are in compliance on a pro forma basis with the covenants set forth in Article
5, recomputed for the most recent Fiscal Quarter for which Financial Statements have been
delivered;




          (e) other dispositions of Property the fair market value of which shall not exceed, in the
aggregate, $575,000;




          (f) any (i) sale or discounting of accounts receivable arising in the Ordinary Course of
Business in connection with the compromise or collection thereof and (ii) involuntary sale,
transfer, assignment or other disposition resulting from a Property Loss Event upon the receipt of
the applicable net proceeds for such Property Loss Event;




          (g) licenses, sublicenses, leases or subleases granted in the Ordinary Course of Business not
interfering with the business of the Group Members in any material respect;




          (h) Property to the extent that (i) such Property is exchanged for credit against the purchase
price of similar replacement Property or (ii) the proceeds of such disposition are promptly applied
to the purchase price of such replacement Property;




          (i) the Group Members may effect any transaction permitted by Section 8.3, 8.5
or 8.7;




          (j) lease of any tangible Property and licensing or contribution of Intellectual Property
pursuant to joint marketing arrangements with other Persons, in each case, in the Ordinary Course
of Business;




          (k) the RCM Sale;




          (l) the A-Life Sale; and




          (m) dispositions of any Property between or among
the Group Members as a substantially concurrent interim disposition in connection with a
disposition of such Property otherwise permitted pursuant to clauses (a) through (k)
above.




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







70









 









          Section 8.5 Restricted Payments. No Group Member shall declare, pay or make any
Restricted Payment except for the following (and Holdings shall not use the proceeds of any
Restricted Payment made in reliance under clause (c) below other than as set forth in such
clause (c)):



          (a) Restricted Payments (i) by a Note Party to any Note Party other than Holdings (except as
otherwise permitted under any other clause of this Section 8.5) and (ii) by any Group
Member that is not a Note Party to any Group Member;




          (b) dividends and distributions declared and paid on the common Stock of any Group Member
ratably to the holders of such common Stock and payable only in common Stock of such Group Member;




          (c) cash dividends or distributions on the Stock of the Group Members (other than Holdings) to
Holdings paid and declared solely for the purpose of funding the following:





     (i) payments by Holdings in respect of taxes then due and owing by Holdings in respect of the
other Group Members;




     (ii) ordinary operating expenses of Holdings; provided, however, that the amount of such cash
dividends paid in any Fiscal Year shall not exceed $6,000,000 in the aggregate;




     (iii) payments with respect to withholding or similar taxes payable or expected to be payable
by or with respect to any present or former employee, director, manager or consultant (or their
respective Affiliates, estates or immediate family members) for any repurchases of Stock or Stock
Equivalents in Holdings including deemed repurchases in connection with the exercise of stock
options, provided in each case that payments made under this clause (iii) shall not exceed
$500,000 in the aggregate; and




     (iv) to pay the consideration necessary to consummate any Permitted Acquisition in accordance
with the agreements evidencing such Permitted Acquisition;


provided, however, that no action that would otherwise be permitted hereunder
in reliance upon this clause (c) (other than clause (i) or (ii) above)
shall be permitted if a Default is then continuing or would result therefrom;




          (d) the Group Members may redeem, acquire, retire or repurchase (and the Group Members may
declare and pay cash Restricted Payments to another Group Member (or any direct or indirect parent
thereof), the proceeds of which are used to so redeem, acquire, retire or repurchase) shares of
Stock or Stock Equivalents of Holdings or any Excluded Foreign Subsidiary (or any options or
warrants or stock appreciation rights issued with respect to any of such Stock or Stock
Equivalents) (or to allow Holdings (or any direct or indirect parent thereof) or any Excluded
Foreign Subsidiary to so redeem, retire, acquire or repurchase its Stock or Stock Equivalents) held
by current or former officers, managers, consultants, directors and employees (or their respective
spouses, former spouses, successors, executors, administrators, heirs, legatees or distributees) of
a Group Member (or any direct or indirect parent thereof), with the proceeds of




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






71









 







cash Restricted Payments from a Group Member, upon the death, disability, retirement or
termination of employment of any such Person or otherwise in accordance with any stock option or
stock appreciation rights plan, any management, director and/or employee stock ownership or
incentive plan, stock subscription plan, employment termination agreement or any other employment
agreements or equity holders’ agreement; provided that





     (i) no Default or Event of Default has occurred and is continuing or would arise as a result
of such Restricted Payment;




     (ii) the aggregate Restricted Payments permitted in any fiscal year of Holdings shall not
exceed $5,000,000; and




     (iii) with respect to any redemption of Stock or Stock Equivalents in an Excluded Foreign
Subsidiary or Stock or Stock Equivalents held by current or former officers, managers, consultants,
directors and employees (or their respective spouses, former spouses, successors, executors,
administrators, heirs, legatees or distributees) of an Excluded Foreign Subsidiary, such Restricted
Payment shall be funded solely by such Excluded Foreign Subsidiary or with the proceeds of an
Investment in such Excluded Subsidiary permitted under Section 8.3 hereof;



          (e) Holdings may redeem in whole or in part any of its Stock or Stock Equivalents for another
class of Stock or Stock Equivalents of Holdings or rights to acquire Stock or Stock Equivalents in
Holdings, provided that (i) the funds used to effect such redemption shall be provided solely from
concurrent equity contributions or issuances of new shares of Holdings’ Stock or Stock Equivalents
and (ii) any terms and provisions material to the interests of the Purchasers, when taken as a
whole, contained in such other class of Stock or Stock Equivalents are at least as advantageous to
the Purchasers as those contained in the Stock or Stock Equivalents redeemed thereby; and




          (f) Restricted Payments by the Group Members to fund Investments permitted by Sections
8.3(e) or (o);




          (g) cash dividends and distributions by any Group Member to fund indemnification payments owed
by Holdings to selling shareholders under stockholders or registration rights agreements entered
into in connection with the Exchange Offer or the Holdings IPO or owed by Holdings under the
Sponsor Consulting Agreement; provided, that at the time of any such dividend or
distribution, no Default or Event of Default shall exist or shall result therefrom;




          (h) repurchases of Stock of selling shareholders other than CBay in connection with the
Exchange Offer or the Holdings IPO for consideration not to exceed $5,000,000 in the aggregate;
provided, that at the time of any such repurchase, no Default or Event of Default shall
exist or shall result therefrom;




          (i) cash dividends and distributions by any Group Member to fund Holdings’ obligation arising
under the Sponsor Consulting Agreement to reimburse Sponsor and Lehman for out-of-pocket expenses
not to exceed $250,000 per Fiscal Year; provided, that at the time of any such dividend or
distribution, no Default or Event of Default shall exist or shall result therefrom; and




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





72












 




          (j) other Restricted Payments by the Group Members not to exceed $500,000 in the
aggregate during the term of this Agreement plus, to the extent the Consolidated Total Leverage
Ratio of Holdings is less than 1.00:1.00 both before and after giving effect to such Restricted
Payment and any Indebtedness incurred in connection therewith, Additional Available Cash;
provided, that at the time any such Restricted Payment is made no Default or Event of
Default shall exist or shall result therefrom.




          Section 8.6 Prepayment of Indebtedness. No Group Member shall prepay, redeem,
purchase, defease or otherwise satisfy prior to the scheduled maturity date thereof any
Junior Subordinated Debt, or set apart any property for such purpose, whether to a sinking
fund, a similar fund or otherwise, make any payment in violation of any subordination or
intercreditor terms applicable to any such Indebtedness.




          Section 8.7 Fundamental Changes. No Group Member shall merge, consolidate or amalgamate with
any Person, or liquidate or dissolve, except for the following:


          (a) to consummate any Permitted Acquisition;


          (b) a Note Party may merge, amalgamate or consolidate with, or dissolve or liquidate into any
other Note Party (other than Holdings), or may merge, amalgamate or consolidate with any other
Person that is incorporated or otherwise organized under the laws of a state of the United States
of America, provided that (i) an Issuer shall be the continuing or surviving entity, or if
an Issuer is not involved with such merger, amalgamation or consolidation, such Guarantor or such
other Person, as the case may be, shall be the continuing or surviving entity, (ii) if such other
Person constitutes the continuing or surviving entity, it shall have become a Guarantor
simultaneously with such transaction and satisfied the requirements of Section 7.10, (iii)
no Default or Event of Default shall have occurred and be continuing at the date of such merger,
amalgamation, consolidation, dissolution or liquidation or would result therefrom and (iv) the
Administrative Agent shall have a first priority Lien on all of the Stock and all Stock Equivalents
on a fully diluted basis in the surviving Issuer, Guarantor or such other Person and on all
Property of the surviving Issuer or Guarantor or to the extent required by Section 7.10,
such other Person;


          (c) Holdings may merge, amalgamate or consolidate with, or dissolve or liquidate into, any
other Note Party; provided that (i) no Default or Event of Default shall have occurred and
be continuing at the date of such merger, amalgamation consolidation, dissolution or liquidation or
would result therefrom, (ii) Holdings shall be the surviving entity and after giving effect to such
merger, amalgamation consolidation, dissolution or liquidation Holdings shall be in compliance with
the requirements of Section 8.8(b) and (iii) the requirements of Section 7.10 shall have
been satisfied;


          (d) any Excluded Foreign Subsidiary may merge, amalgamate or consolidate with, or dissolve or
liquidate into, another Excluded Foreign Subsidiary, provided that no Default or Event of Default
shall have occurred and be continuing at the date of such merger, amalgamation consolidation,
dissolution or liquidation or would result therefrom and the requirements of Section 7.10
shall have been satisfied;


          (e) any Guarantor (other than Holdings) may merge, amalgamate or consolidate with or into any
Group Member that is not a Note Party; provided that if such



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY




73









 








Guarantor is not the surviving entity or the surviving entity has not satisfied the
requirements of Section 7.10, such merger, amalgamation or consolidation shall be deemed to be an
“Investment” and subject to the limitations set forth in Section 8.3(e) or (o);



          (f) any Group Member (other than Holdings or an Issuer) may liquidate or dissolve if (x) the
Issuers determine in good faith that such liquidation or dissolution is in the best interests of
the Issuers and is not materially disadvantageous to the Purchasers and (y) to the extent such
Group Member is a Guarantor, any Property not otherwise disposed of or transferred in accordance
with Sections 8.3 or 8.4, or, in the case of any such business of such Group Member
discontinued, such business, shall be transferred to, or otherwise owned or conducted by, another
Guarantor or an Issuer after giving effect to such liquidation or dissolution


          (g) Holdings may convert to a Delaware corporation pursuant to the provisions of Section 265
of the Delaware Corporation Law; and


          (h) to the extent not otherwise permitted by this Section 8.7, the Group Members may
consummate (i) a merger, dissolution, liquidation, consolidation or amalgamation, the purpose of
which is to effect a disposition permitted pursuant to Section 8.4 or (ii) a merger the
purpose of which is to effect an Investment permitted pursuant to Section 8.3, provided
that, in each case, (x) no Default or Event of Default would result from the consummation thereof,
(y) if such merger, dissolution, liquidation, consolidation or amalgamation undertaken to effect an
Investment pursuant to clause (ii) above involves an Issuer or a Guarantor, such Issuer, or if an
Issuer is not involved, such Guarantor, shall be the continuing or surviving entity and
(z) the parties shall have satisfied the requirements of Section 7.10.




          Section 8.8 Change in Nature of Business. (a) No Group Member (other than
Holdings) shall engage in any material line of business substantially different from those
lines of business carried on by it on the date hereof or any business reasonably related
thereto, complementary thereto, ancillary thereto or a reasonable extension thereof.


          (b) Holdings, and prior to the MedQuist Consolidation Date, MedQuist, shall not engage in any
business activities or own any Property other than (i) ownership of the Stock and Stock Equivalents
of its Subsidiaries or as permitted under Section 8.3, (ii) activities incidental to
maintenance of its corporate existence or as otherwise permitted under this Agreement (including
the payment of tax payables and other corporate overhead expenses), (iii) the Related Transactions,
the Exchange Offer and the Holdings IPO, (iv) performing its obligations incidental to any of the
foregoing under the Note Documents, other Indebtedness permitted by this Agreement and
documentation entered into in connection with the Related Transactions, the Exchange Offer, the
Holdings IPO or any Permitted Acquisition or Investment permitted by Section 8.3, (v) entering into
and consummating transactions expressly permitted under this Agreement and (vi) making Restricted
Payments permitted by Section 8.5.




          Section 8.9 Transactions with Affiliates. No Group Member shall, except as
otherwise expressly permitted herein, enter into any other transaction with, or for the
benefit of, any Affiliate of any Issuer that is not a Note Party (including Guaranty
Obligations with respect to any obligation of any such Affiliate), except for:


          (a) transactions expressly permitted by this Agreement;



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






74









 







          (b) transactions among Note Parties;


          (c) transactions among Group Members that are not Note Parties;


          (d) tax sharing arrangements on customary terms entered into among the Group Members to
provide for the allocation of the tax liability to be discharged with a Restricted Payment under
Section 8.5(c)(i);


          (e) any issuance of Stock or Stock Equivalents in Holdings, or other payments, awards or
grants in cash or Stock or Stock Equivalents of Holdings pursuant to, or the funding of, employment
arrangements, stock options and stock ownership plans approved by the board of directors of
Holdings and in accordance with Requirements of Law, and any issuance of Stock of MedQuist upon the
exercise of stock options existing on the Closing Date;


          (f) employment and severance arrangements and health, disability and similar insurance or
benefit plans between Group Members and their respective directors, officers, employees (including
management and employee benefit plans or agreements, subscription agreements or similar agreements
pertaining to the repurchase of Stock and Stock Equivalents pursuant to put/call rights or similar
rights with current or former employees, officers or directors and stock option or incentive plans
and other compensation arrangements) in the Ordinary Course of Business or as otherwise approved by
the board of directors of the applicable Group Member;


          (g) payment of reasonable compensation to officers and employees for actual services rendered
to Group Members (other than an Excluded Foreign Subsidiary unless such payment is funded solely by
such Excluded Foreign Subsidiary or with the proceeds of an Investment in such Excluded Foreign
Subsidiary permitted under Section 8.3 hereof) in the Ordinary Course of Business;


          (h) the payment of customary fees and reasonable out-of-pocket costs to, and indemnities
provided on behalf of, directors, managers, consultants (other than Sponsor or its Affiliates),
officers and employees of Group Members in the Ordinary Course of Business to the extent
attributable to the ownership or operation of any Group Member (other than an Excluded Foreign
Subsidiary unless such payment is funded solely by such Excluded Foreign Subsidiary or with the
proceeds of an Investment in such Excluded Foreign Subsidiary permitted under Section 8.3);


          (i) the Related Transactions, the Exchange Offer, the Holdings IPO and the payment of expenses
(subject to the limitations set forth in clauses (j) and (k) below with respect to the expenses described therein) with respect thereto;


          (j) reimbursement of expenses of selling shareholders by Holdings required under stockholders
or registration rights agreements entered into in connection with the Exchange Offer or the
Holdings IPO in an aggregate amount not to exceed $2,500,000; provided, that at the time of
any such payment, no Default or Event of Default shall exist or shall result therefrom;


          (k) payments by Holdings to the Sponsor or directors of Holdings designated by the Sponsor
required under agreements to be entered into by Holdings in connection with the Exchange Offer or
the Holdings IPO in an aggregate amount not to exceed $12,000,000;



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





75









 








provided, that at the time of any such payment, no Default or Event of Default shall exist or
shall result therefrom;



          (l) transactions pursuant to permitted agreements in existence or contemplated on the Closing
Date and set forth on Schedule 8.9 or any amendment thereto to the extent such an amendment
is not adverse, taken as a whole, to the Purchasers in any material respect;


          (m) Restricted Payments permitted under Section 8.5;


          (n) mergers, consolidations, amalgamations, liquidations and dissolutions permitted under
Section 8.7;


          (o) Investments permitted by Section 8.3;


          (p) payments to the Sponsor or Lehman in the Stock of Holdings under the Sponsor Consulting
Agreement to satisfy the remaining fees payable thereunder;


          (q) payments to Sponsor or shareholders of any Group Member to the extent such payments could
be made as Restricted Payments under Sections 8.5(g), (h) and (i); and


          (r) all other transactions entered into pursuant to the reasonable requirements of the
business of such Group Member upon fair and reasonable terms substantially as favorable to such
Group Member as would be obtained in a comparable arm’s length transaction with a Person not an
Affiliate of any Group Member.




          Section 8.10 Third-Party Restrictions on Indebtedness, Liens, Investments or
Restricted Payments. No Group Member shall incur or otherwise suffer to exist or become
effective any Contractual Obligation limiting the ability of any Subsidiary of Holdings to
make Restricted Payments to, or loans or advances to, or repay Indebtedness or Sell
property to, any Group Member which is a direct or indirect parent entity of such
Subsidiary, except (i) Contractual Obligations that exist on the Closing Date and (to the
extent not otherwise permitted by this Section 8.10 are listed on Schedule
8.10 hereto) any refinancings and extensions of any such Contractual Obligations if the
terms and conditions thereof, taken as a whole, do not materially expand the scope of such
limitation, (ii) Contractual Obligations representing Indebtedness of a Group Member that
is not a Guarantor to the extent such Indebtedness is permitted by Section 8.1,
(iii) Contractual Obligations that are customary provisions in joint venture agreements and
other similar agreements applicable to joint ventures permitted under this Agreement, that
is applicable solely to such joint venture, (iv) Contractual Obligations that are binding
on a Group Member at the time such Group Member first becomes a Group Member, so long as
such Contractual Obligations were not entered into in contemplation of such Person becoming
a Group Member, (v) Contractual Obligations that arise pursuant to agreements entered into
with respect to any sale, transfer, lease or other disposition of Property or a Person
permitted by Section 8.4 and apply solely to the Property or Person to be so sold,
transferred, leased or otherwise disposed of, (vi) Contractual Obligations that are
customary restrictions on leases, subleases, licenses or asset sale agreements otherwise
permitted hereby so long as such restrictions relate only to the Property subject thereto,
(vii) customary net worth provisions contained in real property leases entered into by a
Group Member, so long as



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





76









 









the Issuers have determined in good faith that such net worth provisions could not
reasonably be expected to impair the ability of the Group Members to meet their respective
ongoing obligations and (viii) restrictions contained in the Note Documents.




          Section 8.11 Modification of Certain Documents. No Group Member shall do any of the
following:


          (a) waive or otherwise modify any term of any Constituent Document of any Note Party
(including the terms of any of their outstanding Stock or Stock Equivalents), except for those
modifications and waivers that do not adversely affect the interests of the Purchasers;


          (b) waive
or otherwise modify any term of any Material Agreement except for those modifications and waivers
that would not reasonably be expected to have a Material Adverse Effect; and


          (c) waive or otherwise
modify any term of any Junior Subordinated Debt except in a manner permitted by the subordination
provisions therein or the subordination agreement applicable thereto, as applicable.




          Section 8.12 Fiscal Year. No Group Member shall change its Fiscal Year or its
method for determining Fiscal Quarters or fiscal months.




          Section 8.13 Margin Regulations. No Group Member shall use all or any portion
of the proceeds of any credit extended hereunder to purchase or carry margin stock (within
the meaning of Regulation U of the Federal Reserve Board) in contravention of Regulation U
of the Federal Reserve Board.




          Section 8.14 Compliance with ERISA. No ERISA Affiliate shall cause or suffer
to exist (a) any event that could result in the imposition of a Lien with respect to any
Title IV Plan or Multiemployer Plan or (b) any other ERISA Event, that would, in the
aggregate, be reasonably expected to have a Material Adverse Effect. No Group Member shall
cause or suffer to exist any event that could result in the imposition of a Lien with
respect to any Benefit Plan.




          Section 8.15 Hazardous Materials. No Group Member shall cause or allow any
Release of any Hazardous Material at, to or from any real property owned, leased, subleased
or otherwise operated or occupied by any Group Member that would violate any Environmental
Law, form the basis for any Environmental Liabilities, other than such violations,
Environmental Liabilities and effects that would not, in the aggregate, reasonably be
expected to have a Material Adverse Effect.




          Section 8.16 Limitation on Layering Indebtedness Notwithstanding the
provisions of Section 8.1, the Note Parties will not, and will not permit any of their
Subsidiaries to, directly or indirectly, incur or suffer to exist any Indebtedness that is
both contractually subordinate or junior in right of payment to the Senior Loan Obligations
and senior in right of payment to the Obligations, excluding the effect of any Liens which
are Permitted Liens.




          Section 8.17 Excess Cash Flow. Unless the Purchasers otherwise agree in
writing, the Issuers shall not agree or otherwise permit the percentage of “Excess



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






77









 










Cash Flow”, or any such similar concept, required to be paid to the Senior Lenders
under the Senior Credit Agreement (as in effect on the date hereof), to be reduced;
provided, that if the Consolidated Total Leverage Ratio is 2.00:1.00 or less (A)
for the last Fiscal Quarter of such corresponding Fiscal Year for which such Excess Cash
Flow amount has been determined (B) from such date until such Excess Cash Flow payment is
actually made to the Senior Lenders and (C) on a pro forma basis for the first full Fiscal
Quarter ending after such payment, then notwithstanding this Section 8.17, the
Issuers shall be permitted to pay a lesser percentage of Excess Cash Flow than such amounts
otherwise required hereby.




          Section 8.18 Notwithstanding anything contained in this Article 8, during the period
commencing on the Closing Date until, but excluding, the Funding Date, the Group Members
shall not be obligated to comply with the covenants in this Article 8 to the extent such
covenants would result in a breach or cause a default under any other Contractual
Obligation to which the Group Members are party which was (i) effective prior to the
Closing Date, (ii) not entered into in contemplated of entering into this Agreement or the
other Note Documents and (iii) not a Contractual Obligation to which only the Group Members
are a party.



ARTICLE 9

EVENTS OF DEFAULT





          Section 9.1 Definition. Each of the following shall be an Event of Default:


          (a) the Issuers shall fail to pay (i) any principal of or premium on any Note when the same
becomes due and payable or (ii) any interest on any Note, any fee under any Note Document or any
other Obligation (other than those set forth in clause (i) above) and, in the case of this
clause (ii), such non-payment continues for a period of five (5) days after the due date
therefor; or


          (b) any representation, warranty or certification made or deemed made by any Note Party (or
any Responsible Officer thereof) in any Note Document shall prove to have been incorrect in any
material respect (without duplication of any materiality qualifier contained herein or therein)
when made or deemed made; or


          (c) any Note Party shall fail to comply with (i) any provision of Article 5 (Financial
Covenants), Section 6.2(a)(i) (Other Events), Section 7.1 (Maintenance of Corporate
Existence), Section 7.9 (Use of Proceeds) or Article 8 (Negative Covenants), (ii) any
provision of Section 6.1 (Financial Statements) if, in the case of this clause
(ii), such failure shall remain unremedied for 15 days after the earlier of (A) the date on
which a Responsible Officer of any Note Party becomes aware of such failure and (B) the date on
which notice thereof shall have been given to the Issuer Representative by the Purchasers or (iii)
any other provision of any Note Document if, in the case of this clause (iii), such failure
shall remain unremedied for 30 days after the earlier of (A) the date on which a Responsible
Officer of any Note Party becomes aware of such failure and (B) the date on which notice thereof
shall have been given to the Issuer Representative by the Purchasers; or


          (d) (i) any Group Member shall fail to make beyond any applicable cure period any payment when
due (whether due because of scheduled maturity, required prepayment



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






78









 








provisions, acceleration, demand or otherwise) on any Indebtedness of any Group Member (other
than the Obligations or the Senior Loan Obligations) and, in each case, such failure relates to
Indebtedness having a principal amount of $5,000,000 or more, (ii) any other event shall occur or
condition shall exist beyond any applicable cure period under any Contractual Obligation relating
to any Indebtedness (other than the Obligations) having a principal amount of $5,000,000 or more or
any Senior Loan Obligations, if the effect of such event or condition is to accelerate the maturity
of such Indebtedness or (iii) any Indebtedness (other than the Obligations) having a principal
amount of $5,000,000 or more or any Senior Loan Obligations shall become or be declared to be due
and payable, or be required to be prepaid, redeemed, defeased or repurchased (other than by a
regularly scheduled required prepayment or a mandatory prepayment), prior to the stated maturity
thereof; or



          (e) (i) any Group Member shall generally not pay its debts as such debts become due, shall
admit in writing its inability to pay its debts generally or shall make a general assignment for
the benefit of creditors, (ii) any proceeding shall be instituted by or against any Group Member
seeking to adjudicate it a bankrupt or insolvent or seeking liquidation, winding up,
reorganization, arrangement, adjustment, protection, relief, composition of it or its debts or any
similar order, in each case under any Requirement of Law relating to bankruptcy, insolvency or
reorganization or relief of debtors or seeking the entry of an order for relief or the appointment
of a custodian, receiver, trustee, conservator, liquidating agent, liquidator, other similar
official or other official with similar powers, in each case for it or for any substantial part of
its property and, in the case of any such proceedings instituted against (but not by or with the
consent of) any Group Member, either such proceedings shall remain undismissed or unstayed for a
period of 60 days or more or any action sought in such proceedings shall occur (including without
limitation any entry of an order for relief in any such proceeding) or (iii) any Group Member shall
take any corporate or similar action to authorize any action described in clause (i) or
(ii)above; or


          (f) one or more judgments, orders or decrees (or other similar process) shall be rendered against
any Group Member (i)(A) in the case of monetary judgments, orders and decrees, involving an
aggregate amount (excluding amounts adequately covered by insurance payable to any Group Member, to
the extent the relevant insurer has not denied coverage therefor) in excess of $5,000,000 or (B) in
the case of non-monetary judgments, that would have, in the aggregate, a Material Adverse Effect
and (ii)(A) enforcement proceedings shall have been commenced by any creditor upon any such
judgment, order or decree or (B) such judgment, order or decree shall not have been vacated or
discharged for a period of 60 consecutive days and there shall not be in effect (by reason of a
pending appeal or otherwise) any stay of enforcement thereof; or


          (g) except pursuant to a valid, binding and enforceable termination or release permitted under the
Note Documents and executed by the Purchasers or as otherwise expressly permitted under any Note
Document, (i) any material provision of any Note Document shall, at any time after the delivery of
such Note Document, fail to be valid and binding on, or enforceable (other than pursuant to the
express terms thereof) against, or shall be revoked or repudiated by any Note Party party thereto,
(ii) any subordination provision set forth in any document governing Junior Subordinated Debt
shall, in whole or in part, terminate or otherwise fail or cease to be valid and binding on, or
enforceable against, any holder of Junior Subordinated Debt or any such holder shall so state in
writing, or (iii) any Group Member shall state in writing that any of the events described in
clause (i) shall have occurred; or



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





79









 







          (h) any Material Agreement shall be terminated for any reason unless (i) such Material
Agreement is replaced with an agreement that is not materially less favorable to the Group Members,
(ii) existing Material Agreements provide substantially the same benefits as such terminated
Material Agreement as are necessary for the proper conduct of such Group Member’s business as
conducted as of the date of such termination, (iii) such Group Member has an alternative source of
obtaining such benefits (including by internal development) or (iv) the termination of such
Material Agreement could not reasonably be expected to have a Material Adverse Effect; or


          (i) any Holding Company shall incur any Indebtedness or issue any Stock or Stock Equivalent
and use the proceeds of such incurrence or issuance to make dividend, payment or other distribution
with respect to the holders of its Stock or Stock Equivalents;


          (j) there shall occur any Change of
Control; or


          (k) either (i) one or more ERISA Events shall have occurred, (ii) there is or arises an
Unfunded Pension Liability with respect to any Title IV Plan, or (iii) there is or arises any
potential Withdrawal Liability, if any ERISA Affiliate were to withdraw completely from one or more
Multiemployer Plans, and the liability of any ERISA Affiliate contemplated by the foregoing
clauses (i), (ii) and (iii), either individually or in the aggregate, has
had, or would reasonably be expected to have, a Material Adverse Effect.




          Section 9.2 Remedies. During the continuance of any Event of Default, the
Required Purchasers may, by notice to the Issuer Representative and in addition to any
other right or remedy provided under any Note Document or by any applicable Requirement of
Law, declare immediately due and payable all or part of any Obligation (including any
accrued but unpaid interest thereon, whether payable in cash or in kind), whereupon the
same shall become immediately due and payable, without presentment, demand, protest or
further notice or other requirements of any kind, all of which are hereby expressly waived
by Holdings and each Issuer (and, to the extent provided in any other Note Document, other
Note Parties); provided, however, that, effective immediately upon the
occurrence of the Events of Default specified in Section 9.1(e)(ii), each Obligation
(including in each case any accrued all accrued but unpaid interest thereon) shall
automatically become and be due and payable, without presentment, demand, protest or
further notice or other requirement of any kind, all of which are hereby expressly waived
by Holdings and each Issuer (and, to the extent provided in any other Note Document, any
other Note Party).



ARTICLE 10

RESERVED




ARTICLE 11

MISCELLANEOUS





          Section 11.1 Amendments, Waivers, Etc. (a) No amendment or waiver of any
provision of any Note Document and no consent to any departure by any Note Party therefrom
shall be effective unless the same shall be in writing and signed by the Required
Purchasers and the Issuers; provided, however, that no amendment, consent or waiver
shall, unless in writing and signed by each Purchaser directly affected thereby,



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





80









 









in addition to any other Person the signature of which is otherwise required pursuant to
any Note Document, do any of the following:




          (i) [Reserved.];




          (ii) reduce (including through release, forgiveness, assignment or otherwise) (A) the
principal amount of, the interest rate on, any outstanding Note owing to such Purchaser or (B) any
fee or accrued interest payable to such Purchaser hereunder; provided, however,
that this clause (ii) does not apply to (x) any reduction in incremental interest or fees
payable during the continuance of an Event of Default or to any payment of any such incremental
interest or fees;




          (iii) waive or postpone any scheduled maturity date or other scheduled date fixed for the
payment, in whole or in part, of principal of or interest on any Note or fee owing to such
Purchaser; provided, however, that this clause (iii) does not apply to any
change to mandatory prepayments, including those required under Section 2.6;




          (iv) release all or substantially all of the Guarantors from their guaranty of the Obligations
of the Issuers;




          (v) reduce or increase the proportion of Purchasers required for the Purchasers (or any subset
thereof) to take any action hereunder or change the definition of the terms “Required Purchasers”,
“Pro Rata Share” or “Pro Rata Outstandings”; or




          (vi) amend Section 11.9 (Sharing of Payments), Section 2.10 (Application of
Payments) or this Section 11.1;



it being agreed that all Purchasers shall be deemed to be directly affected by an amendment,
consent or waiver of the type described in the preceding clauses (v) and (vi), and provided,
further, that the consent of the Issuers shall not be required to change any order of priority set
forth in Section 2.10(c). Notwithstanding the foregoing or anything else set forth herein
to the contrary, no Sponsor Affiliated Purchaser shall have any voting or consent rights with
respect to any matter under or with respect to any Note Document or constitute a Purchaser (or
be, or have its Notes included in the determination of “Required Purchasers” or “Purchasers
directly affected”) under or with respect to any provisions in any Note Document governing voting
or consent rights, provided that (A) the principal of a Sponsor Affiliated Purchaser s
Notes may not be reduced or forgiven, and (B) the interest rate applicable to Obligations owing to
a Sponsor Affiliated Purchaser may not be reduced in such a manner that by its terms affects such
Purchaser more adversely than other Purchasers, in each case without the consent of such Purchaser.



          (b) Each waiver or consent under any Note Document shall be effective only in the specific
instance and for the specific purpose for which it was given. No notice to or demand on any Note
Party shall entitle any Note Party to any notice or demand in the same, similar or other
circumstances. No failure on the part of any Purchaser to exercise, and no delay in exercising, any
right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any
such right preclude any other or further exercise thereof or the exercise of any other right.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





81









 









  
   Section 11.2 Assignments and Participations; Binding Effect. (a)
Binding Effect. This Agreement shall become effective when it shall have been
executed by Holdings, the Issuers and the Purchasers. Thereafter, it shall be binding upon
and inure to the benefit of, but only to the benefit of, Holdings, the Issuers and the
Purchasers and, in each case, their respective successors and permitted assigns. Except as
expressly provided in any Note Document, none of Holdings or the Issuers shall have the
right to assign any rights or obligations hereunder or any interest herein.


          (b) Right to Assign. Each Purchaser may at any time sell, transfer, negotiate or
assign all or a portion of its rights and obligations hereunder (including all or a portion of its
rights and obligations with respect to the Notes) to (i) any existing Purchaser, (ii) any Affiliate
of any existing Purchaser which is under common control with such Purchaser or (iii) any other
Person acceptable to the Required Purchasers, provided that, in the absence of an Event of
Default, Required Purchasers may not assign any portion of its rights and obligations hereunder to
any Person pursuant to clause (iii) who has been designated as unacceptable by Issuers in a writing
delivered to and agreed to by the initial Purchasers prior to the Closing Date; provided
 further that no sale shall be made to a Group Member or an Affiliate of a Group Member (other
than a Sponsor Affiliated Purchaser). Sponsor Affiliated Purchasers shall have no rights to receive
notice of, attend or participate in any meetings with other Purchasers, receive information
requested or prepared on behalf of the Purchasers, or otherwise have any rights of a Purchaser
hereunder, other than the right to receive payments required hereunder.


          (c) [Reserved.]


          (d) Effectiveness. Subject to the recording of an Assignment by the Issuer
Representative in the Register pursuant to Section 2.12(b), (i) the assignee thereunder
shall become a party hereto and, to the extent that rights and obligations under the Note Documents
have been assigned to such assignee pursuant to such Assignment, shall have the rights and
obligations of a Purchaser, including the obligation to deliver tax forms pursuant to Section
2.17(f), (ii) any applicable Note shall be transferred to such assignee through such entry and
(iii) the assignor thereunder shall, to the extent that rights and obligations under this Agreement
have been assigned by it pursuant to such Assignment, relinquish its rights (except for those
surviving the payment in full of the Obligations) and be released from its obligations under the
Note Documents, other than those relating to events or circumstances occurring prior to such
assignment (and, in the case of an Assignment covering all or the remaining portion of an assigning
Purchaser’s rights and obligations under the Note Documents, such Purchaser shall cease to be a
party hereto except that each Purchaser agrees to remain bound by Section 11.9 (Sharing of
Payments).


          (e) Grant of Security Interests. In addition to the other rights provided in this
Section 11.2, each Purchaser may grant a security interest in, or otherwise assign as collateral,
any of its rights under this Agreement, whether now owned or hereafter acquired (including rights
to payments of principal or interest on the Notes), without notice to the Issuers and without the
execution of an assignment agreement to (A) any federal reserve bank (pursuant to Regulation A of
the Federal Reserve Board) or (B) any holder of, or trustee for the benefit of the holders of, such
Purchaser’s Securities; provided, however, that no such holder or trustee, whether because of such
grant or assignment or any foreclosure thereon (unless such foreclosure is made through an
assignment in accordance with clause (b) above), shall be entitled to any rights of such Purchaser
hereunder and no such Purchaser shall be relieved of any of its obligations hereunder.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY




82









 







          (f) Participants. In addition to the other rights provided in this Section
11.2, each Purchaser may, (x) without notice to or consent from any Issuer, sell participations
to one or more Persons in or to all or a portion of its rights and obligations under the Note
Documents (including all its rights and obligations with respect to the Notes); provided,
however, that, whether as a result of any term of any Note Document or of such grant or
participation, (i) no such participant shall have a commitment, or be deemed to have made an offer
to commit, to purchase Notes hereunder, and, except as provided in the applicable option agreement,
none shall be liable for any obligation of such Purchaser hereunder, (ii) such Purchaser’s rights
and obligations, and the rights and obligations of the Note Parties towards such Purchaser, under
any Note Document shall remain unchanged and each other party hereto shall continue to deal solely
with such Purchaser, which shall remain the holder of the Obligations in the Register, except that
(A) each such participant shall be entitled to the benefit of Section 2.17 (Taxes),
but only to the extent such participant delivers the tax forms such Purchaser is required to
collect pursuant to Section 2.17(f) and then only to the extent of any amount to which such
Purchaser would be entitled in the absence of any such participation; provided, however, that in no
case (including pursuant to clause (A) above) shall a participant have the right to enforce any of
the terms of any Note Document, and (iii) the consent of such participant shall not be
required (either directly, as a restraint on such Purchaser’s ability to consent hereunder or
otherwise) for any amendments, waivers or consents with respect to any Note Document or to exercise
or refrain from exercising any powers or rights such Purchaser may have under or in respect of the
Note Documents (including the right to enforce or direct enforcement of the Obligations), except
for those described in clauses (ii) and (iii) of Section 11.1(a) with
respect to amounts, or dates fixed for payment of amounts, to which such participant would
otherwise be entitled and, in the case of participants, except for those described in Section
11.1(a)(iv). Each Purchaser that sells a participation shall, acting solely for this purpose
as a non-fiduciary agent of the Issuers, maintain a register on which it enters the name and
address of each participant and the principal amounts (and stated interest) of each participant’s
interest in the Notes or other obligations under this Agreement (the “Participant Register”). The
entries in the Participant Register shall be conclusive absent manifest error, and such Purchaser
shall treat each person whose name is recorded in the Participant Register as the owner of such
participation for all purposes of this Agreement notwithstanding any notice to the contrary.




          Section 11.3 Costs and Expenses. Any action taken by any Note Party under or
with respect to any Note Document, even if required under any Note Document or at the
request of any Purchaser, shall be at the expense of such Note Party, and no Purchaser
shall be required under any Note Document to reimburse any Note Party or Group Member
therefor except as expressly provided therein. In addition, the Issuers agree to pay or
reimburse upon demand (a) the Purchasers for all reasonable out-of-pocket costs and
expenses incurred by it or any of its Related Persons in connection with the investigation,
development, preparation, negotiation, syndication, execution, interpretation or
administration of, any modification of any term of or termination of, any Note Document,
any other document prepared in connection therewith or the consummation and administration
of any transaction contemplated therein (including reasonable fees, charges and
disbursements of legal counsel to the Purchasers or such Related Persons, and expenses
related to Intralinks® or any other E-System), (b) each of the Purchasers for
all reasonable out-of-pocket costs and expenses incurred in connection with (i) any
refinancing or restructuring of the credit arrangements provided hereunder in
the nature of a “work-out” (including, without limitation, fees and disbursements of
consultants), (ii) the enforcement or preservation of any right or remedy under any Note



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





83









 










Document, any Obligation or any other related right or remedy or (iii) the
commencement, defense, conduct of, intervention in, or the taking of any other action with
respect to, any proceeding (including any bankruptcy or insolvency proceeding) related to
any Group Member, Note Document, Obligation or Related Transaction (or the response to and
preparation for any subpoena or request for document production relating thereto),
including fees and disbursements of counsel, and (c) reasonable fees and disbursements of
one law firm on behalf of all Purchasers, incurred in connection with any matters referred
to in clause (b) above.




          Section 11.4 Indemnities. (a) The Issuers agree to indemnify, hold harmless
and defend the Purchasers and each of their respective Related Persons (each such Person
being an “Indemnitee”) from and against all Liabilities (including brokerage
commissions, fees and other compensation) that may be imposed on, incurred by or asserted
against any such Indemnitee in any matter relating to or arising out of, in connection with
or as a result of (i) any Note Document, any Related Document, any Disclosure Document, any
Obligation (or the repayment thereof), the use or intended use of the proceeds of any Note,
any Related Transaction, or any securities filing of, or with respect to, any Group Member,
(ii) any commitment letter, proposal letter or term sheet in connection with any of the
foregoing and any Contractual Obligation entered into in connection with any E-Systems or
other Electronic Transmissions, (iii) any actual or prospective investigation, litigation
or other proceeding in connection with any of the foregoing, whether or not brought by any
such Indemnitee or any of its Related Persons, any holders of Securities or creditors (and
including reasonable and documented attorneys fees’ in any case), whether or not any such
Indemnitee, Related Person, holder or creditor is a party thereto, and whether or not based
on any securities or commercial law or regulation or any other Requirement of Law or theory
thereof, including common law, equity, contract, tort or otherwise, or (iv) any other act,
event or transaction related, contemplated in or attendant to any of the foregoing
(collectively, the “Indemnified Matters”); provided, however, that the Issuers shall not
have any liability under this Section 11.4 to any Indemnitee with respect to any
Indemnified Matters, to the extent such liability has resulted from the gross negligence,
bad faith or willful misconduct of such Indemnitee, as determined by a court of competent
jurisdiction in a final non-appealable judgment or order. Any amounts payable under this
Section shall be without duplication of any amounts payable in respect of Taxes under
Section 2.17.


          (b) Without limiting the foregoing, “Indemnified Matters” includes all Environmental
Liabilities, including those arising from, or otherwise involving, any property of any Related
Person or any actual, alleged or prospective damage to property or natural resources or harm or
injury alleged to have resulted from any Release of Hazardous Materials on, upon or into such
property or natural resource or any property on or contiguous to any real property of any Related
Person, whether or not, with respect to any such Environmental Liabilities, any Indemnitee is a
mortgagee pursuant to any leasehold mortgage, a mortgagee in possession, the successor-in-interest
to any Related Person or the owner, lessee or operator of any property of any Related Person
through any foreclosure action, in each case except to the extent such Environmental Liabilities
(i) are incurred solely following foreclosure by any Purchaser or following any Purchaser having
become the successor-in-interest to any Note Party and (ii) are attributable solely to acts of such
Indemnitee.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY







84









 









          Section 11.5 Survival. Any indemnification or other protection provided
to any Indemnitee pursuant to any Note Document (including pursuant to Section
2.17 (Taxes), Section 11.3 (Costs and Expenses), Section 11.4
(Indemnities) or this Section 11.5) shall (A) survive the payment in full of other
Obligations and (B) inure to the benefit of any Person that at any time held a right
thereunder (as an Indemnitee or otherwise) and, thereafter, its successors and permitted
assigns.




          Section 11.6 Limitation of Liability for Certain Damages. In no event shall
any Indemnitee be liable on any theory of liability for any special, indirect,
consequential or punitive damages (including any loss of profits, business or anticipated
savings). Holdings and each Issuer hereby waives, releases and agrees (and shall cause
each other Note Party to waive, release and agree) not to sue upon any such claim for any
special, indirect, consequential or punitive damages, whether or not accrued and whether
or not known or suspected to exist in its favor.




          Section 11.7 Noteholder-Issuer Relationship. The relationship between the
Purchasers, on the one hand, and the Note Parties, on the other hand, is solely that of
noteholder and issuer. No Purchaser has any fiduciary relationship or duty to any Note
Party arising out of or in connection with, and there is no agency, tenancy or joint
venture relationship between the Purchasers and the Note Parties by virtue of, any Note
Document or any transaction contemplated therein.




          Section 11.8 [Reserved.]




          Section 11.9 Sharing of Payments, Etc. If any Purchaser, directly or through
an Affiliate or branch office thereof, obtains any payment of any Obligation of any Note
Party (whether voluntary, involuntary or through the exercise of any right of setoff)
other than pursuant to 2.17 (Taxes) and such payment exceeds the amount such
Purchaser would have been entitled to receive if all payments had gone to, and been
distributed by, the Issuers in accordance with the provisions of the Note Documents, such
Purchaser shall purchase for cash from other Purchasers such participations in their
Obligations as necessary for such Purchaser to share such excess payment with such
Purchasers to ensure such payment is applied as though it had been received by the
Purchasers and applied in accordance with this Agreement (or, if such application would
then be at the discretion of the Issuers, applied to repay the Obligations in accordance
herewith); provided, however, that (a) if such payment is rescinded or
otherwise recovered from such Purchaser in whole or in part, such purchase shall be
rescinded and the purchase price therefor shall be returned to such Purchaser without
interest and (b) such Purchaser shall, to the fullest extent permitted by applicable
Requirements of Law, be able to exercise all its rights of payment (including the right of
setoff) with respect to such participation as fully as if such Purchaser were the direct
creditor of the Issuers in the amount of such participation. For the avoidance of doubt,
this Section 11.9 shall not apply to assignments and participations to the extent
allowed under this Agreement.




          Section 11.10 [Reserved.]




          Section 11.11 Notices. (a) Addresses. All notices, demands, requests,
directions and other communications required or expressly authorized to be made by this
Agreement shall, whether or not specified to be in writing but unless otherwise expressly
specified to be given by any other means, be given in writing and (i) addressed to (A) if



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





85









 







to Holdings or any Issuer, to MedQuist, Inc. as Issuer Representative, Attention: Mark
Sullivan, General Counsel, 1000 Bishops Gate Blvd., Suite 300, Mt. Laurel, New Jersey
08054, Tel: (856) 206-4210, Fax: (856) 206-4211, with copy to Simpson Thacher & Bartlett
LLP, 425 Lexington Avenue, New York, New York 10017, Attention: Marissa C. Wesely Tel:
(212) 455-7173, Fax: (212) 455-2502, and (B) if to the Purchasers, then at the address
specified opposite such Purchaser’s name on Schedule II or on the signature page of
any applicable Assignment, (ii) posted to Intralinks® (to the extent such system
is available and set up by or at the direction of the Purchasers prior to posting) in an
appropriate location by uploading such notice, demand, request, direction or other
communication to www.intralinks.com, faxing it to 866-545-6600 with an appropriate
bar-coded fax coversheet or using such other means of posting to Intralinks® as
may be available and reasonably acceptable to the Required Purchasers prior to such
posting, (iii) posted to any other E-System set up by or at the direction of the Purchasers
in an appropriate location or (iv) addressed to such other address as shall be notified in
writing in the case of the Issuers, Holdings and the Purchasers, to the other parties
hereto. Transmission by electronic mail (including E-Fax, even if transmitted to the fax
numbers set forth in clause (i) above) shall not be sufficient or effective to
transmit any such notice under this clause (a) unless such transmission is an
available means to post to any E-System. Notwithstanding the foregoing, materials required
to be delivered pursuant to Sections 6.1(b), 6.1(c) and 6.3 shall
be deemed delivered to the Purchasers on the date on which Holdings or the Issuers cause
such materials to be posted on the Internet at www.sec.gov or at such other website
identified by the Issuer Representative in a written notice to the Purchasers and that is
accessible by the Purchasers without charge.


          (b) Effectiveness. All communications described in clause (a) above and all other
notices, demands, requests and other communications made in connection with this Agreement shall be
effective and be deemed to have been received (i) if delivered by hand, upon personal delivery,
(ii) if delivered by overnight courier service, one (1) Business Day after delivery to such courier
service, (iii) if delivered by mail, when deposited in the mails, (iv) if delivered by facsimile
(other than to post to an E-System pursuant to clause (a)(ii) or (a)(iii) above),
upon sender’s receipt of confirmation of proper transmission, and (v) if delivered by posting to
any E-System, on the later of the date of such posting in an appropriate location and the date
access to such posting is given to the recipient thereof in accordance with the standard procedures
applicable to such E-System; provided, however, that no communications to any Purchaser pursuant to
Article 2 shall be effective until received by such Purchaser.




          Section 11.12 Electronic Transmissions. (a) Authorization. Subject to the
provisions of Section 11.11(a), each of the Purchasers, the Issuers, and each of
their Related Persons is authorized (but not required) to transmit, post or otherwise make
or communicate, in its sole discretion, Electronic Transmissions in connection with any
Note Document and the transactions contemplated therein. Each of Holdings, each Issuer and
each Purchaser hereby acknowledges and agrees, and Holdings and each Issuer shall cause
each other Group Member to acknowledge and agree, that the use of Electronic Transmissions
is not necessarily secure and that there are risks associated with such use, including
risks of interception, disclosure and abuse and each indicates it assumes and accepts such
risks by hereby authorizing the transmission of Electronic Transmissions.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






86









 







          (b) Signatures. Subject to the
provisions of Section 11.11(a), (i)(A) no posting
to any E-System shall be denied legal effect merely because it is made electronically, (B) each
E-Signature on any such posting shall be deemed sufficient to satisfy any requirement for a
“signature” and (C) each such posting shall be deemed sufficient to satisfy any requirement for a
“writing”, in each case including pursuant to any Note Document, any applicable provision of any
UCC, the federal Uniform Electronic Transactions Act, the Electronic Signatures in Global and
National Commerce Act and any substantive or procedural Requirement of Law governing such subject
matter, (ii) each such posting that is not readily capable of bearing either a signature or a
reproduction of a signature may be signed, and shall be deemed signed, by attaching to, or
logically associating with such posting, an E-Signature, upon which each Purchaser and Note Party
may rely and assume the authenticity thereof, (iii) each such posting containing a signature, a
reproduction of a signature or an E-Signature shall, for all intents and purposes, have the same
effect and weight as a signed paper original and (iv) each party hereto or beneficiary hereto
agrees not to contest the validity or enforceability of any posting on any E-System or E-Signature
on any such posting under the provisions of any applicable Requirement of Law requiring certain
documents to be in writing or signed; provided, however, that nothing herein shall limit such party
s or beneficiary’s right to contest whether any posting to any E-System or E-Signature has been
altered after transmission.


          (c) Separate Agreements. All uses of an E-System shall be governed by and subject to,
in addition to Section 11.11 and this Section 11.12, separate terms and conditions posted or
referenced in such E-System and related Contractual Obligations executed by Purchasers and Group
Members in connection with the use of such E-System.


          (d) Limitation of Liability. All E-Systems and Electronic Transmissions shall be
provided “as is” and “as available”. None of the Purchasers or any of their Related Persons
warrants the accuracy, adequacy or completeness of any E-Systems or Electronic Transmission, and
each disclaims all liability for errors or omissions therein. No warranty of any kind is made by
the Purchasers or any of their Related Persons in connection with any E-Systems or Electronic
Communication, including any warranty of merchantability, fitness for a particular purpose,
non-infringement of third-party rights or freedom from viruses or other code defects. Holdings,
each Issuer and each Purchaser agrees (and Holdings and each Issuer shall cause each other Note
Party to agree) that the Purchasers have no responsibility for maintaining or providing any
equipment, software, services or any testing required in connection with any Electronic
Transmission or otherwise required for any E-System.




          Section 11.13 Governing Law. This Agreement, each other Note Document that
does not expressly set forth its applicable law, and the rights and obligations of the
parties hereto and thereto shall be governed by, and construed and interpreted in
accordance with, the law of the State of New York.




          Section 11.14 Jurisdiction. (a) Submission to Jurisdiction. Any legal
action or proceeding with respect to any Note Document shall be brought exclusively in the
courts of the State of New York located in the City of New York, Borough of Manhattan, or
of the United States of America for the Southern District of New York and, by execution and
delivery of this Agreement, each party hereto hereby accepts for itself and in respect of
its property, generally and unconditionally, the jurisdiction of the aforesaid courts;
provided that nothing in this Agreement shall limit the right of the Purchasers to commence
any proceeding in the federal or state courts of any other jurisdiction to the extent the
Purchasers determine that such action is necessary or




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






87









 










appropriate to exercise its rights or remedies under the Note Documents. The parties
hereto (and, to the extent set forth in any other Note Document, each other Note Party)
hereby irrevocably waive any objection, including any objection to the laying of venue or
based on the grounds of forum non conveniens, that any of them may now or hereafter have to
the bringing of any such action or proceeding in such jurisdictions.


          (b) Service of Process. Holdings and each Issuer (and, to the extent set forth in any other
Note Document, each other Note Party) hereby irrevocably waives personal service of any and all
legal process, summons, notices and other documents and other service of process of any kind and
consents to such service in any suit, action or proceeding brought in the United States of America
with respect to or otherwise arising out of or in connection with any Note Document by any means
permitted by applicable Requirements of Law, including by the mailing thereof (by registered or
certified mail, postage prepaid) to the address of the Issuer Representative specified in
Section 11.11 (and shall be effective when such mailing shall be effective, as provided
therein). Holdings and each Issuer (and, to the extent set forth in any other Note Document, each
other Note Party) agrees that a final judgment in any such action or proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided
by law.




          Section 11.15 Waiver of Jury Trial. Each party hereto hereby irrevocably
waives trial by jury in any suit, action or proceeding with respect to, or directly or
indirectly arising out of, under or in connection with, any Note Document or the
transactions contemplated therein or related thereto (whether founded in contract, tort or
any other theory). Each party hereto (A) certifies that no other party and no Related
Person of any other party has represented, expressly or otherwise, that such other party
would not, in the event of litigation, seek to enforce the foregoing waiver and (B)
acknowledges that it and the other parties hereto have been induced to enter into the Note
Documents, as applicable, by the mutual waivers and certifications in this Section
11.15.




          Section 11.16 Severability. Any provision of any Note Document being held
illegal, invalid or unenforceable in any jurisdiction shall not affect any part of such
provision not held illegal, invalid or unenforceable, any other provision of any Note
Document or any part of such provision in any other jurisdiction.




          Section 11.17 Execution in Counterparts. This Agreement may be executed in
any number of counterparts and by different parties in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken together shall
constitute one and the same agreement. Signature pages may be detached from multiple
separate counterparts and attached to a single counterpart. Delivery of an executed
signature page of this Agreement by facsimile transmission or Electronic Transmission shall
be as effective as delivery of a manually executed counterpart hereof.




          Section 11.18 Entire Agreement. The Note Documents embody the entire
agreement of the parties and supersede all prior agreements and understandings relating to
the subject matter thereof and any prior letter of interest, commitment letter, fee letter,
confidentiality and similar agreements involving any Note Party and any of the Purchasers
or any of their respective Affiliates relating to a financing of substantially similar
form, purpose or effect. In the event of any conflict between the terms of this Agreement
and any other Note Document, the terms of this Agreement shall govern



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






88









 










(unless such terms of such other Note Documents are necessary to comply with
applicable Requirements of Law, in which case such terms shall govern to the extent
necessary to comply therewith).




          Section 11.19 Use of Name. Holdings and each Issuer agrees, and shall cause
each other Note Party to agree, that it shall not, and none of its Affiliates shall, issue
any press release or other public disclosure (other than any document required to be filed
with any Governmental Authority under the securities laws) using the name, logo or
otherwise referring to any Purchaser, without at least two (2) Business Day’s prior notice
to such Purchaser and without the prior consent of such Purchaser except to the extent
required to do so under applicable Requirements of Law.




          Section 11.20 Non-Public Information; Confidentiality. (a) Each Purchaser
acknowledges and agrees that it may receive material non-public information hereunder
concerning the Note Parties and their Affiliates and Securities and agrees to use such
information in compliance with all relevant policies, procedures and Contractual
Obligations and applicable Requirements of Laws (including United States federal and state
security laws and regulations).


          (b) Each Purchaser agrees to use all reasonable efforts to maintain, in accordance with its
customary practices, the confidentiality of information obtained by it pursuant to any Note
Document and designated in writing by any Note Party as confidential, except that such information
may be disclosed (i) with the Issuer Representative’s consent, (ii) to Related Persons of such
Purchaser that are advised of the confidential nature of such information and are instructed to
keep such information confidential, (iii) to the extent such information presently is or hereafter
becomes available to such Purchaser, as the case may be, on a non-confidential basis from a source
other than any Note Party, (iv) to the extent disclosure is required by applicable Requirements of
Law or other legal process or requested or demanded by any Governmental Authority, (v) to the
extent necessary or customary for inclusion in league table measurements or in any tombstone or
other advertising materials (and the Note Parties consent to the publication of such tombstone or
other advertising materials by the Purchasers or any of their Related Persons), (vi) to the
National Association of Insurance Commissioners or any similar organization, any examiner or any
nationally recognized rating agency or otherwise to the extent consisting of general portfolio
information that does not identify issuers, (vii) to current or prospective assignees, grantees of
any option described in Section 11.2(f) or participants, direct or contractual counterparties to
any Hedging Agreement permitted hereunder and to their respective Related Persons, in each case to
the extent such assignees, participants, counterparties or Related Persons agree to be bound by
provisions substantially similar to the provisions of this Section 11.20 and (viii) in connection
with the exercise of any remedy or the enforcement of any right under any Note Document. In the
event of any conflict between the terms of this Section 11.20 and those of any other Contractual
Obligation entered into with any Note Party (whether or not a Note Document), the terms of this
Section 11.20 shall govern.




          Section 11.21 Patriot Act Notice. Each Purchaser subject to the USA Patriot
Act of 2001 (31 U.S.C. 5318 et seq.) (the “Patriot Act”) hereby notifies the Issuers that,
pursuant to Section 326 thereof, such Purchaser is required to obtain, verify and record
information that identifies each Issuer, including the name and address of such Issuer and
other information allowing such Purchaser to identify such Issuer in accordance with such
act.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





89









 









ARTICLE 12

CROSS-GUARANTY





          Section 12.1 Cross-Guaranty. Each Issuer hereby agrees that such Issuer is jointly
and severally liable for, and hereby absolutely and unconditionally guarantees to the Purchasers
and their respective successors and assigns, the full and prompt payment (whether at stated
maturity, by acceleration or otherwise) and performance of, all Obligations owed or hereafter owing
to the Purchasers by each other Issuer ( “Guaranteed Obligations”). Each Issuer agrees
that its guaranty obligation hereunder is a continuing guaranty of payment and performance and not
of collection, that its obligations under this Article 12 shall not be discharged until payment and
performance, in full, of the Obligations has occurred, and that its obligations under this Article
12 shall be absolute and unconditional, irrespective of, and unaffected by:


          (a) the genuineness, validity, regularity, enforceability or any future amendment of, or
change in, this Agreement, any other Note Document or any other agreement, document or instrument
to which any Issuer is or may become a party;


          (b) the absence of any action, against any Person other than such Issuer, to enforce this
Agreement (including this Article 12) or any other Note Document or the waiver or consent
by the Purchasers with respect to any of the provisions thereof;


          (c) the existence, value or condition of, or failure to perfect its Lien against, any security
for the Obligations or any action, or the absence of any action, by the Purchasers in respect
thereof (including the release of any such security);


          (d) the insolvency of any Note Party; or


          (e) any other action or circumstances that might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor.



Each Issuer shall be regarded, and shall be in the same position, as principal debtor with respect
to the Guaranteed Obligations.





          Section 12.2 Waivers by Issuers. Each Issuer expressly waives all rights it
may have now or in the future under any statute, or at common law, or at law or in equity,
or otherwise, to compel the Purchasers to marshal assets or to proceed in respect of the
Obligations guaranteed hereunder against any other Note Party, any other party or against
any security for the payment and performance of the Guaranteed Obligations before
proceeding against, or as a condition to proceeding against, such Issuer. It is agreed
among each Issuer, the Purchasers that the foregoing waivers are of the essence of the
transaction contemplated by this Agreement and the other Note Documents and that, but for
the provisions of this Article 12 and such waivers, the Purchasers would decline to
enter into this Agreement.




          Section 12.3 Benefit of Guaranty. Each Issuer agrees that the provisions of
this Article 12 are for the benefit of the Purchasers and their respective
successors, transferees, endorsees and assigns, and nothing herein contained shall impair,
as between any other Issuer and the Purchasers, the obligations of such other Issuer under
the Note Documents.



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY






90









 










          Section 12.4 Subordination of Subrogation, Etc. Notwithstanding anything
to the contrary in this Agreement or in any other Note Document, and except as set forth in
Section 12.7, each Issuer hereby expressly and irrevocably subordinates to payment
of the Obligations any and all rights at law or in equity to subrogation, reimbursement,
exoneration, contribution, indemnification or set off and any and all defenses available to
a surety, guarantor or accommodation co-obligor until the Obligations are paid in full in
cash and the applicable preference period has passed. Each Issuer acknowledges and agrees
that this subordination is intended to benefit the Purchasers and shall not limit or
otherwise affect such Issuer’s liability hereunder or the enforceability of this
Article 12, and that the Purchasers and their respective successors and assigns are
intended third party beneficiaries of the waivers and agreements set forth in this
Section 12.4.




          Section 12.5 Election of Remedies. If, in the exercise of any of its rights
and remedies, any Purchaser shall forfeit any of its rights or remedies, including its
right to enter a deficiency judgment against any Issuer or any other Person, whether
because of any applicable laws pertaining to “election of remedies” or the like, each
Issuer hereby consents to such action by the Purchaser and waives any claim based upon such
action, even if such action by the Purchaser shall result in a full or partial loss of any
rights of subrogation that such Issuer might otherwise have had but for such action by the
Purchaser. Any election of remedies that results in the denial or impairment of the right
of any Purchaser to seek a deficiency judgment against any Issuer shall not impair any
other Issuer’s obligation to pay the full amount of the Obligations.




          Section 12.6 Limitation. Notwithstanding any provision herein contained to the
contrary, each Issuer’s liability under this Article 12 (which liability is in any event in
addition to amounts for which such Issuer is primarily liable under Article 2) shall be limited to
an amount not to exceed as of any date of determination the greater of:


          (a) the net amount of
proceeds of the issuance of Notes received by any other Issuer under this Agreement and then
re-loaned or otherwise transferred to, or for the benefit of, such Issuer; and


          (b) the amount that
could be claimed by the Purchasers from such Issuer under this Article 12 without rendering such
claim voidable or avoidable under Section 548 of Chapter 11 of the Bankruptcy Code or under any
applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar
statute or common law after taking into account, among other things, such Issuer’s right of
contribution and indemnification from each other Issuer under Section 12.7.




          Section 12.7 Contribution with Respect to Guaranty Obligations.


          (a) To the extent that
any Issuer shall make a payment under this Article 12 of all or any of the Obligations (other than
the proceeds of Notes received directly by such Issuer for which it is primarily liable) (a
“Guarantor Payment”) that, taking into account all other Guarantor Payments then previously
or concurrently made by any other Issuer, exceeds the amount that such Issuer would otherwise have
paid if each Issuer had paid the aggregate Obligations satisfied by such Guarantor Payment in the
same proportion that such Issuer’s “Allocable Amount” (as defined below) (as determined immediately
prior to such Guarantor



NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





91









 








Payment) bore to the aggregate Allocable Amounts of each of the Issuers as determined
immediately prior to the making of such Guarantor Payment, then, following payment in full in cash
of the Obligations, termination of the Commitments and the passage of the applicable preference
period, such Issuer shall be entitled to receive contribution and indemnification payments from,
and be reimbursed by, each other Issuer for the amount of such excess, pro rata based upon their
respective Allocable Amounts in effect immediately prior to such Guarantor Payment.



          (b) As of any date of determination, the “Allocable Amount” of any Issuer shall be equal to
the maximum amount of the claim that could then be recovered from such Issuer under this Article 12
without rendering such claim voidable or avoidable under Section 548 of Chapter 11 of the
Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent
Conveyance Act or similar statute or common law.


          (c) This Section 12.7 is intended only to define the relative rights of the Issuers
and nothing set forth in this Section 12.7 is intended to or shall impair the obligations
of the Issuers, jointly and severally, to pay any amounts as and when the same shall become due and
payable in accordance with the terms of this Agreement, including Section 12.1. Nothing
contained in this Section 12.7 shall limit the liability of any Issuer to pay the Notes to
such Issuer and accrued interest, Fees and expenses with respect thereto for which such Issuer
shall be primarily liable.


          (d) The parties hereto acknowledge that the rights of contribution and indemnification
hereunder shall constitute assets of the Issuers to which such contribution and indemnification is
owing.


          (e) The rights of the indemnifying Issuers against other Note
Parties under this Section 12.7 shall be exercisable upon the full and
payment of the Obligations, the termination of the Commitments and the passage
of the applicable preference period.




          Section 12.8 Liability Cumulative. The liability of the Issuers under this
Article 12 is in addition to and shall be cumulative with all liabilities of each Issuer to
the Purchasers under this Agreement and the other Note Documents to which such Issuer is a
party or in respect of any Obligations or obligation of the other Issuers, without any
limitation as to amount, unless the instrument or agreement evidencing or creating such
other liability specifically provides to the contrary.




          Section 12.9 Subordination. This Agreement and the rights and obligations
evidenced hereby are subordinate to the Senior Loan Obligations in the manner and to the
extent set forth in the Subordination Agreement.



[SIGNATURE PAGES FOLLOW]




NOTE PURCHASE AGREEMENT

MEDQUIST AND CBAY





92












 





     IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by
their respective officers thereunto duly authorized, as of the date first above written.



	 	 	 	 	 
	 	CBAY INC., as Issuer

 	 
	 	By:  	/s/ Clyde Swoger	 
	 	 	Name:  	Clyde Swoger	 
	 	 	Title:  	CFO 	 
	 
	 	MEDQUIST INC., as Issuer

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	MEDQUIST TRANSCRIPTIONS, LTD., as Issuer

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	CBAYSYSTEMS HOLDINGS LIMITED, as Holdings

 	 
	 	By:  	/s/ Clyde Swoger	 
	 	 	Name:  	Clyde Swoger	 
	 	 	Title:  	CFO 	 



Signature Page to Senior Subordinated Note Purchase Agreement




 









 









     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective officers thereunto duly authorized, as of the date first above written.



	 	 	 	 	 
	 	CBAY INC., as Issuer

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 
	 	MEDQUIST INC., as Issuer

 	 
	 	By:  	/s/ Mark R. Sullivan
 	 
	 	 	Name:  	Mark R. Sullivan 	 
	 	 	Title:  	General Counsel 	 
	 
	 	MEDQUIST TRANSCRIPTIONS, LTD., as Issuer

 	 
	 	By:  	/s/ Mark R. Sullivan
 	 
	 	 	Name:  	Mark R. Sullivan 	 
	 	 	Title:  	General Counsel 	 
	 
	 	CBAYSYSTEMS HOLDINGS LIMITED, as Holdings

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 



Signature Page to Senior Subordinated Note Purchase Agreement




 









 








	 	 	 	 	 
	 	PURCHASERS:





BLACKROCK KELSO CAPITAL CORPORATION, 

By: BLACKROCK KELSO CAPITAL ADVISORS 

LLC, its Investment Manager, 

as Purchaser

 	 
	 	By:  	/s/ Michael B. Lazar
 	 
	 	 	Name:  	Michael B. Lazar 	 
	 	 	Title:  	Chief Operating Officer 	 



Signature Page to Senior Subordinated Note Purchase Agreement




 









 








	 	 	 	 	 
	 	PENNNANTPARK INVESTMENT CORPORATION, 

as Purchaser

 	 
	 	By:  	/s/ Arthur Penn
 	 
	 	 	Name:  	Arthur Penn 	 
	 	 	Title:  	CEO 	 



Signature Page to Senior Subordinated Note Purchase Agreement




 









 








	 	 	 	 	 
	 	CITIBANK, N. A., as Purchaser

 	 
	 	By:  	/s/
Michael P. Girondo 	 
	 	 	Name:  	Michael P. Girondo	 
	 	 	Title:  	Vice President 	 
	 



Signature Page to Senior Subordinated Note Purchase Agreement




 









 








	 	 	 	 	 
	 	THL CREDIT, INC., as Purchaser

 	 
	 	By:  	/s/ Hunter Stropp
 	 
	 	 	Name:  	Hunter Stropp 	 
	 	 	Title:  	Co-President 	 
	 



Signature Page to Senior Subordinated Note Purchase Agreement





 











 





Exhibit A

TO

Note Purchase Agreement




Form
of Assignment




     This ASSIGNMENT (this “Assignment”), dated as of the Effective Date, is
entered into between the Assignor and the Assignee (each as defined below).



     The parties hereto hereby agree as follows:



	 	 	 

	Issuers:

	 	CBay Inc., a Delaware corporation (“CBay);
MedQuist Inc., a New Jersey corporation (“MedQuist”); and
MedQuist Transcriptions, Ltd., a New Jersey corporation (“MedQuist
Transcriptions” and together with CBay and MedQuist, the “Issuers”).
	 
	 	 
	Purchasers:

	 	BlackRock Kelso Capital Corporation, a Delaware corporation
(“BKC”), PennantPark Investment Corporation, a Maryland corporation
(“Pennant”), Citibank, N.A., a national association (“Citibank”), and
THL Credit, Inc., a Delaware corporation (“THL” and together with
BKC, Pennant and Citibank, the “Purchasers”).
	 
	 	 
	Note Purchase 

Agreement:

	 	Senior Subordinated Note Purchase Agreement, dated as of September
30, 2010, among the Issuers, CBaySystems Holdings Limited, as one of
the Guarantors, and the Purchasers (as the same may be amended,
restated, supplemented or otherwise modified from time to time, the
“Note Purchase Agreement”; capitalized terms used herein without
definition are used as defined in the Note Purchase Agreement)
	 
	 	 
	[Trade Date:

	 	               ,      ]
	 
	 	 
	Effective Date:

	 	               ,      







	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Aggregate	 	 	Aggregate	 	 	 	 
	Assignor	 	Assignee	 	principal	 	 	principal	 	 	Percentage	 
	(collectively,	 	(collectively,	 	amount of	 	 	amount of	 	 	Assigned of	 
	the	 	the	 	Notes for all	 	 	Notes	 	 	Aggregate	 
	"Assignors")	 	"Assignees")	 	Purchasers	 	 	Assigned	 	 	Amount	 
	[Name of Assignor]
	 	[Name of Assignee] [Affiliate] [Approved Fund] of [Name of Purchaser]	 	$	 	 	 	$	 	 	 	 	   .   	%
	 
	 	 	 	 	 	 	 	 	 	 	 





A-2


ASSIGNMENT          

FOR MEDQUIST INC.’S NOTE PURCHASE AGREEMENT












 






	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Aggregate	 	 	Aggregate	 	 	 	 
	Assignor	 	Assignee	 	principal	 	 	principal	 	 	Percentage	 
	(collectively,	 	(collectively,	 	amount of	 	 	amount of	 	 	Assigned of	 
	the	 	the	 	Notes for all	 	 	Notes	 	 	Aggregate	 
	"Assignors")	 	"Assignees")	 	Purchasers	 	 	Assigned	 	 	Amount	 
	[Name of Assignor]
	 	[Name of Assignee] [Affiliate] [Approved Fund] of [Name of Purchaser]	 	$	 	 	 	$	 	 	 	 	   .   	%
	 
	 	 	 	 	 	 	 	 	 	 	 
	[Name of Assignor]
	 	[Name of Assignee] [Affiliate] [Approved Fund] of [Name of Purchaser]	 	$	 	 	 	$	 	 	 	 	   .   	%
	 
	 	 	 	 	 	 	 	 	 	 	 





[The Remainder of this Page Was Intentionally Left Blank]




A-3


ASSIGNMENT          

FOR MEDQUIST INC.’S NOTE PURCHASE AGREEMENT












 





     1. Assignment, Assignor hereby sells and assigns to Assignee, and Assignee
hereby purchases and assumes from Assignor, Assignor’s rights and obligations in its capacity
as Purchaser under the Note Purchase Agreement (including Liabilities owing to or by Assignor
thereunder) and the other Note Documents, in each case to the extent related to the amounts
identified above (the “Assigned Interest”).



     2. Representations, Warranties and Covenants of Assignor, Assignor (a) represents
and warrants to Assignee that (i) it has full power and authority, and has taken all actions
necessary for it, to execute and deliver this Assignment and to consummate the transactions
contemplated hereby and (ii) it is the legal and beneficial owner of its Assigned Interest and
that such Assigned Interest is free and clear of any Lien and other adverse claims, and (iii) by
executing, signing and delivering this Assignment via any E-System, the Person signing,
executing and delivering this Assignment on behalf of the Assignor is an authorized signer for
the Assignor and is authorized to execute, sign and deliver this Agreement, (b) makes no other
representation or warranty and assumes no responsibility, including with respect to the
aggregate amount of the Notes, the percentage of the Notes represented by the amounts assigned, any
statements, representations and warranties made in or in connection with any Note Document or
any other document or information furnished pursuant thereto, the execution, legality,
validity, enforceability or genuineness of any Note Document or any document or information provided in
connection therewith, (c) assumes no responsibility (and makes no representation or warranty)
with respect to the financial condition of any Group Member or Note Party or the performance
or nonperformance by any Note Party of any obligation under any Note Document or any document
provided in connection therewith and (d) attaches any Notes held by it evidencing at least in
part the Assigned Interest of such Assignor.



     3. Representations, Warranties and Covenants of Assignee, Assignee (a) represents
and warrants to Assignor that (i) it has full power and authority, and has taken all actions
necessary for Assignee, to execute and deliver this Assignment and to consummate the
transactions contemplated hereby, (ii) to the extent indicated above, is an Affiliate of the
Purchaser set forth above, (iii) it is sophisticated with respect to decisions to acquire
assets of the type represented by the Assigned Interest assigned to it hereunder and either such Assignee or
the Person exercising discretion in making the decision for such assignment is experienced in
acquiring assets of such type, and (iv) by executing, signing and delivering this Assignment
via any E-System, the Person signing, executing and delivering this Assignment on behalf of the
Assignor is an authorized signer for the Assignor and is authorized to execute, sign and
deliver this Assignment, (b) shall perform in accordance with their terms all obligations that, by the
terms of the Note Documents, are required to be performed by it as a Purchaser, (c) confirms it has
received such documents and information as it has deemed appropriate to make its own credit
analysis and decision to enter into this Assignment and shall continue to make its own credit
decisions in taking or not taking any action under any Note Document independently and without
reliance upon any Purchaser and based on such documents and information as it shall deem
appropriate at the time, (d) acknowledges and agrees that, as a Purchaser, it may receive
material non-public information and confidential information concerning the Note Parties and their
Affiliates and Securities and agrees to use such information in accordance with Section
11.20 of the Note Purchase Agreement, (e) specifies as its applicable offices (and addresses for
notices) the offices at the addresses set forth beneath its name on the signature pages hereof, and (f)
to the extent required pursuant to Section 2.17(f) of the Note Purchase Agreement, attaches
two completed originals of Forms W-8ECI, W-8BEN or W-9.



A-2


ASSIGNMENT          

FOR MEDQUIST INC.’S NOTE PURCHASE AGREEMENT













 





     4. Determination of Effective Date; Register, Following the due execution and
delivery of this Assignment by Assignor, Assignee and, to the extent required by Section
11.2(b) of the Note Purchase Agreement, the Issuers, this Assignment (including its attachments) will
be delivered to the Issuer Representative for recording in the Register. The effective date of
this Assignment (the “Effective Date”) shall be the recording of this Assignment in the
Register. The Issuer Representative shall insert the Effective Date when known in the space provided
therefor at the beginning of this Assignment.



     5. Effect. As of the Effective Date, (a) Assignee shall be a party to the Note
Purchase Agreement and, to the extent provided in this Assignment, have the rights and
obligations of a Purchaser under the Note Purchase Agreement and (b) Assignor shall, to the
extent provided in this Assignment, relinquish its rights (except those surviving the
termination of the Commitments and payment in full of the Obligations) and be released from its obligations
under the Note Documents other than those obligations relating to events and circumstances
occurring prior to the Effective Date.



     6. Distribution of Payments. On and after the Effective Date, the Issuers shall make
all payments under the Note Documents in respect of each Assigned Interest (a) in the case of
amounts accrued to but excluding the Effective Date, to Assignor and (b) otherwise, to the
Assignee.



     7. Miscellaneous. This Assignment is a Note Document and, as such, is subject to
certain provisions of the Note Purchase Agreement, including Sections 1.6
(Interpretation), 11.14 (Jurisdiction) and 11.15 (Waiver of Jury Trial) thereof. On and
after the Effective Date, this Assignment shall be binding upon, and inure to the benefit of, the Assignors, Assignees and
their Related Persons and their successors and assigns. This Assignment shall be governed by, and be
construed and interpreted in accordance with, the law of the State of New York. This
Assignment may be executed in any number of counterparts and by different parties in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement. Signature pages may be detached from multiple
separate counterparts and attached to a single counterpart. Delivery of an executed
signature page of this Assignment by facsimile transmission or Electronic Transmission shall be as
effective as delivery of a manually executed counterpart of this Assignment.



[Signature Pages Follow]






A-3


ASSIGNMENT          

FOR MEDQUIST INC.’S NOTE PURCHASE AGREEMENT












 





     IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be executed by their
respective officers thereunto duly authorized, as of the date first above written.



	 	 	 	 	 
	 	[NAME OF ASSIGNOR]

as Assignor 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 
	 	[NAME OF ASSIGNEE]

as Assignee 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 



[signature page for assignment for medquist inc.’s note purchase agreement]





 









 





Exhibit B

TO

Note Purchase Agreement




Form of Note



This instrument and the rights and obligations evidenced hereby are subordinate in the manner
and to the extent set forth in that certain Subordination and Intercreditor Agreement (the
“Subordination Agreement”) among blackrock kelso capital corporation (“BKC”), pennantpark
Investment Corporation (“Pennant”), Citibank, N.A. (“Citibank”), THL Credit,
Inc. (“THL” and together with BKC, Pennant and Citibank, the “Purchasers”), CBay
Inc., a Delaware corporation (“CBay”), MedQuist Inc., a New Jersey corporation (“medquist”),
medquist transcriptions, ltd., a new jersey corporation (“medquist transcriptions”, and together
with cbay and MedQuist, the “Issuers”) and General Electric Capital Corporation (“Agent”), to the
indebtedness (including interest) owed by the issuers pursuant to that certain Credit Agreement
dated as of October 1,2010 among the Issuers, Agent and the lenders from time to time
party thereto, as such credit agreement has been and hereafter may be amended, supplemented or
otherwise modified from time to time and to indebtedness refinancing the indebtedness under that
agreement as contemplated by the subordination agreement; and each holder of this instrument, by
its acceptance hereof, irrevocably agrees to be bound by the provisions of the subordination
agreement.




			
	 	 	 
	 	 	 
	Purchaser: [NAME OF PURCHASER]
	 	New York, New York
	Principal Amount: $          
	 	               ,      






     FOR VALUE RECEIVED, the undersigned Issuers, hereby jointly and severally promise to pay to
the Purchaser set forth above the Principal Amount set forth above, or, if less or if more as a
result of the capitalization of interest paid in kind hereon, the aggregate unpaid principal amount
of Notes held by the Purchaser, payable at such times and in such amounts as are specified in the
Note Purchase Agreement (as defined below).



     The Issuers jointly and severally promise to pay interest on the unpaid principal amount of
the Notes from the date made until such principal amount is paid in full in cash, payable at such
times and at such interest rates as are specified in the Note Purchase Agreement. Demand,
diligence, presentment, protest and notice of non-payment and protest are hereby waived by the
Issuers.



     Both principal and interest are payable in Dollars to the Purchaser
at                      or such other place as the Purchaser may designate from time to time
pursuant to the Note Purchase Agreement, in immediately available funds.



B-1









 





     This Note is one of the Notes referred to in, and is entitled to the benefits of, the
Senior Subordinated Note Purchase Agreement, dated as of September 30, 2010 (as the same may be
amended, restated, supplemented or otherwise modified from time to time, the “Note Purchase
Agreement”), among the Issuers, CBaySystems Holdings Limited, as one of the Guarantors, and
the Purchasers Capitalized terms used herein without definition are used as defined in the Note
Purchase Agreement.



     The Note Purchase Agreement, among other things, contains provisions for acceleration of the
maturity of the unpaid principal amount of this Note upon the happening of certain stated events
and also for prepayments on account of the principal hereof prior to the maturity hereof upon the
terms and conditions specified therein.



     This Note is a Note Document, is entitled to the benefits of the Note Documents and is
subject to certain provisions of the Note Purchase Agreement, including Sections 1.6
(Interpretation), 11.14(a) (Submission to Jurisdiction) and
11.15 (Waiver of Jury Trial) thereof.



     This Note is a registered obligation, transferable only upon notation in the Register, and no
assignment hereof shall be effective until recorded therein.



     This Note shall be governed by, and construed and interpreted in accordance with, the law of
the State of New York.



[Signature pages follow]




B-2


[$          ] note

of cbay inc., medquist inc. and medquist transcriptions, ltd. for the benefit of [name of

purchaser]












 





     IN WITNESS WHEREOF, the Issuers have caused this Note to be executed and delivered by its duly
authorized officer as of the day and year and at the place set forth above.



	 	 	 	 	 
	 	CBAY INC.

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 
	 	MEDQUIST INC.

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 
	 	MEDQUIST TRANSCRIPTIONS,

LTD.

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 




B-3









 





Exhibit C

TO

Note Purchase Agreement




FORM OF PIK ELECTION NOTICE




                     ,           




Attention: Purchasers




	 	 	 

	Re:

	 	CBay Inc. (“CBay”), MedQuist Inc. (“MedQuist”) and
	 

	 	MedQuist Transcriptions, Ltd. (“MedQuist
	 

	 	Transcriptions” and together with CBay and MedQuist,
	 

	 	the “Issuers”)






     Reference is made to the Senior Subordinated Note Purchase Agreement, dated as of September
30, 2010, (as the same may be amended, restated, supplemented or otherwise modified from time to
time, the “Note Purchase Agreement”), among the Issuers, CBaySystems Holdings Limited, as
one of the Guarantors, BlackRock Kelso Capital Corporation (“BKC”), PennantPark Investment
Corporation (“Pennant”), Citibank, N.A. (“Citibank”) and THL Credit, Inc. (“THL”
and together with BKC, Pennant and Citibank, the “Purchasers”). Capitalized terms used
herein without definition are used as defined in the Note Purchase Agreement.



     The Issuer Representative, on behalf of the Issuers, hereby gives you irrevocable notice
pursuant to Section 2.7(a) of the Note Purchase Agreement of its election to have
the interest payable for the quarter ending on , 20 equal to the PIK Rate.



     The Issuer Representative, on behalf of the Issuers, hereby certifies that on the date hereof
no Default has occurred and is continuing.



	 	 	 	 	 
	 	MEDQUIST INC., as Issuer Representative

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 




C-1









 





Exhibit D

to Note Purchase Agreement




Form
of Compliance Certificate




               ,      1



This certificate is delivered pursuant to
Section 6. 1(d) of, and in connection with
the consummation of the transactions contemplated in, the Senior Subordinated Note Purchase
Agreement, dated as of September 30, 2010 (as the same may be amended, restated, supplemented or
otherwise modified from time to time, the “Note Purchase Agreement”), among CBay Inc. a
Delaware corporation (“CBay”), MedQuist Inc., a New Jersey corporation (“MedQuist”) and
MedQuist Transcriptions, Ltd., a New Jersey corporation (“MedQuist Transcriptions” and
together with CBay and MedQuist, the “Issuers”), CBaySystems Holdings Limited, as one of
the Guarantors, BlackRock Kelso Capital Corporation, a Delaware (“BKC”), PennantPark Investment
Corporation, a Maryland corporation (“Pennant”), Citibank, N.A., a national association
(“Citibank”) and THL Credit, Inc., a Delaware corporation (“THL” and together with BKC,
Pennant and Citibank, the “Purchasers”). Capitalized terms used herein and not otherwise
defined herein are used herein as defined in the Note Purchase Agreement.



The undersigned, a duly authorized Responsible Officer of the Issuer Representative having the name
and title set forth below under his signature and as such is duly authorized to execute and deliver
this certificate on behalf of the Issuers, hereby certifies, solely in the capacity of Responsible
Officer and not in any individual capacity, on behalf of the Issuers for the benefit of the
Purchasers that such Responsible Officer is familiar with the Note Purchase Agreement and that, in
accordance with each of the following sections of the Note Purchase Agreement, each of the
following is true on the date hereof, both before and after giving effect to any Notes to be issued
on or before the date hereof:



In accordance with Section 6.1[(b)/(c)] of the Note Purchase Agreement, attached hereto as
Annex A are the Financial Statements for the [Fiscal Quarter/Fiscal Year] ended,           ,      
required to be delivered pursuant to Section 6.1 [(b)/(c)] of the Note Purchase Agreement.
Such Financial Statements fairly present in all material respects the Consolidated financial
position, results of operations and cash flow of Holdings and, with respect to periods ending on
or prior to the MedQuist Consolidation Date, the Consolidated financial position of MedQuist in
each case as at the dates indicated therein and for the periods indicated therein in accordance
with GAAP [(subject to the absence of footnote disclosure and normal year-end audit
adjustments)]2 [without qualification as to the scope of the audit or as to going
concern and without any other similar qualification, together with the certificate from the Group
Members’ Accountants with respect to such Consolidated Financial Statements required to be
delivered pursuant to Section 6.1(c) of the Note Purchase Agreement. The examination by
the Issuers’ Accountants in connection with such Financial Statements has been made in accordance
with the standards of the United States’ Public Company accounting Oversight Board (or any
successor entity).]3






 




			
	1	 	Insert date of delivery of certificate.
	 
	2	 	Insert language in brackets only for monthly and quarterly reports.
	 
	3	 	Insert language in brackets only for annual certifications.





G-1









 




In accordance with [Section 6.1(d)(i) and]4 Section 6.1(d)(ii) of the Note
Purchase Agreement, attached hereto as Annex B are the calculations used to determine
compliance with each financial covenant contained in Article V of the Note Purchase
Agreement, [and the calculations used in determining Excess Cash Flow]5.



In accordance with Section 6.1(d)(iii) of the Note Purchase Agreement, no Default or Event
of Default is continuing as of the date hereof [, except as provided for on Annex C
attached hereto, with respect to each of which the applicable Issuer proposes to take the actions
set forth on AnnexC]. [In accordance with Section 6. 1(e) of the Note Purchase
Agreement, (i) the [Corporate Chart attached hereto as Annex D[-1]] [last Corporate Chart
delivered pursuant to such Section)], is correct and complete as of the date hereof, (ii) all
documents (including updated schedules as to acquisition of Intellectual Property) required to be
delivered pursuant to the Note Documents by any Note Party in the preceding Fiscal Quarter have
been delivered thereunder (or such delivery requirement was otherwise duly waived or extended) and
(iii) complete and correct copies of all documents modifying any term of any Constituent Document
of any Group Member or any Subsidiary or joint venture thereof on or prior to the date hereof have
been delivered to the Purchasers [or are attached hereto as Annex D[-2]]



[In accordance with Section 6.1(g) of the Note Purchase Agreement, attached hereto as
Annex G are complete and correct copies of each management letter, audit report or similar
letter or report received by any Group Member from any independent registered certified public
accountant (including the Group Members’ Accountants) in connection with such Financial Statements
or any audit thereof.].6




[Signature page follows]






 




			
	4	 	Insert if Consolidated Financial Statements are delivered with Certificate.
	 
	5	 	Insert if Consolidated Financial Statements are delivered with Certificate.
	 
	6	 	Insert bracketed language only for annual reports.





G-2









 




IN WITNESS WHEREOF, the undersigned has executed this certificate on the date first written
above.




	 	 	 	 	 
	 	MEDQUIST INC., as Issuer Representative

 	 
	 	By:  	 	 
	 	Name:  	 	 
	 	Title:  	 	 
	 



[signature page to compliance certificate of medquist transcriptions, ltd. dated                      ,           ]





 









 





ANNEX A

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




financial statements




D-4









 





ANNEX B

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




financial calculations




D-5









 





[ANNEX C

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




continuing defaults]7






 




			
	7	 	Delete if not used in the text of the certificate.





D-6









 





[ANNEX D[-1]

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




corporate chart




D-7









 





[ANNEX D[-2]

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




modifications to constituent documents




D-8









 





ANNEX G

TO

COMPLIANCE CERTIFICATE OF MEDQUIST INC.

DATED           ,      




[management letters]





D-9